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Abstract
The aim of this thesis was to develop novel carbon-based biosensors and sensors for
real-time metabolite and drug detection, to provide the next generation of medical devices
which can give clinicians relevant chemical information in real-time at the patient bedside.
An autocalibration system was developed using LabSmith programmable components
to give precise ﬂuid delivery and excellent temporal control of multiple liquid streams. This
enables a 5-point calibration to be carried out using two solutions in 12 minutes. Systems
using chitosan, poly(ethylene glycol)diglycidyl ether hydrogel, electrodeposition and self-
assembly to immobilise enzymes on a combined needle electrode surface were studied and
their performances were investigated using a microﬂuidic platform. The autocalibration
system was combined with the graphene oxide-based biosensors in a microchip coupled
with a microdialysis probe and was examined as a proof-of-concept clinical on-line analysis
system. A reduced graphene oxide-based sensor was fabricated using a combined needle
electrode for on-line neurotransmitter detection of dopamine. Its performance was compared
with that of a platinum electrode.
A microﬂuidic sensor based on a carbon nanotube-epoxy composite was fabricated to
detect the presence of carboplatin (anti-cancer drug) in healthy tissue in real time during
chemotherapy. Detection of carboplatin was carried out using diﬀerential pulse voltammetry
ﬁrstly in a beaker, in which carbon nanotube-epoxy composite electrodes performed better
than glassy carbon electrodes for oxidation of free purine bases and than DNA-modiﬁed car-
bon nanotube-epoxy composite sensors for detection of carboplatin. Carboplatin detection
was then performed in a microﬂuidic platform. The methodology for on-line carboplatin
detection was optimised in terms of the analysis time and for the repeated determination of
carboplatin using the same electrode. Microdialysis and microﬂuidic techniques have been
combined to give a proof-of-concept system real-time carboplatin detection using the carbon
nanotube-epoxy composite sensors.
i
ii
Declaration of Originality
The work presented in this thesis was carried out between January 2012 and October 2015
in the Department of Bioengineering at Imperial College London under the supervision of
Professor Martyn G. Boutelle. The material herein is original and has not been submitted
for a degree or diploma at any other university.
TONGHATHAI PHAIRATANA
Declaration of Copyright
The copyright of this thesis rests with the author and is made available under
a Creative Commons Attribution Non-Commercial No Derivatives licence. Re-
searchers are free to copy, distribute or transmit the thesis on the condition
that they attribute it, that they do not use it for commercial purposes and that
they do not alter, transform or build upon it. For any reuse or redistribution,
researchers must make clear to others the licence terms of this work.
iii
iv
Acknowledgements
First and foremost, I would like to thank my supervisor, Professor Martyn G. Boutelle,
for the opportunities and inspirations to work on this project. I am extremely grateful for
his endless encouragement, advice and guidance throughout, and for being so generous with
his time. Secondly, I would like to special thank to everyone that has been involved with
this thesis, in particular,
• Dr Sally A.N. Gowers for her help with careful proofreading my thesis and all invalu-
able support and advice on my work
• Dr Chi Leng Leong and Dr Michelle L. Rogers for their all invaluable support and
advice on my work.
• Dr Bhavik Patel for his support in fabrication of carbon nanotube-epoxy composite
electrodes at the University of Brighton
without their assistance and support, the work described would not have been possible.
I would also like to express my gratitude to all the lab members for their advice and
support, and for making my time so special and enjoyable. I have been very fortunate to
work with my beloved group.
I am grateful for funding from Royal Thai Government without which this work would
not have been possible. Lastly, I am immensely thankful to my family and friends, for their
encouragement and always being there for me.
v
vi
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5-HT Serotonin
AA Ascorbic acid
ACB Acetate buﬀer
AE Auxiliary electrode
Ag|AgCl Silver/silver chloride
AFM Atomic force microscopy
AMP Adenosine monophosphate
CFE Carbon ﬁbre electrode
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FSCV Fast scan cyclic voltammetry
FTIR Fourier transform infrared spectroscopy
R Gas constant, R = 8.314 J K−1 mol−1
GOx Glucose oxidase
GO Graphene oxide
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H2O2 Hydrogen peroxide
HOPG Highly ordered pyrolytic graphite
ISF Interstitial ﬂuid
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Kd Dissociation constant
Km Michealis-Menten constant
LBL Layer-by-layer
LOx Lactate oxidase
MD Microdialysis
mPD m-phenylenediamine
MWCNT Multi-walled carbon nanotube
NHS N-hydroxysuccinimide
OD Outer diameter
OPA Operational ampliﬁer
PBS Phosphate buﬀered saline
PDMS Polydimethylsiloxane
PEGDE Poly(ethylene glycol)diglycidyl ether hydrogel
PEEK Polyether ether ketone
pI Isoelectric point
Pt Platinum
RE Reference electrode
rGO Reduced graphene oxide
rsMD Rapid sampling microdialysis
SD Standard deviation
SEM Scanning electron microscopy
S/N Signal-to-noise ratio
ssDNA Single-stranded deoxyribonucleic acid
SWCNT Single-walled carbon nanotube
T90 90% response time
WE Working electrode
W1/2 Width at half-height of peak
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Chapter 1
Introduction
This chapter introduces methods of monitoring the dynamics of the chemical changes in
the body in vivo. It begins with a consideration of the extracellular space as a monitoring
matrix, before moving to consider diﬀerent methods of monitoring chemical changes in this
space including using microdialysis as a sampling technique. The development of electro-
chemical biosensors for use with microdialysis is discussed as well as modifying biosensors
with nanomaterials. More detailed reviews speciﬁc to carbon-based sensors in this thesis
are given in the relevant chapters. The chapter ﬁnishes with an outline of the thesis.
1.1 Extracellular Space
In the tissue of multicellular organisms, cells play a crucial role in communicating with
neighbouring cells to manipulate their biochemical properties and to condition their local
environment by secreting soluble factors into the extracellular space (ECS) [1]. The ECS
is the thin, connected space between cells, outside their plasma membrane as shown in
Figure 1.1. The ECS is ﬁlled by the extracellular ﬂuid, which contains an ionic solution
mainly consisting of sodium chloride, macromolecules of the extracellular matrix, negatively-
charged proteoglycans and glycosaminoglycans [2].
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Figure 1.1: Geometry of the extracellular space (ECS). Electronmicrograph of a small region of
a rat cortex. The ECS is outlined in red. The letter "S" represents a dendritic spine and "P"
represents a presynaptic terminal. Image taken from Nicholson et al. [3].
The ECS provides a path for the transport of substances such as metabolites and
nutrients to move between cells and blood vessels [4]. It also provides a reservoir of ions to
establish the resting and action potentials of cells and it mediates active chemical signalling
[5, 6]. In addition, the ECS mediates the delivery of soluble drugs to cells in the tissue [7].
These processes are mainly mediated by diﬀusion, although there is also the possibility of
convection due to lymphatic ﬂow through the tissue. In the brain, these processes had until
recently been thought to be mediated by diﬀusion alone, however, recently a "glymphatic"
convective system has been identiﬁed [8, 9].
The volume and composition of the ECS diﬀers between tissues and can change as
a result of pathological conditions. Therefore, changes in the diﬀusive properties of the
ECS can aﬀect neurotransmission, neurotrophic eﬀects, general electrical activity, basic
cellular homeostasis, and drug delivery [6] in tissue. To understand what happens during
intercellular communication processes in tissue and how tissue is aﬀected when drugs are
delivered locally into the target tissue, it is desirable to monitor the dynamic changes of
chemicals and drugs in the tissue.
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1.2 Methods of Invasive in vivo Monitoring
Implantable microsensors and microdialysis are the most common methods used for in
vivo measurement of the dynamic concentration changes of neurotransmitters and related
substances in the brain ECS. Both methods are invasive as they are implanted directly into
the tissue and they remove chemical substances from the ECS.
1.2.1 Implantable Microsensors
Microsensors are miniaturised analytical devices for chemical measurements in biological
systems. While, in principle, microsensors could be optical devices, electrochemical sensors
have better sensitivity and cheaper support electronics and therefore dominate the research
literature.
Microsensors provide the capability of measuring rapid dynamic chemical events (mil-
lisecond scale), which are typically induced by an external electrical or chemical stimu-
lus, with high temporal resolution [10]. Most microsensors used currently for neurochem-
ical studies are based on carbon-ﬁbre microelectrodes with diameters in the range of 5-10
µm [11–13]. Carbon ﬁbres cause minimal tissue damage in the brain [14–16]. It has been
shown that carbon ﬁbres are advantageous compared with larger electrodes as they provide
a fast response time, do not distort the highly resistive environment and alter the diﬀusion
ﬁeld [17]. However, there are some drawbacks for in vivo chemical measurement using elec-
trochemical microsensors. They suﬀer in terms of their sensitivity and selectivity so using
electrochemical microsensors requires careful attention in validation of the signals obtained
during in vivo experiments [10, 18]. For sensitivity, it is impossible to calibrate the sensors
once they are implanted in the tissue because the concentration of neurotransmitters in the
ECS cannot be controlled. There is also the problem of electrode fouling during long-term
implantation due to large molecules such as proteins adhering to the electrode surface lead-
ing to changes in sensitivity [19]. In terms of selectivity, when the microsensor is implanted
into the complex environment of the tissue, it is possible for interferent species to be elec-
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trochemically detected by the microsensors. Several methods have been used to improve the
selectivity, such as immobilising enzyme onto the electrode surface [20–22] or coating the
microsensor with an ion-selective polymer (such as Naﬁon) [23, 24]. Naﬁon allows the pas-
sage of cations to the microsensor surface but anions and larger molecules are excluded. The
Somber group [20] developed a carbon ﬁbre microsensor modiﬁed with an electrodeposited
chitosan hydrogel encapsulating glucose oxidase. The microbiosensor showed stability under
physiological normoxic conditions and minimal interference from endogenous electroactive
substances. They suggest that the method used for modifying the enzyme-based microsen-
sor enables rapid monitoring of many non-electroactive enzyme substrates. A more detailed
review of using microsensors is given in Chapter 5.
Another area of interest for implantable microsensors is monitoring for diabetic pa-
tients as real-time. The information about their glucose levels is critical for disease man-
agement. The continuous glucose monitoring (CGM) is an FDA-approved device made by
Dexcom which uses a needle-type device to monitor glucose using interstitial ﬂuid (ISF) as
the diagnostic bioﬂuid to track the glucose levels of people with diabetes. The needle-type
electrochemical glucose sensor is implanted into the subcutaneous tissue and detects glucose
levels in the ISF. As this method detects glucose levels in the dermal ISF rather than in
the blood, time lags of up to 25-45 minutes have been reported when compared to ﬁnger
capillary blood readings, which aﬀects the "real-time" accuracy of the sensor [25, 26]. This
is a particular problem for rapid changes in glucose levels. Microneedle array technology has
great potential as it oﬀers pain-free monitoring and has good accuracy, which extends into
the hypoglycemic range [27]. The microneedles are minimally invasive as they penetrate the
stratum corneum and do not impinge on the dermal nerve ﬁbres or blood vessels to access
the ISF. Wang et al. [28] reported using microneedles for analysis of glucose in extracted
ISF and showed that the microneedle measurements correlated well with capillary blood
glucose readings and with lag time of less than 20 minutes. Recently, the Cass group [29]
developed enzyme-immobilised microspike arrays coated with epoxy-polyurethane which
they combined with a novel microﬂuidic platform. The microspike sensors were compared
with CGM and were found to have improved signal:noise ratio and therefore sensor accu-
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racy [27]. Therefore they have potential to be used for the detection of glucose, even in the
hypoglycemic range, in the dermal ISF. Also, this device can be used for lactate detection
with good dynamic range.
Alternatively, in vivo measurement of changes in the levels of small molecules in the
ECS can be carried out using microdialysis sampling. Microdialysis has been widely used
as a monitoring technique both clinically [30–32] and experimentally [33–36] for monitor-
ing neurotransmitters and other molecules in interstitial tissue ﬂuid. This technique allows
continuous monitoring of multiple analytes simultaneously in a single sample. Microdialysis
can be coupled with a wide range of analytical techniques for example with chromatog-
raphy [37], mass spectrometry [38], capillary electrophoresis [39] and with electrochemical
sensors [40]. This allows detection of a wide range of molecules with high selectivity and
sensitivity. This method also allows calibrations to be carried out during the monitoring
period, therefore the analyte concentration can be accurately determined. More detail on
microdialysis is given in the following sections.
1.2.2 Microdialysis
Microdialysis is a powerful sampling technique that is capable of continuously monitoring
the ECS both in vivo and in vitro. Microdialysis was ﬁrst introduced by Ungerstedt and
Pycock in 1974 [41] for use in measuring neurotransmitter concentrations within the rat
brain. In 1990, the same group was the ﬁrst to use this technique in the human brain
[42]. Microdialysis has been approved by the Food and Drug Administration for use in
humans and has been used in a range of organs including the myocardium [43], brain [44],
stomach [45], liver [46] and also in tumours [47, 48]. Microdialysis sampling has been used
extensively for monitoring amino acids, neurotransmitters and energy metabolites such as
glucose, lactate and pyruvate in the brain for both fundamental and clinical research studies
from clinical patients primarily with traumatic brain injuries, but also with epilepsy, stroke
and gliomas [11, 49, 50]. Apart from monitoring analytes, the sampling probes have also
been used to deliver drugs or other substances for pharmacokinetic and drug metabolism
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studies in the blood and various tissues of both animals and humans [51,52], and have also
been used to investigate drug distribution to speciﬁc regions [53]. However, there are some
drawbacks of microdialysis. Compared to implanted microsensors, microdialysis provides
information on time scales considerably slower, and it also provides larger tissue damage
area in the surrounding tissue due to the physical dimensions of microdialysis probe (200-500
µm diameter) [18].
Microdialysis Principle
Microdialysis probes typically have an outer diameter in the range of 200 to 500 µm and
a length of 10 mm for human probes and 1-4 mm for animal probes [11]. A microdialysis
probe is designed to mimic a blood capillary, which allows molecular exchange between the
blood capillary and the surrounding tissue. As seen in Figure 1.2, a typical microdialysis
probe is composed of inlet and outlet tubing, which is connected to a shaft that has a length
of semi-permeable hollow ﬁbre membrane at its tip. The membrane is manufactured in a
range of diﬀerent pore sizes, external diameters and lengths, the choice of which is based on
the tissue and the chemical species being investigated. The semi-permeable membrane can
exclude large molecules such as proteins from the dialysate, which might otherwise foul the
sensor.
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Figure 1.2: Schematic of a microdialysis probe. It has a semi-permeable membrane at the tip.
The magnified membrane region shows net diffusion of an analyte of interest (yellow), which diffuses
down its concentration gradient from the ECS into the probe and net diffusion of perfusate (light
blue) from the probe into the ECS.
A microdialysis probe is implanted into the tissue of interest. A physiological solution
(perfusate) containing a mixture of ions chosen to match the composition of the tissue
extracellular ﬂuid, with the exception of the species of interest, is slowly pumped through
the inlet tubing of the probe at a low ﬂow rate of approximately 0.1-5 µl/min [48]. This
allows an exchange of molecules between the physiological solution and the extracellular
ﬂuid. In Figure 1.2 the molecules in the tissue diﬀuse through the ECS to reach the probe.
The semi-permeable membrane of the probe acts as a ﬁlter, allowing only molecules below
its pore size to cross the membrane from the extracellular ﬂuid into the dialysate by passive
diﬀusion. In passive diﬀusion, the direction of analyte ﬂow is driven by the concentration
gradient, from a region of high concentration to a region of low concentration. The dialysate
stream is carried to the outlet tubing for collection and analysis. Analysis of microdialysis
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samples can be divided into two groups, either oﬀ-line or on-line analysis.
Off-line Analysis
Traditional microdialysis is used for collection of discrete dialysate samples into microvials,
which are usually 1-20 µl, for analysis at a later time. It has been found that analyte
recovery in microdialysis depends on perfusion ﬂow rate and that the higher the perfusion
ﬂow rate, the lower the analyte recovery. A long collection period, typically 30-60 minutes
for a ﬂow rate of 1 -2 µl/min, is required to obtain suﬃcient volume per sample for use
with the analysis systems. As a result, oﬀ-line microdialysis has poor temporal resolution.
For analytes at low concentration (such as dopamine), time resolution depends on the mass
sensitivity of the analysis system. In clinical use, where concentrations are typically higher,
time resolution is determined by the availability of staﬀ to change the sample vial. There is
therefore a delay in obtaining information regarding the condition of the tissue, due to the
collection and analysis time. There is also a risk of errors in the sample order as a result
of mis-labelling. Thus, oﬀ-line microdialysis is not suitable for resolving dynamic metabolic
changes. To overcome these limitations, on-line microdialysis has been introduced, in which
the dialysate from the microdialysis probe is directly injected into the analytical device.
On-line Analysis
On-line microdialysis oﬀers a number of advantages over oﬀ-line analysis. The main advan-
tage of an on-line system is that collection, manipulation, injection, and all analysis steps
for a sample can be performed on a device in a continuous process. As a result, prob-
lems associated with the submicrolitre volume of the samples including mislabelling, sample
loss, evaporation, surface tension and sample degradation (samples exposed to air such as
ascorbic acid and catecholamines) are no longer an issue [54]. Small sample volumes can be
manipulated and analysed on-line, allowing further improvement of the temporal resolution.
This can provide near real-time data, which yields immediate feedback on the biological pro-
cesses. Microdialysis sampling together with separation (capillary electrophoresis or chro-
1.3. Biosensors for Continuous on-line Detection 9
matography) and detection can be used to monitor several analytes simultaneously in near
real time [55–57]. However, it is still diﬃcult to track chemical events on the millisecond to
second time scale due to problems of dispersion in the ﬂuidic system.
There are many analytical measurements that can be to coupled to microdialysis for
on-line detection, including liquid chromatography [58,59], capillary electrophoresis [55,60],
mass spectrometry [61] and biosensors [62]. The scope of this review is focused on advances
related to microdialysis coupled with biosensors, which are described in more detail in the
following sections.
1.3 Biosensors for Continuous on-line Detection
Biosensors are analytical devices, which are used for the detection of non-electroactive chem-
icals. They oﬀer speciﬁc detection with high time resolution and play a signiﬁcant role in
clinical monitoring including tissue and brain monitoring [63–65]. Biosensors provide many
unique capabilities compared to other conventional bio-analytical techniques in clinical mon-
itoring, for example, excellent sensitivity, compact size, simplicity of use, rapid analysis, and
absence of radioactivity. A biosensor consists of two main components, a biorecognition el-
ement such as an enzyme or antibody and a transducer such as an electrochemical or an
optical device. The output from the transducer is conditioned in analogue electronics (e.g. I
to V converter) before digitisation and subsequent signal processing to give a concentration
of the analyte as shown in Figure 1.3.
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Figure 1.3: Schematic showing the components of a typical biosensor in an analyte stream.
Selectivity membrane can be coated directly on the electrode surface or the outer layer.
An ideal biosensor is required to continuously and reliably monitor analyte levels in
patient ﬂuids bodily with a fast analysis time. There are several types of biosensors. Many
of them are enzyme-based and use either electrochemical or optical detection. Electrochem-
ical biosensors are widely used for detection of the concentration of an analyte of interest
due to their high sensitivity, easy operation and low cost [66]. Electrochemical biosensors
are typically based on enzymatic catalysis of a reaction. The enzyme recognises and binds
speciﬁcally to its substrate, the chemical species of interest, producing a product that is
electroactive. A constant potential is applied to the working electrode, where the electro-
chemical reaction takes place. Depending on the potential applied, an oxidation or reduction
reaction occurs at the electrode surface leading to electron exchange between the electrode
and the electroactive species. These electrons are detected in term of current by an amper-
ometric transducer. The current that is produced by the oxidation or reduction of these
electroactive species is correlated to the concentration of the analyte of interest.
For continuous monitoring of chemicals in tissue, microdialysis is coupled to electro-
chemical biosensors, which detect changes in the concentration of the analyte. The outlet
tubing of the microdialysis probe is connected to the biosensor system. The dialysate stream
containing the analyte of interest ﬂows past the biosensor, which measures the analyte con-
centration in real time. The resulting currents are correlated to the concentration of the
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analyte of interest. This information is useful for determination of the tissue health.
On-line microdialysis sampling has been successfully coupled to biosensors. This has
been reported for analytes such as ascorbate [67], glucose, lactate [32, 44] and glutamate
[68]. The requirements for an ideal on-line microdialysis biosensor system are to have a
low internal volume, typically 1 µl/min for collecting sample, high mass sensitivity and
speciﬁcity for the analytes of interest in the presence of the other endogenous electroactive
species [69]. In the initial studies, extracellular glucose, lactate and glutamate levels were
monitored in the brain of freely moving rats using ﬂow injection enzyme-packed bed systems
coupled to a microdialysis probe for on-line measurement [68, 70, 71]. In 1993, Korf et al.
introduced microdialysis combined with an enzyme-based continuous ﬂow system for in vivo
monitoring of glucose and lactate in the human brain [72]. Additionally, the Korf group [73]
developed a minimised ﬂow-through nanolitre biosensor system, which was directly coupled
to a microdialysis probe for the detection of glucose and lactate. The study reported that
the minimised ﬂow-through nanolitre biosensor system provided good performance in terms
of selectivity, sensitivity and fast response. The ﬁrst dual glucose/lactate on-line system
using mediated enzyme beds for use with clinical microdialysis in the intensive care unit
and during neurosurgical operations was developed by the Boutelle group [74]. The on-line
assay has allowed simultaneous measurement of glucose and lactate levels in the dialysate
with high time resolution (30 s sampling intervals). Furthermore, Deeba et al. [75] has
used the on-line rapid sampling microdialysis (rsMD) analyser coupled to the outlet of a
microdialysis probe to monitor glucose and lactate changes caused by ischemia occurring in
a segment of the human bowel during and after resection for intestinal ischemia. Similarly,
using rsMD to monitor glucose and lactate levels as a means to detect tissue ischemia
during free ﬂap surgery has been reported by Rogers et al. [40]. Monitoring the metabolic
health of a free ﬂap in real time was achieved by measuring the relative changes in glucose
and lactate. The study is an important example of the relevance of on-line microdialysis
in clinical practice. The results clearly showed dynamic trends, which reﬂected the tissue
health during and after free ﬂap reconstruction surgery.
Microﬂuidics has attracted a great deal of attention for miniaturisation of diagnostic
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devices due to their low analysis volume, short time for analysis, compact size and low
cost [76]. Microﬂuidic devices have been commonly used in chemical analysis and in biolog-
ical studies, for example in cell studies [77–79], in polymerase chain reactions [80–82] and
in diagnosis [83–85]. Continuous on-line microdialysis using microﬂuidic sensors has been
developed by the Boutelle group for investigating of dynamic neurometabolic changes [86].
A glucose biosensor and potassium sensor were placed within the analysis chamber of a
microﬂuidic chip to analyse the sample of dialysate continuously. The system successfully
monitored biochemical changes in the dialysate with high temporal resolution and has po-
tential for the analysis of multiple analytes in real time within the low-volume dialysate
sample.
Recently, segmented ﬂow in a microﬂuidic chip has been studied by using an immiscible
ﬂuid [87, 88]. It oﬀers many advantages for microdialysis users. The Kennedy group [87]
segmented the outﬂow of a microdialysis probe into droplets, which were separated by
ﬂuorinated oil (immiscible ﬂuid). The study was performed using a microﬂuidic chip with
a T-junction, which segmented samples so that they could not mix by ﬂow or by diﬀusion,
leading to an increase in temporal resolution down to a few seconds, without considering
the length of connection tubing required. They reported that the segmented ﬂow method
can improve temporal resolution for in vivo microdialysis. This provides several advantages,
such as faster detection time and reduced sample volume required. In addition, a successful
droplet-based system for enzyme inhibition assay was reported by Sun et al. [89]. The
Boutelle group showed that by careful optimisation of the detection chamber subsecond
resolution of the detector could be obtained [88].
Carbon-based Sensors and Biosensors
Traditionally, biosensors have used noble metals such as gold or platinum, which are chemi-
cally inert and ductile. However, their performance often degrades quickly when exposed to
biological samples due to proteins adsorbing onto the surface, blocking the redox sites.
Over last two decades, advances in nanomaterials for sensors and biosensors has been
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made [90–92]. These nanomaterials include graphene and carbon nanotubes (CNTs). The
biggest argument for using carbon-based materials is that many biomolecules adsorb irre-
versibly on to gold and platinum and these metals have slow electron kinetics.
Graphene consists of a single layer of sp2-hybridised carbon atoms packed tightly
into a two-dimensional honeycomb crystal lattice. This material is the basic component of
other graphitic materials including buckyballs, carbon nanotubes and graphite. As shown in
Figure 1.4, graphene (2D) can be wrapped into a zero-dimensional buckyball, can be rolled
into a one-dimensional carbon nanotube, or can be stacked into three-dimensional graphite.
Figure 1.4: Schematic representation of all graphitic structures. Graphene is a 2D honeycomb
material, which is the basis of carbon materials of all other dimensionalities. It can be wrapped
up into buckyballs, rolled into nanotubes and stacked into graphite. Image taken from Geim et
al. [93].
Graphene was ﬁrst discovered in 2004. In 2010, Andre Geim and Konstantin Novoselov
from the University of Manchester won the Nobel Prize in Physics for groundbreaking ex-
periments regarding the 2D material graphene. Graphene has received a great deal of
attention in several ﬁelds including physics, chemistry, materials and medical sciences due
to its exceptional properties. These properties include its electronic properties, thermal and
electrical conductivity and its mechanical strength [93]. In addition, this material provides
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a high surface areas and good electron transport capabilities. These outstanding physic-
ochemical properties have led to the widespread use of graphene in the development of
many applications such as ﬁeld-eﬀect transistors, transparent conductive ﬁlms, clean energy
devices, sensors and especially biosensors. It has great potential in the ﬁeld of electrochem-
istry [94–96]. For instance, owing to its high surface area, it can enable a higher density of
attached analyte molecules on the electrically conductive graphene. This is an important
requirement and facilitates high sensitivity for sensing strategies. In addition, it provides
rapid electron transfer between the redox species and the graphene sheet [97]. More detail
on graphene is given in Chapter 2.
Carbon nanotubes (CNTs) were discovered by Iijima in 1991 [98] and are one of
the most interesting in materials to be used for electrochemical biosensors and sensors.
CNTs are cylindrical shape and are several nanometres in diameter and micrometres in
length. They are composed of a hexagonal lattice of carbon atoms as shown in Figure 1.4.
CNTs have remarkable mechanical properties, high electronic conductivity and chemical
stability. Additionally, they oﬀer a large surface area, ability for fast electron transfer in
electrochemical reactions and easy enzyme immobilisation, which are signiﬁcant properties
to improve biosensing [99]. In general, CNTs can be classiﬁed into two groups, single-
walled carbon nanotubes (SWCNTs) and multi-walled nanotubes (MWCNTs). SWCNTs
comprise tens to hundreds of parallel tubes in contact with each other, whereas MWCNTs
are composed of several layers of concentric graphitic cylinders like the rings of a tree
trunk. There have been a number of studies on the construction of enzyme-based electrodes
modiﬁed with CNTs. The studies showed their promising in promoting electron transport
for sensor applications.
Jo et al. [100] developed platinum electrodes modiﬁed with SWCNTs and phytic acid to
detect dopamine electrochemically. The results showed that the modiﬁed electrode could en-
hance the electrochemical properties in terms of the sensitivity and selectivity without the in-
terference of ascorbic acid and uric acid. In addition, the Macpherson group [101] developed
a microﬂuidic ﬂow cell with a network of SWCNT-covered band electrodes for dopamine
detection under ﬂow conditions. They found that the devices showed good performance
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with low background currents and also that they could be used repeatly for many months.
Recently, cisplatin detection in vitro using functionalised MWCNT-modiﬁed screen-printed
electrodes has been reported by Materon et al. [102]. In this study, the MWCNTs, which
had been modiﬁed by the anionic surfactant sodium dodecyl sulphate, showed highly speci-
ﬁcity to cisplatin in human serum. The quantiﬁcation of cisplatin was analogous to the
result obtained by high-performance liquid chromatography. In this thesis, MWCNTs were
used as a sensor to detect carboplatin (anti-cancer drug). More detail is given in Chapter
6.
1.4 Outline of Thesis
This thesis describes novel carbon-based sensors and biosensors for on-line monitoring of
patients in vivo. Diﬀerent types of carbon-based electrode were investigated their perfor-
mances for real-time use in three main biomedical applications. In Chapter 4 and 5, graphene
oxide and reduced graphene oxide were used as a supporting material to modify combined
needle microelectrodes for glucose biosensor and dopamine sensor fabrication, respectively.
Multiwalled carbon nanotube-epoxy composite electrodes were used for drug detection as
shown in Chapter 6 and 7.
Chapter 2 describes the chemical synthesis of graphene oxide and reduced graphene
oxide. The characterisation of synthesised graphene oxide and reduced graphene oxide using
diﬀerent techniques is also described. The performance of the synthesised graphene oxide
and reduced graphene oxide for biosensors and sensors is investigated in Chapters 4 and 5.
Chapter 3 describes common methods and materials used in this thesis. Fabrication
of combined needle electrodes for use in Chapters 4 and 5 and of carbon nanotube-epoxy
composite electrodes for use in Chapters 6 and 7 is also described. Additionally, fabrication
of PDMS-based microﬂuidic chips and setting up of the LabSmith autocalibration board is
described in this chapter.
In Chapter 4, the development of a novel electrochemical biosensor using graphene ox-
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ide as a supporting material is described. The performance of glucose and lactate biosensors
is discussed. Finally, in a proof-of-concept experiment, the graphene-based glucose biosen-
sor was used in a microﬂuidic platform coupled with a microdialysis probe to demonstrate
its potential for in vivo monitoring.
Chapter 5 describes the use of reduced graphene oxide to modify a combined needle
electrode for electrochemical detection of dopamine. The stability of these sensors was
compared with that of a bare platinum (Pt) sensor using cyclic voltammometry. Interference
of ascorbic acid at these electrodes was also investigated and compared with a bare Pt
electrode.
In chapters 6 and 7, a system to detect a platinum-based anti-cancer drug (carboplatin)
is developed. Chapter 6 describes preliminary experiments using diﬀerent types of electrode
to detect the oxidation peak of free purine bases using diﬀerential pulse voltammetry. At the
end of the chapter, the detection of carboplatin is demonstrated in a beaker. In Chapter 7,
a microﬂuidic platform for carboplatin detection is developed using LabSmith components.
The optimisation of parameters for carboplatin detection is described. Finally, a proof-
of-concept study is shown in which the microﬂuidic device incorporating the carbon-based
sensor is connected to the outlet of a microdialysis probe for detection of carboplatin in the
dialysate stream. Chapter 8 concludes the thesis and describes possible future work.
Chapter 2
Graphene Synthesis
In this chapter, the three common methods of graphene synthesis are described as well as
the beneﬁt of using graphene oxide for electrochemical biosensors. The chemical synthesis
of graphene oxide and reduced graphene oxide, which were conducted in this study will
be described. At the end of this chapter I will describe the characterisation of synthesised
graphene oxide and reduced graphene oxide using diﬀerent techniques, namely Fourier trans-
form infrared spectroscopy, scanning electron microscopy and atomic force microscopy. The
electrochemical characterisation of the materials is reported in Chapter 4.
2.1 Graphene Synthesis Method
Graphene is an allotrope of carbon with a planar of sp2 structure; it consists of a single layer
of carbon atoms arranged into a two-dimensional honeycomb crystal lattice. Graphene has
obtained a lot of attention in a variety of ﬁelds including physics, chemistry, materials
and medical science due to its exceptional properties as mentioned earlier in Chapter 1.
Generally, there are three main methods of graphene production, which are mechanical
exfoliation of high-quality graphite using adhesive tape, chemical vapour deposition (CVD)
and reduction of graphite oxide. Each method of making graphene has its limitations and
these methods will brieﬂy be explained.
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Firstly, the method of mechanical exfoliation of graphite was discovered in 2004 by
Andre Geim’s group at the University of Manchester. It is also known as scotch tape or
peel-oﬀ method. In this procedure, adhesive tape is employed to peel oﬀ layers of high-
quality graphite such as highly ordered pyrolytic graphite (HOPG) by multiple exfoliation
steps until only one-layer remains, which is then transferred to a silicon substrate [103].
This method is simple, produces the best quality and least modiﬁed form of graphene and
keeps its unique properties. However, it requires a lot of patience to fabricate high-quality
graphene and it results in production of only a small volume, which contains an uncertain
number of layers [104].
In the case of CVD method, graphene is produced by passing hydrocarbon vapour
over metallic substrates, such as nickel and copper, and then heating them to about 1000℃.
Although this CVD approach is less suitable for maintaining the conventional properties
of graphene than the ﬁrst method it can produce macroscale areas of graphene. Graphene
ﬁlm, which has been fabricated using this method can be transferred to other substrates
after the metallic support has been dissolved [105]. However, controlling of the number of
graphene layers is still a key challenge.
Finally, reduction of graphite oxide is the most popular method for production of
graphene, particularly for electrochemical applications [95]. This method uses oxidation to
convert graphite into graphite oxide under strongly acidic conditions, which results in the
creation of a number of oxygen-containing functional groups, for example, carboxyl, epoxide
and hydroxyl groups on its surface [106]. The graphite oxide is then exfoliated into graphene
oxide (GO) using an ultrasonicator as seen in Figure 2.1. These oxygen functional groups
provide GO with hydrophilic properties, which allows it to be dispersed in water or polar
organic solvents. In addition, this approach can also enable mass production of graphene.
However, GO produced in this way is an electrical insulator due to these functional groups,
which change its structure due to the large proportion of sp3 hybridised C-O bonds. This
leads to loss of its unique properties.
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Graphite powder                                     Graphite oxide                                        Graphene oxide
    
Ultrasonication
Oxidation by
strong acids
Figure 2.1: Schematic of GO synthesis adapted from Fu et al. [107].
To regain its structure and its unique properties, especially its conductivity, GO is
reduced either using chemical reducing agents or by thermal annealing treatment at 900℃.
This method was chosen to be used for graphene production in this study. Synthesis of
graphene and reduced graphene using this approach will be described more detail in section
2.4. All three current graphene synthesis methods are summarised in Table 2.1.
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Table 2.1: Summary of graphene synthesis methods
Synthesis Method Brief Description/ Remarks
Mechanical - Using adhesive tape to peel oﬀ graphene from HOPG
exfoliation - Simple method, requires a lot of patience
- High quality graphene (ﬂakes 5-10 µm)
- Small-scale production
CVD growth graphene - Using transition metal substrate (e.g. Ni, Cu) as catalyst
and ﬂowing carbon source (CH4) and reactant gases (H2) at
∼ 1000℃ for the nucleation of graphene
- Moderate scalability
- High cost
- High quality with thin graphene ﬁlms (≤ 75 cm)
- Applications in touch screens, and solar cells
Chemical reduction of
graphite oxide
- Converting graphite into graphite oxide under strong acidic
conditions, creating oxygen functional groups and mechani-
cally exfoliating into GO
- GO reduced to graphene by chemical reducing agents or by
thermal annealing treatment
- Low purity
- Low cost
- High scalability with nanoﬂake/powder (nm to a few µm)
- Applications in conductive inks, battery electrodes, super-
capacitors, biosensors and sensors
GO, the product of this chemical method, is of great interest in enzyme-based biosen-
sors. This will be discussed in more detail in the next section.
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2.2 Graphene Oxide in Electrochemical Biosensors
GO has already shown promise in graphene-based electrochemical applications. GO is a
single layer of graphite oxide with a large proportion of sp3 hybridised C-O bonds. In its
structure, GO is considered as containing a graphene sheet decorated with various oxygen
functional groups on the both basal planes and edges. The oxygen-containing functional
groups of GO include hydroxyl (-OH) and epoxy (C-O-C) groups on the basal plane and
small amounts of carboxyl (COOH) and carbonyl (C=O) at the edge of the sheets [97].
Two modelling GO structures [108] are currently considered by the literature, which are the
Lerf-Klinowski (Figure 2.2a) and the Dekany structure (Figure 2.2b).
(a)                                                                                                                        (b)
Figure 2.2: Chemical structure of GO containing oxygen functional groups. (a) Lerf-Klinowski
model and (b) DeKany model [108].
There are several approaches for the preparation and functionalisation of GO. One
of the most common approaches to synthesise graphene oxide is the oxidation of graphite
with strong oxidising agents such as sulfuric acid (H2SO4) and sodium nitrate (NaNO3), and
potassium permanganese (KMnO4). This process is followed by dispersion and exfoliation
in water or organic solvents by ultrasonication [109, 110]. As a result of this process, many
oxygen functional groups are generated on the graphene sheets.
These oxygen functional groups, particularly those on the basal plane of GO result in
a loss of electrical conductivity. This depends on the amount of structural disorder caused
by the existence of a substantial amount of sp3-carbons which is correlated to the intrin-
sic insulating nature of graphene oxide [97]. The presence of structural disorder causes
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corresponding electron transport barriers leading to disruption of electron percolation path-
ways among the sp2-carbon bonding network, which allow classical carrier transport to oc-
cur [111]. These eﬀects lead to chemically synthesised GO being an insulator that exhibits
high resistance values.
Much research has been reported to attempt to recover the electrical conductivity in-
cluding various methods of removal of oxygen functional groups on GO sheets using chemical
and thermal treatments [112, 113]. For example, an electrochemical method has been used
to reduce the oxygen functional groups on GO. The electrochemical reduction process can be
performed by cyclic voltammetry (CV), linear sweep voltammetry (LSV), diﬀerential pulse
voltammetry (DPV), or by application of a constant potential [112, 113]. This approach
provides many advantages for the production of quality graphene materials as it is easy,
fast, scalable, cheap and environmentally friendly. Ambrosi et al. [114] and Stankovich et
al. [115] reported using hydrazine hydrate as a reducing agent to chemically reduce these
oxygen functional groups by adding the agent into GO solution. The reaction solution was
heated to 100℃ until precipitation of the reduced graphene oxide (rGO) occured [114,115].
Additionally, thermal annealing at high temperature has been used to produce rGO. For
instance, Xu’s group demonstrated thermally reducing GO sheets in a simple horizontal
tube furnace by passing nitrogen gas at temperatures from 200 to 900℃ [116]. Wei and
coworkers used the hydrothermal method to prepare rGO by maintaining it at 180℃ for 12
hours [117]. However, although both chemically and thermally reducing GO can decrease
its resistance, the properties of the product obtained from both methods are diﬀerent from
pristine graphene. This leads to transformation of GO into a semiconductor. Nevertheless,
the presence of oxygen functional groups in GO can provide potential advantages for use
GO in biosensors. The important properties of GO in electrochemical biosensors are given
below.
The oxygen functional groups of GO make it strongly hydrophilic making it easy to
dissolve in a range of polar solvents such as water, N-methyl-2-pyrrolidone, dimethylfor-
mamide, and tetrahydrofuran. This is a useful property for processing and further deriva-
tion. In addition, stable dispersion of GO can be deposited onto a substrate to fabricate a
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thin conductive ﬁlm supported by the underlying substrate. Methods include drop-casting,
spraying, and spin-coating [97].
Biomolecule Immobilisation
GO has a large speciﬁc surface area and abundant oxygen functional groups such as hydroxyl,
epoxy, and especially carboxyl groups, with well-established coupling chemistry. This makes
GO an ideal material for biomolecule immobilisation as it provides high-loading densities.
The reason for this is that these oxygen functional groups on its surface have the capability
of coupling with biomolecules and can be used to immobilise various biomolecules through
either chemical bonds by chemical modiﬁcation of GO, or physical adsorption. This is useful
for the design of sensitive electrochemical biosensors. In the case of physical adsorption and
entrapment by incubation of the biomolecules with GO solution, the interaction between
the biomolecules and the GO sheets includes electrostatic, hydrogen bonding, and π − π
stacking interactions. According to Zhang et al. [118], GO was used as a matrix for enzyme
immobilisation without using any cross-linking reagents or additional surface modiﬁcation
and characterised using AFM to investigate the biomolecules on the GO sheets and their
catalytic activity. In this study, they found that horseradish peroxidase (HRP) and lysozyme
can be spontaneously immobilised on GO sheets through incubation with the enzymes. In
addition, they compared the loading diﬀerence between HRP (positively charged, isoelectric
point (pI) = 7.2) and lysozyme (positively charge, pI = 10.3) on the GO sheets (negatively
charged) through electrostatic interaction in aqueous solution (pH 7.4). It was reported
that the amount of lysozyme loading (700 µg/mg of GO) was 7 times higher than the HRP
loading (lower positive charge) and that loadings of both enzymes were much higher than
on many other reported materials owing to the strong electrostatic interaction of GO sheets
with the enzymes and also to the contribution of hydrogen bonding [118]. However, it
suggests that this method is not suitable for enzymes that are negatively charged at pH 7,
for example glucose oxidase, which has an isoelectric point of 4.2 [119].
In addition, biomolecule immobilisation by covalent attachment has been frequently
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studied. Generally, coupling agents such as carbodiimides have been used to covalently
attach the amine group of the biomolecules with the carboxylic acid groups on GO. For ex-
ample, Wan and coworkers [120] developed an electrochemical biosensor combined with
GO sheet and silver particles for bacterial detection. The amine groups of antibodies
were bound covalently to the carboxylic acid groups on the GO sheets via 1-ethyl-3-(3-
dimethylaminoprophy) carbondiimide hydrochloride (EDC) and N-hydroxysuccinimide (NHS)
coupling [120]. Similarly, Liu et al. [121] fabricated GO-based glucose biosensors using co-
valent attachment via EDC/NHS coupling of the amine group of glucose oxidase (GOx)
to the carboxylic acid groups on the GO [121]. They reported excellent performance of
the GO-GOx biosensors including a broad linear range up to 22 mM, which is higher than
the requirement for practical use in blood glucose detection (15 mM), and a high sensitiv-
ity of 8.045 µA·mM−1·cm−2. In addition, it exhibited good reproducibility (5.8% relative
standard deviation (RSD)), and good storage stability for one month in phosphate buﬀered
saline at 4℃ with a 20% decrease in sensitivity. Some studies have been reported the co-
valent immobilisation of biomolecules on GO using electrochemical methods without any
cross-linking agents or modiﬁers in the procedure [113, 122]. For instance, Unnikrishnan et
al. [113] demonstrated a simple electrochemical approach to fabricate GOx-rGO in a single
step in a short time. In this study, they dropped GO-GOx biocomposite on a glassy carbon
electrode and employed cyclic voltammetry to reduce the oxygen functional groups on the
GO-GOx biosensor. Their results showed good performances with a wide linear range from
0.1-27 mM, sensitivity of 1.85 µA·mM−1·cm−2 and excellent reproducibility (3.58% RSD)
and storage stability with the biosensor retaining 81% of its initial response after 50 days.
Comparing the GO-GOx biosensor results in the two studies above, both methods
reveal that covalently linked GO-GOx biosensors provided a wide linear range, good re-
producibility and stability. However, the sensitivity resulting from using coupling agents
was almost 4 times higher than that for the biosensor fabricated without coupling agents,
although this latter method can be carried out within shorter times than the former.
In summary, GO production by oxidation of graphite oﬀers a method that is easily
accessible, low cost, and large scale. In this study both GO and rGO were synthesised by
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chemical oxidation of graphite. The materials and procedure for graphene synthesis will be
described in the following section. Both GO and rGO have useful properties in their own
right. Therefore, both carbon materials were investigated as potential supporting materials
for biosensor and sensor fabrication. This is described in Chapter 4 and 5 respectively.
2.3 Materials and Reagents
In this thesis, all chemical reagents were an analytical, AnalaR grade, or better. Deionised
water (DI) used in this thesis was from SELECT FUSION water puriﬁcation system (PU-
RITE Ltd, UK), reverse osmosis and ﬁnal polishing stage of typically 18.2 MΩ.cm. All
glassware (grade A) was cleaned using a dishwasher (Miele Professional, USA) to remove
organic and inorganic residues.
Graphite powder (synthetic, conducting grade -325 mesh, 99.9995% metals basis) was
purchased from Alfa Aesar. Potassium permanganese (ACS reagent, >99% KMnO4) and
hydrogen peroxide (AnalaR, 30 wt% H2O2) were obtained from Fisher and VWR com-
pany, respectively. Sodium nitrate (ACS reagent, >99.9% NaNO3), hydrochloric acid (ACS
reagent, 37 wt% HCl), sulfuric acid (ACS reagent, >95% H2SO4) and hydrazine hydrate
(reagent grade 60% N2H4) were obtained from Sigma-Aldrich.
For reduction of the oxygen functional groups from synthesised GO using thermally
annealing method, an alumina boat crucible (69mm × 24mm with tail and hole) was
obtained from Almath crucubles Ltd. A quartz tube (50mmOD× 42mm ID× 1200mm
length) with ends cut square and ﬂame polished was purchased from Cambridge glassblowing
Ltd.
2.4 Preparation of Graphene Oxide
The GO used in this study was synthesised using chemical oxidation of graphite according
to the modiﬁed Hummer’s method [123] which has been a popular and extensively used
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method to achieve eﬃcient GO synthesis with a number of oxygen functional groups [107,
110,120,121]. In this study, graphite powder was used as a precursor. The graphite powder
was converted into graphite oxide under strong acidic conditions, and then exfoliated into
GO using an ultrasonicator as shown in Figure 2.1. In detail, 2 g graphite powder (synthetic,
conducting grade -325 mesh) was dispersed in 46 ml H2SO4 (95%) under agitation. 1.2 g of
NaNO3 and 6 g KMnO4 were added slowly into the mixture in an ice bath for 2 hours and
the reaction was allowed to reach room temperature. After the mixture cooled down, it was
heated to 35℃ in a water bath for 30 minutes. 92 ml DI water was added gradually into the
heated mixture. The temperature was increased to 98℃, and the reaction was maintained
for 40 minutes. Following this, the volume of the resultant suspension was adjusted to 280
ml with DI water. To remove unreacted KMnO4 and manganese dioxide (MnO2), 30 wt%
H2O2 was added slowly until gas evolution stopped. As a result, the colour of the suspension
changed from dark brown to bright-yellow. The warm oxidised graphite solution was ﬁltered
through 0.1 µm membrane under a vacuum. In the washing process, the ﬁltered graphite
oxide was centrifuged and washed with 5 wt% HCl and followed by DI water repeatedly
until its pH is neutral. The synthesised graphite oxide was dried at 50℃ overnight and was
then ground to become a powder. In order to produce GO, the brownish graphite oxide
powder was dissolved in DI water and exfoliated using an ultrasonicator (model UCS200TH
Ultrasonic Bath, VWR), for 3 hours before use. The GO obtained was characterised using
diﬀerent range of techniques to conﬁrm that the GO synthesis had been successful.
Reduced Graphene Oxide Synthesis
To recover its electrical conductivity, some oxygen functional groups need to be eliminated
from the carbon aromatic surface of the GO. There are two means to reduce the oxygen-
containing functional groups, either by a chemical or by a thermal method. In this research,
the removal of oxygen functional groups on GO sheets was demonstrated both chemically
using a reducing agent (hydrazine hydrate) and thermally by annealing treatment.
In the chemical reduction method, 1 mg/ml graphite oxide in DI water was sonicated
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for 3 hours to obtain a GO solution. 20 ml of this solution was stirred in a water bath and
heated to 47℃. 6 µl hydrazine hydrate was added gradually to the GO solution under stirred
conditions. After adding the hydrazine hydrate, the colour of the suspension changed from
bright-yellow to black. The reaction mixture was heated to 100℃ for 24 hours in the water
bath. The rGO was seen as dark particles that precipitated out from the water. Finally,
the chemically rGO was dried in an oven at 60℃ overnight.
In the case of the thermal annealing method, rGO was obtained by heating GO under
hydrogen at 900℃ [124]. Graphite oxide was exfoliated in water by ultrasonication, and
the suspension was ﬁltered and dried at 60℃ overnight. The obtained GO was placed in an
alumina boat crucible and placed inside a vacuum-tight quartz glass tube furnace within
a controlled atmosphere. The sample was then ﬂushed with hydrogen gas by repeated
evacuation of the tube furnace to remove any traces of oxygen. The temperature in the
furnace was increased at 10℃/hour until it reached 900℃. The temperature was held at
this point for 30 minutes before being allowed to cool down to room temperature.
The above procedure is summarised in Figure 2.3. Both synthesised GO and rGO
were characterised and the results are shown in the following sections.
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Figure 2.3: Schematic procedure of GO and rGO synthesis.
2.5 Characterisation of Graphene
Fourier transform infrared (FTIR) spectroscopy, scanning electron microscopy (SEM), and
atomic force microscopy (AFM) were employed to examine the chemical structures of the
synthesised carbon materials, their surface characteristics, and the thickness of the graphene
sheets, respectively. The principle of these techniques and the results are reported in the
following sections.
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2.5.1 Fourier Transform Infrared (FTIR) Spectroscopy
FTIR spectroscopy is a powerful tool, which is widely used to determine the structure of
molecules in various applications, particularly in organic chemistry. FTIR analysis is com-
monly used for identifying materials such as organic chemicals and inorganics compounds
and is capable of analysing gas, liquid and solid samples. When sample molecules are ex-
posed to infrared radiation, they selectively absorb radiation of speciﬁc wavelengths. This
results in a change of dipole moment in the sample molecules leading to a change in the
vibrational energy levels from the ground state to an excited state. The vibrational energy
gap determines the frequency of the absorption peak. The number of absorption peaks
indicates the diﬀerent functional groups which are diﬀerent in vibrational freedom of each
molecule. The intensity of the absorption peaks is aﬀected by the change of dipole moment
and the possibility for the transition between energy levels. Therefore, the absorption spec-
trum for the bond natural vibration frequencies indicates the presence of various chemical
bonds and functional groups existing in the sample.
Generally, FTIR spectroscopy is composed of a source, an interferometer, a sample
compartment, a detector, an ampliﬁer, an analogue-to-digital converter, and a computer.
The principle of this instrument is shown in Figure 2.4, the source generates radiation,
which travels to the sample through the interferometer before reaching the detector. The
signal is then ampliﬁed and converted into a digital signal by the ampliﬁer and the analogue-
to-digital converter, respectively. Finally, the signal is transferred to a computer in which
a Fourier transform is carried out. Most molecules are infrared active except for several
homonuclear diatomic molecules such as O2, N2 and Cl2 due to the zero dipole change in
the vibration and rotation of these molecules. Typically, the wavenumber is measured in
the range 400-4000 cm−1, which is the common region for the absorption of radiation for
most organic and inorganic compounds.
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Figure 2.4: Schematic of a FTIR spectrometer.
In this study, FTIR spectra analysis was conducted to investigate the structures and
the oxygen functional group content of graphite powder, GO and rGO. These samples
were prepared as powders and examined using a FTIR spectrometer (Nicolet iS10 module,
Thermo Scientiﬁc) and analysed using OMNIC software.
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-OH
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Figure 2.5: FTIR spectra of graphite, rGO, and GO. The spectrum shows peaks for GO represent-
ing the O-H stretching vibration observed at 3400 cm−1, C=O at 1720 cm−1, and C-O stretching
vibration observed at 1060 cm−1. In the spectrum of rGO, these peaks are absent.
As shown in Figure 2.5, the GO spectrum (red) displays a broad band at 3400 cm−1 due
to the hydroxy group (-OH) stretching vibration, a peak at 1720 cm−1 due to the stretching
vibration of carboxylate (C=O), the peak at 1621 cm−1 is low for C=O group and has been
attributed to sp2 bonding between carbon atoms [125], a peak at 1220 cm−1 due to the epoxy
group (C-O) stretching vibration , and a peak at 1043 cm−1 due to the alkoxy (C-O). This
result agrees with the FTIR spectrum of modiﬁed Hummer method-synthesised graphene
oxide obtained by Song et al. [110] and Babak et al. [126]. In comparison with the spectrum
of graphite (black) the results conﬁrmed that the graphite powder had been oxidised into
GO. When synthesised GO was processed further in order to reduce the oxygen functional
groups on its surface by both chemical and thermal reduction methods, the peaks of these
oxygen functional groups disappeared from its spectrum as seen in the rGO spectrum (blue),
which is similar to graphite spectrum. This can also conﬁrm the successful reduction of GO
process.
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2.5.2 Scanning Electron Microscopy (SEM)
Scanning electron microscopy (SEM) is a potential tool for investigating the surface of
materials in the range of nanometers. This technique produces images of a specimen by
scanning it with a focused beam of electrons. The electrons interact with atoms in the
specimen. SEM is composed of an electron source, which produces an electron beam that
hits the surface of the specimen and scans it rapidly. This causes the release of scattered
electrons, which are called secondary electrons, and other types of radiations from the
specimen surface. The secondary electrons are collected by a detector and are converted
into electronic signals leading to the production of a SEM image. The intensity of these
secondary electrons depends upon the shape and the chemical composition of the specimen’s
surface resulting in diﬀerent topography.
Figure 2.6: Schematic of a scanning electron microscope.
In this study, the morphology of graphene synthesised chemically by the modiﬁed
Hummer method was examined using a scanning electron microscopy (JEOL JSM-6010 LA
with 0.5-35 kV). To prepare the sample, the synthesised graphene was dissolved in DI water
and dropped onto silicon wafers. The samples were heated at 70℃ to evaporate the solvent
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and were mounted on a circular metallic sample holder. As the electron beam is incident
on the specimen in SEM analysis it is essential that the samples are electrically conductive.
This was achieved by sputtering the graphene samples with 20-50 nm thick gold to ensure
the graphene was suﬃciently conductive for observation of its surface using SEM.
Figure 2.7: SEM image showing the morphology of chemically synthesised GO.
The SEM image was used to characterise the surface of the graphene that had been
synthesised chemically by the modiﬁed Hummer method. As shown in the Figure 2.7,
chemically synthesised GO has a rigid stack/plate-like morphology with a crumpled and
rippled structure on its surface. The size of the synthesised GO plate was approximately
1-3 µm. The morphology of GO agrees with the results obtained by Zhang et al. [127],
and Fu et al. [128]. However, the number of layers of fabricated GO showing stack-like
morphology will be veriﬁed using atomic force microscopy (AFM).
2.5.3 Atomic Force Microscopy (AFM)
AFM is a versatile and powerful technique which is widely used to characterise carbon
materials on the nanometer scale. It is capable of measuring the roughness of a sample
surface at high resolution or of distinguishing a sample based on its mechanical properties,
for example, its hardness and roughness. This technique provides surface topography in
three dimensions and also allows measurement of various types of surface samples, both stiﬀ
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and soft. AFM is commonly employed to investigate the thickness of graphene or few layers
of graphene sheets.
In AFM a ﬂexible cantilever with a sharp tip is used to scan over a sample surface.
When the tip approaches the surface interaction between the tip and the surface occurs and
causing the cantilever to be deﬂected towards the surface. The cantilever bends vertically
upwards and downwards due to the repulsive or attractive forces of the interaction, respec-
tively. An incident laser beam is reﬂected oﬀ the back surface of the cantilever onto the
position-sensitive photodiode detector. The detector then monitors the change in direction
of the reﬂected beam with great sensitivity due to the optical lever and hence generates an
accurate topographic map of the surface features.
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Figure 2.8: Schematic of AFM using laser beam deflection detection.
In this thesis, an atomic force microscope (Bruker Dimension 3100) was used to in-
vestigate the thickness of GO. The sample was prepared by dissolving the synthesised GO
in DI water at 1 mg/ml concentration. The GO solution was then dropped onto a glass
slide and baked at 70℃ in order to allow it to dry before investigation its thickness. The
prepared specimen was placed on the sample stage of the microscope in a vacuum system.
The sample was scanned in close contact (tapping) mode. The roughness and thickness of
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all samples was investigated at the size of 1 µm × 1 µm by NanoScope Analysis software.
(a)
scan length / nm
height / nm
125 nm
3nm
(b)
Figure 2.9: Tapping mode AFM image of GO on a glass slide (a) 3D AFM image in the size of 1
µm × 1 µm. (b) profile shows the thickness of GO, which is approximately 1-4 nm.
As shown in Figure 2.9a, the 3D image (a) shows the roughness of the GO surface.
Figure 2.9b shows the height proﬁle section analysis and therefore the thickness of the
sample. The blue and red traces indicate the GO thickness at the position of the two white
lines with blue and red crosses shown in the image on the left, which were dragged across
the particles. For example, in the red trace the width and the height of the particle is
around 125 nm and 3 nm, respectively. The AFM images revealed the thickness of the
GO synthesised by the modiﬁed Hummer method to be approximately 1-4 nm, which is
larger than the 0.8 nm thickness measured for a single layer of graphene by Novoselov and
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Geim [103]. This suggests that the fabricated GO comprises a few layers of graphene (1-4
layers). This agrees with the AFM results of GO synthesised by the modiﬁed Hummer
method, which were obtained by Wu et al. [129]. However, the thickness measurement also
indicated that GO consisting of a few layers had been synthesised.
2.6 Conclusion
The synthesis of GO and rGO, prepared by the modiﬁed Hummer method, was successful.
This is proven by using diﬀerent characterisation techniques including FTIR, SEM, and
AFM. The FTIR results showed that the synthesised GO contained oxygen functional groups
on its surface. When the process of oxygen functional group reduction was conducted, the
functional group absorption peaks disappeared indicating that the rGO had been achieved.
Additionally, the SEM image shows the physical surface of GO and the size of the plates
were about 1-3 µm. AFM images showed that the thickness of the GO was approximately
1-4 nm. These results conﬁrm the successful synthesis of GO and rGO.
Chapter 3
Methods and Materials
In this chapter, I will describe the common methods used in this thesis, namely electro-
analytical chemistry methods, fabrication of working electrodes, soft lithography used to
fabricate a microﬂuidic device, and a Labsmith automated calibration system. Materials
and reagents are also described at the end of this chapter.
3.1 Electroanalytical Chemistry
Dynamic electrochemical methods are sensitive analytical techniques for measuring the con-
centration of analytes that can be either oxidised or reduced. Typically, electrochemical
sensors are operated in a potentiostatic mode where the potential of the detector elec-
trode is controlled and the resulting ﬂow of current, due to the oxidation or reduction of
the analyte, is measured. The conﬁguration of an electrochemical sensor is a three-electrode
system, which consists of a working electrode (WE), a reference electrode (RE), and an aux-
iliary electrode (AE). These electrodes are connected to two operational ampliﬁers (OPA)
as shown in Figure 3.1.
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Figure 3.1: Schematic of a three-electrode system circuit, which is connected to two operation
amplifiers (OPA1 and OPA2)
OPA1 eﬀectively biases the RE potential to a value, -Vw. OPA2 holds the WE at local
ground, current due to the oxidation/reduction process taking place at the WE surface, iw,
is forced through a gain resistor (R) to give an output voltage at OPA2 of Vout= iw R.
The purpose of OPA1 is to ensure that this iw passes through the AE rather than the RE.
This is important as passing signiﬁcant current through the RE would change its potential
or damage it. A range of potentials is applied between the WE and the RE. The current
is measured against the applied potential diﬀerence between the WE and the AE. The
oxidation and reduction processes occur on the WE surface. Throughout this thesis, a
three-electrode cell was employed to study electrode and biosensor characterisation.
3.1.1 Cyclic Voltammetry
Cyclic voltammetry (CV) is a voltammetric technique, which is widely used for character-
isation of an electrochemically active species that can be either oxidised or reduced. This
technique is a simple, rapid and powerful method. In CV, the potential of the WE is ap-
plied linearly versus time in a triangular waveform between two potential values E1 and E2.
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When the potential reaches E2, the WE potential is swept in the opposite direction back to
E1 as shown in Figure 3.2. This process can be repeated over multiple cycles.
Figure 3.2: Cyclic voltammetry applied staircase waveform as a function of time.
A resulting cyclic voltammogram (CVgram) which shows the current response as a
function of the applied potential is illustrated in Figure 3.3. The CV can provide qualitative
information such as electron transfer kinetics, the oxidation state stability, and the reversibil-
ity of the reaction. Moreover, this technique is used to obtain quantitative information such
as the surface area and the geometry of the WE.
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Figure 3.3: CVgrams of (a) carbon nanotubes-epoxy composite macroelectrode in 1 mM potassi-
ium ferrocyanide (b) platinum microelectrode (50 µm in diameter) in 1.5 mM ferrocene monocar-
boxylic acid at a scan rate of 10 mV/s, Ag|AgCl was used as a RE.
Figure 3.3a illustrates an example of a typical CVgram at a macroelectrode, which was
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obtained by scanning from -0.3 V to 0.6 V in 1 mM potassium ferrocyanide at 10 mV/s scan
rate. The peak current for a reversible couple (at 25℃) depends on the diﬀusion coeﬃcient,
the bulk concentration of the redox solution, the electrode area, the number of electrons
transferred in the redox reaction, and the scan rate, which is given by the Randles-Sevcik
equation:
Ip = (2.69× 10
5)n3/2ACD1/2v1/2 (3.1)
where Ip is the peak current, n is the number of electrons transferred in the redox reaction,
A is the electrode surface area, C is the bulk concentration of the electroactive species, D
is the diﬀusion coeﬃcient, and v is the scan rate.
The ratio of the anodic peak current (Ipa) and the cathodic peak current (Ipc) is unity
for a simple reversible couple as shown in equation 3.2 below.
|
Ipa
Ipc
| = 1 (3.2)
The ratio can be strongly aﬀected by chemical reactions coupled to the redox process.
The position of both the peaks on the potential axis is related to the formal potential of
the redox reaction. The formal potential for a reversible couple is calculated by the anodic
peak potential (Epa) and the cathodic peak potential (Epc) as given by equation 3.3.
E° =
Epa + Epc
2
(3.3)
When the electrode process is reversible, the separation between the peak potentials for a
reversible couple is given in equation 3.4.
∆Ep = Epa −Epc =
59mV
n
(3.4)
However, for a microelectrode the CV shape is diﬀerent from case of a macroelectrode
and the peak current is not observed, as shown in Figure 3.3b. This is because the diﬀusion
layer of a macroelectrode is small compared with the size of the electrode surface, whereas
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a microelectrode has smaller dimensions resulting in edge eﬀects dominating, causing the
diﬀusion ﬁeld to become hemispherical and to exceed the electrode dimensions, as detailed in
section 3.2). This leads to enhanced ﬂux to the microelectrode under steady-state conditions.
For a microdisc electrode, the steady-state current, Iss, is given by equation 3.5.
Iss = 4nFDCr (3.5)
where Iss is the steady-state limiting current (A), n is the number of electrons transferred
in the reaction, F is Faraday’s constant (96485 C/mol), D is the diﬀusion coeﬃcient (m2/s)
(5.73x10−10 m2/s in case of ferrocene monocarboxylic acid [130]), C is the concentration of
analyte in bulk solution (moles/10−3m3), and r is the radius of the electrode surface (m).
To investigate the surface area of the electrode and its geometry prior to biosensor
fabrication, standard redox couples such as ferrocene monocarboxylic acid (Fc) and potas-
sium ferrocyanide (Fe(CN)4−6 ) were used. In this thesis, CV was carried out using Echem
software (eDAQ, UK) in a three-electrode system.
The CVgram shown in Figure 3.3b was obtained using a disc platinum electrode of
diameter 50 µm, which was performed in a solution of 1.5 mM Fc (see section 3.9) in the
potential range of -0.1 V to 0.5 V at a scan rate of 10 mV/s. The oxidation of Fc to Fc+
occurs when the potential is swept in a positive direction, and the reduction of Fc+ to Fc
occurs when the potential is swept back in a negative direction. The CVgram was obtained
by plotting the relationship between the current and the applied voltage. The plateau
current (8.2 ± 0.1 nA) agrees well with the value predicted using equation 3.5 of 8.29 nA.
3.1.2 Differential Pulse Voltammetry
Diﬀerential pulse voltammetry (DPV) is an electrochemical technique, which can be used to
study the redox properties of extremely small amounts of chemicals. This technique oﬀers
two unique advantages. One is that the eﬀect of the charging current can be decreased
leading to high sensitivity being achieved. The other advantage is that only faradaic current
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is extracted, thus electrode reactions can be analysed more precisely. On the other word,
this technique can eliminate the contribution of non-faradaic current, such as capacitative
contribution to the current signal.
In DPV a rectangular pulse is applied, and the current is measured twice in each
pulse period, whereas in CV the current is measured continuously. A potential waveform
and a typical voltammogram for DPV technique are illustrated in Figure 3.4. The potential
waveform is a series of staircase pulses which are superimposed on a linear potential sweep
waveform, so the base potential is incremented in a staircase. As seen in Figure 3.4a, the
current is sampled twice in each pulse period, which is once before the pulse (1st red band)
and again at the end of the pulse (2nd red band). The output current is the diﬀerence
between the two sampled currents that are measured. When the diﬀerence between the two
sampled current (△I = I2-I1) is plotted against the staircase potential, this results in a peak
shape, as shown in Figure 3.4b. The choice of pulse amplitude is a compromise between
maximising the peak current (which increases with pulse height) and resolution of the peak.
Typical range of DPV parameters are shown in Table 3.1.
Table 3.1: Typical range of DPV parameters
DPV parameters typical range This thesis
Pulse amplitude (mV) 10-100 50
Pulse width (ms) 20-100 70
Scan rate (mV/s) 1-10 5
In DPV the peak current is proportional to the analyte concentration. Reversible
reactions show symmetrical peaks, whereas irreversible reactions show asymmetrical peaks.
In reversible reactions, the peak potential (Ep) indicates the half-wave potential which is
Ep = E1/2 −
△E
2
(3.6)
where Ep is the peak potential, E1/2 is the half-wave potential, and △E is pulse amplitude.
In the DP voltammogram, the expression for the peak width at half-height (W1/2) is
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shown in equation 3.7, which is a value of 90.4 mV for n=1 at 298 K. This is narrower than
for CV at a macroelectrode and is one reason that DPV has excellent sensitivity.
W1/2 =
3.52RT
nF
(3.7)
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Figure 3.4: Differential pulse voltammetry (DPV) (a) DPV waveform as a function of time and
(b) a typical differential pulse voltammogram (red trace) of a platinum electrode (in diameter 50
µm) in 1.5 mM Fc at pulse amplitude 50 mV, pulse width 70 ms, and a scan rate of 10 mV/s as
compared by using CV (green trace).
DPV was used as a very sensitive method for the determination of DNA bases ox-
idation, including adenine, guanine, adenosine monocarboxylate (AMP), and guanosine
monocarboxylate (GMP). These results were described in Chapter 6.
3.1.3 Amperometry
Amperometry is an electrochemical technique in which the current is measured when a
constant potential is applied. This is accomplished by applying a constant potential between
the WE and the RE (Ag|AgCl), and monitoring the current over time. An AE is often used
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to measure the current ﬂow in order to avoid the current pass through RE, which can lead
to changing the constant potential applied between RE and WE. When a ﬁxed potential is
applied, the driving force for the electron transfer reaction occurs and the produced current
is directly measured. As seen this is in turn given by the ﬂux of electroactive species to the
electrode surface. In this thesis, this technique was used for two common methods, which
are electropolymerisation (see section 3.5), and sensor calibration and autocalibration (see
section 3.7).
3.2 Macroelectrodes and Microelectrodes
Macroelectrodes and microelectrodes are deﬁned by their dimensions. A macroelectrode
possesses dimensions in the range of centimetres and millimetres, and a microelectrode is in
the range of 0.1 to 50 µm [131]. In addition, a microelectrode can be deﬁned as an electrode
that has a characteristic surface dimension smaller than the thickness of the diﬀusion layer on
the time scale of the electrochemical experiment. The diﬀerence in the electrode dimensions
inﬂuences the diﬀusion ﬁeld at the electrode surface, which causes diﬀerences in diﬀusional
mass transport.
It is known that the current-time response of diﬀusion of electroactive species to a
disc electrode surface can be described by the equation of current density (Id) as given by
equation 3.8.
Id =
4nFDC∞
πr
+
nFD1/2C∞
π1/2t1/2
(3.8)
where n is the number of electrons transferred in the reaction, D is the diﬀusion coeﬃcient
for the electroactive species, r is the radius of the electrode, C∞ is the concentration of the
electroactive species, t is time, and F is the Faraday’s constant.
When considering short time conditions where t is very small, the second term in
equation 3.8 will be much larger than the ﬁrst term. Thus, the Id is given by the Cottrell’s
3.2. Macroelectrodes and Microelectrodes 45
equation, as shown in equation 3.9.
Id =
nFD1/2C∞
π1/2t1/2
(3.9)
In this situation, both a macroelectrode and a microelectrode exhibit a similar shaped
diﬀusion ﬁeld with planar diﬀusion as shown in Figure 3.5a and c.
Macroelectrode
Microelectrode
At short times At long times
Planar
Hemi-spherical
(a) (b) 
(c) (d) 
Figure 3.5: Schematic of the diffusion field of electrodes. The electrodes are shown in yellow and
the diffusion of molecules to the electrode surface is indicated by the arrows.
At long times, when t becomes large enough, the second term (the transient current)
will decrease to a negligible value, so that the Id depends on a steady-state value (the ﬁrst
term) as given by
Id =
4nFDC∞
πr
(3.10)
As described in the equation 3.10, the Id is inversely proportional to the radius of the
electrode. This means that a microelectrode will have a larger Id than a macroelectrode.
Hence, the size of electrode is an important factor in the current density.
As shown in Figure 3.5d at a microelectrode surface, the dimension of the diﬀusion
ﬁeld exceeds its surface area at long time scales and diﬀusion becomes hemispherical. There-
fore, the molecules diﬀusing to the electrode surface come from the hemispherical volume
resulting in a depletion region, which increases with time. This leads to enhanced ﬂux to
the microelectrode. For a macroelectrode, this situation does not occur as planar diﬀusion
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dominates (Figure 3.5b).
3.3 Fabrication of Multiwalled Carbon Nanotube - epoxy
Composite Electrodes
Multiwalled carbon nanotubes (MWCNT, 6-13 nm OD, 2.5-20 µm length) were purchased
from Sigma-Aldrich. Epoxy resin and hardener were obtained from Robnor (RX771C/NC,
and HY1300). Plastic pipette tips (10 µl size) were employed to contain the carbon-
composite. MWCNT were ground into a ﬁne powder using a pestle and mortar to remove
existing clumps. Epoxy resin was then prepared by mixing resin and hardener in the ra-
tio of 3:1, and a sonicator was used to remove any bubbles formed during the mixing. The
MWCNT powder was thoroughly combined with the prepared epoxy resin in the proportion
of 1:4 by weight and stirred well until a thick paste was performed. Once both substances
were mixed thoroughly, a pipette tip was ﬁlled densely with the mixed MWCNT/epoxy
nanocomposite paste by a tapping and dragging method. Then an electrical wire with the
insulator removed at the end was inserted into the ﬁlled pipette. In this step, the pipette
tip with the electrical wire was ﬁlled with the composite again to ensure there were no gaps
between the electrical wire and the composite surrounding. Then it was allowed to dry at
room temperature for 2 days. The electrical wire was glued to the edge of the plastic pipette
using Araldite glue in order to ﬁx the wire in place. The epoxy resin with the same ratio
as mentioned above was used to ﬁll up the internal volume of the pipette tip using an 18G
hypodermic needle, and it was allowed to cure in an upright position for two days. After
this process, a scalpel was used to cut the end of the electrode to expose a surface area of
the MWCNT/epoxy composite that was approximately 0.46 mm in diameter as shown in
Figure 3.6. These electrodes were employed as a WE in an electrochemical sensor system
for anti-cancer drug detection (Chapter 6 and 7). Overall, this method was 90% in success
for electrode fabrication.
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Figure 3.6: Photograph of MWCNT-epoxy composite electrodes
The MWCNT-epoxy composite electrodes can be reused after an experiment. The end
of electrode was cleaned by polishing carefully (with ultraﬁne sandpaper (P4000 grit size))
for 5-10 minutes. The electrode was held ﬂat against the ultraﬁne sandpaper and moved
in a Figure of 8. Then the electrode tip was washed well with DI water using a sonicator
for 30 seconds to remove any particles from the end before use. This creates a smooth and
shiny electrode surface. CV-experiments were used to examine the surface of the electrode
in order to make sure that the tip was clean and smooth. Figure 3.7 illustrates an example
of MWCNT-epoxy composite electrode CV showing both unsatisﬁed and satisﬁed electrode
characteristics.
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Figure 3.7: Examples of MWCNT-composite electrode CVgrams in 1 mM potassium ferrocyanide
at scan rate 10 mV/s (a) unsatisfied electrode after polishing with 0.05 µm alumina slurry (△ E=
140 mV,
Ipc
Ipc
= 1.37) and (b) good electrode after polishing using a ultrafine sandpaper (△ E= 66
mV,
Ipc
Ipc
= 1.06).
Figure 3.7a shows a CVgram when the MWCNT-epoxy composite electrode had been
polished using 0.05 µm alumina slurry for 5 minutes and sonicated in DI water to remove
any particles. The CVgram has high capacitance, which indicates that the electrode surface
is not clean. The alumina slurry is quite sticky leading to diﬃculties in removing it from
the electrode. However, when I tried sonicating the electrode in DI water for a longer time
it still had the same shape as in Figure 3.7a. In contrast, cutting the end of the tip to
open its fresh surface or cleaning using the ultraﬁne sandpaper results in a good condition
of CVgram, which clearly shows the peak currents for oxidation and reduction, and the
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diﬀerence between the oxidation and reduction potentials is approximately 80 mV as shown
in Figure 3.7b.
3.4 Fabrication of Combined Needle Microelectrodes
As shown in Figure 3.8, a combined needle microeectrode was fabricated which contained
a three-electrode cell, comprised of a WE, RE, and AE, and was developed previously
in the group [86]. To fabricate the needle electrode, 27G hypodermic needles (400 µm
outer diameter, Terumo) were employed to contain a polytetraﬂuoroethylene insulated plat-
inum/iridium (90%:10%) wire with a diameter of 50 µm (Advent Research Materials Ltd.,
UK) and a polyester coated silver wire with diameter of 50 µm (Goodfollow Inc.) The
insulator of both wires was stripped using a lighter to expose the metal. Both the platinum
(Pt) wire and the silver (Ag) wire were each connected to electrical wire using a conductive
silver epoxy glue (RS Components, UK) and left them dry at 65℃ for 1 hour. The other
end of the electrical wire had already been soldered previously onto crimp pins (Farnell,
UK) to make the connection to the potentiostats. The connected wires were glued to the
inside of the hypodermic needle using Araldite glue after checking the connectivity with a
voltmeter. Then two solutions of epoxy resin purchased from Robnor resin, CY1301 and
HY1300 were mixed well in the ratio of 3:1 (resin and hardener) and sonicated to remove
any bubbles. The mixed solution was used to ﬁll the internal volume of the needle to seal
all the wires in place. This was done using a piece of tube and a second hypodermic needle.
The needle was left to cure for 2-3 days at room temperature. After the glue had cured, the
sharp end of the needle was cut using a diamond saw before polishing the end using three
grit sizes of ultraﬁne sandpapers to make the end of the needle ﬂat. Typically, I used P1200,
P2500, and P4000 grit size (SiC grinding paper, Buehler, Germany). For each sandpaper
the electrode was held perpendicularly to the sandpaper and moved in a ﬁgure of 8 motion
75 times before rotating the needle 90°repeating 3 times. Finally, the stainless steel needle
shaft, which serves as the AE was connected to an electrical wire using a conductive silver
epoxy glue and was cured at 65℃ for 1 hour. Overall, this method was 95% in success for
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electrode fabrication.
Pt
Ag|AgCl
a
b
c
Figure 3.8: A needle microelectrode (a) Photograph of a combined needle microelectrode (b) SEM
image of the tip of a needle microelectrode showing three-electrode system (c) Energy-dispersive
X-ray spectrums to identify the composition of the wires.
To clean the needle electrode, the end of needle was polished carefully using 3 grades
of alumina slurries (Micropolish, Buehler), 1 µm, 0.3 µm, and ﬁnally 0.05 µm. The electrode
was held ﬂat against the polishing pads (Microcloth PSA, Buehler) and moved in a ﬁgure
of 8, which it was rotated 90° and this was repeated 3 times. The electrode tip was then
cleaned with DI water (see section 3.9) using a sonicator for 3 min to remove any particles
of the slurry before moving to the next size of alumina slurry.
To make the Ag|AgCl RE on the silver wire of the fabricated electrode, the polished
ﬂat electrode was chloridised by immersing it in potassium dichromate solution (BASi, US)
for 5 seconds followed by hydrochloric acid solution (10% HCl in DI water) for 20 seconds
to remove the oxide layer from the WE and RE. For this step, I noticed that it should
not be immersed in potassium dichromate solution for longer than this time as the WE
can be damaged. Then the electrode tip was rinsed well with DI water and dried at room
temperature for 20 minutes. CV experiments were used to examine the surface of the
electrode. If the electrode did not show a satisfactory CVgram, the electrode was polished
again with the alumina slurries.
As mentioned previously in section 3.1.1, CV can be used to assess quantitative in-
3.4. Fabrication of Combined Needle Microelectrodes 51
formation such as the surface area and the geometry of the WE. The shape of the CVgram
and the steady-state oxidation current were used to verify that both the electrode surface
and RE were satisfactory after polishing. To characterise the fabricated electrodes, CV was
carried out in 1.5 mM Fc. The WE was scanned from -100 mV to 500 mV, compared to
a Ag|AgCl RE at 10 mV/s scan rate. An example of a CVgram with satisfactory char-
acteristics has been shown previously in Figure 3.3b. Examples of unsatisﬁed electrode
charaterisatics which required repolishing are shown in Figure 3.9.
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Figure 3.9: Examples of unsatisfactory platinum disc microelectrode CVgrams ( diameter 50 µm)
in different cases, which were carried out in 1.5 mM Fc at a scan rate of 10 mV/s (a) the peak
corresponds to silver particles adhering to the WE (b) high capacitance of the electrode (c) cross
over of forward and backward scans and (d) shifted CV due to unsatisfied RE.
Figure 3.9a shows a CVgram with a peak at ± 40 mV, which indicates that silver
particles were present on the WE surface. This might occur during polishing, where Ag
particles can be transferred onto the Pt WE surface. The particles can be removed by
sonication for 5 minutes, however, if the silver particles still remains, the electrode needs
to be polished again. In the case of Figure 3.9b, this is an example of a CVgram with
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high capacitance, where it shows a large diﬀerence in current between the forward and the
backward scans. In this case, it indicates that the surface of the WE was not clean. The
electrode can be re-polished with 0.3 µm and 0.05 µm alumina slurries to reduce the high
capacitance.
The ﬁnal two cases of unsatisﬁed electrode characteristics are cross over of forward
and backward scans, and shifted CVgram shapes. In Figure 3.9c, the shape of the CVgram
exhibits the backward scan crossing over the forward scan, while both oxidation and re-
duction potential peaks were shifted to the right (higher potential) in Figure 3.9d. These
CVgrams indicate that the RE is unstable. This can occur when the electrode is re-polished
many times resulting in removal of the Ag|AgCl layer on the silver wire. Both of these cases
indicated that the RE needed to be re-chloridised.
3.5 Electropolymerisation
Pt disc microelectrodes, which exhibited a satisfactory CVgram were used to fabricate
biosensors. An electrode potential was applied to initiate polymerisation of monomer
molecules in order to make a thin ﬁlm cover on the WE surface with m-phenylenediamine
(mPD). As reported in a previous study [132] mPD ﬁlm showed a good performance which
can be used to prevent large molecule interferences such as dopamine, ascorbic acid, sero-
tonin and uric acid. All of the biosensors fabricated in this thesis were coated with an
electropolymerised poly(m-phenylenediamine) ﬁlm before the process of enzyme immobili-
sation in order to prevent the interference of other electroactive species (i.e. ascorbic acid,
serotonin and uric acid), which might be detected during biochemical monitoring in the
brain or tissue.
In the electropolymerisation process, the polished Pt WE was held at 0 V for 20
seconds before a constant potential of 0.7 V was applied for 20 minutes. Then, the electrode
was held at 0 V for a further 5 minutes to allow the coated ﬁlm to stabilise. A typical
trace of the electropolymerisation of mPD is shown in Figure 3.10. The initial high current
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is usual with a potential step. The sustained current of about 3 nA reﬂects the continued
oxidation of the mPD monomer.
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Figure 3.10: A typical trace was seen during electropolymerisation to the microelectrode surface
in 100 mM mPD in phosphate buffered saline (PBS) pH 7.4 at 0.7 V for 20 minutes.
To characterise the success of the coating of the mPD thin ﬁlm on the WE surface,
CV was employed in 1.5 mM Fc at a scan rate of 10 mV/s. In Figure 3.11, the blue and the
red curves show CVgrams of a bare Pt electrode (50 µm diameter) before (blue) and after
(red) coating with mPD.
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Figure 3.11: CV of Pt microelectrode before (blue) and after (red) mPD electropolymerisation
in 1.5 mM Fc at 10 mV/s scan rate.
The bare electrode CVgram was a sigmoidal curve (characterisation of a microelec-
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trode), while after mPD coating the electrode CVgram shape was ﬂat. It is clear that the
mPD ﬁlm blocks the access of the large negatively charged Fc moiety to the electrode surface.
The CVgrams can conﬁrm that the WE surface was coated well with the electropolymerised
mPD ﬁlm. In addition, investigation of interferences of other electroactive species was also
conducted and more information on this interference study is given in Chapter 4.
3.6 Operation of Biosensors
As stated previously, a biosensor comprises two main components, which are a biological
recognition component such as an enzyme, and a physicochemical transducer. Hence, in the
fabrication of a biosensor the enzyme layer is a crucial factor. After the electropolymerisation
step, the mPD-coated Pt microelectrode was coated with a layer of enzyme as shown in
Figure 3.12.
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Figure 3.12: Schematic cross-section of a needle biosensor tip modified with a mPD layer and an
enzyme layer.
In this thesis, diﬀerent approaches of enzyme immobilisation were studied. More detail
of enzyme immobilisation methods will be described in Chapter 4.
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After fabricating the biosensors, they were tested using an amperometric technique in
an integrated three-electrode cell, including a WE (Pt wire), a RE (Ag|AgCl) and an AE
(stainless steel of hypodermic needle). Experiments were conducted using an in-house po-
tentiostat. The methodology of biosensor characterisation will be described in the following
section.
3.7 Sensor Calibration and Autocalibration
Sensors have inherent variability as they are fabricated by hand. They also typically suﬀer
from falling sensitivity due to, for example, enzyme loss. To compensate for this, regular
calibration is required. In this thesis, biosensors characterisation was performed in both a
beaker (calibration by hand) and a microﬂuidic chip (ﬂow cell with autocalibration).
Calibration by hand is a simple way. The biosensors were investigated in a beaker
which contained 10 ml of phosphate buﬀered saline (PBS, pH 7.4 see section 3.9) under
stirred conditions. Calibrations were carried out by injecting aliquots of a concentration of
substrate solution to give ﬁnal concentrations in the range from 0.2 mM to 80 mM in PBS.
In the calibration experiment, all measurements were performed at 0.7 V vs Ag|AgCl to
drive hydrogen peroxide (H2O2) oxidation reaction. After allowing the biosensors to reach
a stable background current, the analyte was added into the beaker to create step change of
concentration. The step changes in current corresponded to the concentration of substrate
added.
However, calibration by hand depends on skill and is always not reproducible. Thus,
autocalibration is required. In autocalibration, a biosensor was placed in a microﬂuidic
chip (see section 3.8), and calibrated using an autocalibration board (LabSmith) which was
controlled by uProcess software. The autocalibration system was used to perfuse the stan-
dard solution in varying concentrations. More detail of the automated calibration system is
described below. In both systems, the biosensor was connected to an in-house potentiostat
and held at a constant potential.
56 Chapter 3. Methods and Materials
In clinical diagnosis, patient monitoring requires fast, precise analysis techniques to
give the clinician relevant chemical information in real-time. Electrochemical biosensors
can provide precise detection, however, they require frequent calibration to obtain reliable
information. Thus, an automated calibration system is important for the development
of patient monitoring. Automated calibration allows observation of changes in biosensor
sensitivity during electrochemical detection and ensures that reliable continuous information
is obtained.
In our research group, we have perused the development of microﬂuidic circuits using
LabSmith components (California, US) that can give us precise ﬂuid delivery and excellent
temporal control of multiple liquid streams. An automated board was employed to control
the calibration of biosensors as mentioned earlier. The components on the autocalibration
board include two of 1 ml reservoirs, which contain the substrate of interest and the buﬀer
solution without the substrate, two 20 µl syringe pumps, and two valves for controlling
the direction of solution ﬂow through the analysis system, as shown in Figure 3.13. All
components connected to the LabSmith board were automatically controlled via uProcess
software. This allows the automated calibration system to be programmed by the purpose-
written script, which can reﬁll the pump, control the ﬂow rate of each solution and switch
the direction of the solutions. Also, the script can be written on a loop, which means that
the sensors can be calibrated frequently by running a script. The automated board was
connected to the inlet hole of the microﬂuidic chip housing the biosensor through polyether
ether ketone (PEEK) tubes (150 µm inner and 360 µm outer diameter, Upchurch Scientiﬁc
Inc.). Calibration using the automated system was studied under continuous ﬂow conditions
at 2 µl/min ﬂow rate with 5 diﬀerent substrate concentrations. To clean this system, it was
ﬂushed with DI water, methanol 50% (v/v), and DI water again at 100 µl/min before and
after each experiment.
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valves
reservoirs
syringe pumps
Figure 3.13: Automated calibration system
This paragraph will explain the work carried out to perform a calibration for each
detection method using the autocalibration system. To perform calibrations, two pumps,
two reservoirs and two 3-port valves were set up on the board as depicted in Figure 3.14.
The autocalibration "microﬂuidic circuit" allows me to vary the concentrations of standard
solution which ﬂows into the PDMS microﬂuidic device housing a biosensor by controlling
the ﬂow rate of each solution.
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Figure 3.14: Schematic representation of the configuration of the autocalibration system
For each detection method, a ﬁve-point calibration was achieved by running a script
through using uProcess software. Two steps were used to control the auto-calibration system
as shown in Figure 3.14. Initially (Step 1), standard solution and phosphate buﬀered saline
(PBS) contained in each reservoir (1 ml) were ﬁlled into their own 20 µl syringe pump
simultaneously. In step 2, the standard solution and PBS ﬂowed to the direction of the
PDMS chip at diﬀerent ﬂow rate ratios in order to give ﬁve diﬀerent concentrations of the
standard solution. For example, PBS and 1 mM standard solution were set to the ﬂow rate
of 2 µl/min and zero, respectively, resulting in the system giving the background current
(baseline). When the ﬂow rate of standard solution and PBS were both set to 1 µl/min, it
gave a ﬁnal concentration of 0.5 mM standard solution ﬂowing past the biosensor placed in
the PDMS chip.
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Figure 3.15: Example of raw data for 5-point Fc calibration from 1.5 to 0 mM at 2 µl/min using
a 50 µm Pt electrode.
Figure 3.15 shows the example of raw data of a 5-point Fc calibration at a Pt electrode
carried out using the automated calibration board. Here, Fc was used as the standard
solution. The Pt electrode was held at 0.7 V vs Ag|AgCl. The trace shows decreasing steps
of 1.5, 1.125, 0.75, 0.375, and 0 mM Fc (indicated on the graph).
3.8 Fabrication of A PDMS-based Microfluidic Device
Microﬂuidics is a very attractive technology, and has been employed in this study for the
miniaturisation of diagnostic devices due to the ultra low volume requirements for samples
and reagents, and the requirements for short analysis times, compact size and low cost.
Microﬂuidic devices can be used to manipulate and control ﬂuids, typically in the range
of microlitres to picolitres, in networks of microchannels. Many elastomers can be used
to create microﬂuidic chips such as polystyrene (PS), polycarbonate (PC), polyvinyl chlo-
ride (PVC), polymethyl methacrylate (PMMA), and polydimethylsiloxane (PDMS) [133].
Among this variety of elastomers, PDMS has been the most commonly used for fabrication
of microﬂuidic devices because it provides several advantages as it is transparent, inert,
ﬂexible, non-toxic, non-ﬂammable, and easy to fabricate [133, 134]. As a result of these
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properties, it is employed in a wide variety of applications from contact lens to medical
devices. Generally, PDMS-based microﬂuidic devices can be easily manufactured using soft
lithography.
Soft lithography is a group of techniques that incorporates lithography and moulding,
for fabrication of polymer-based devices on the micrometre scale, using elastomeric mate-
rials. This technique involves the replication of a topographically deﬁned microstructure
on a master that has the desired pattern in a 3-dimensional relief. The master can be
created using photolithography techniques, electrode beam lithography, or micromachining.
The process of soft lithography is simple, rapid, non-photolithographic, and inexpensive.
Additionally, replication using this technique can be repeated multiple times from a single
master.
In this study, PDMS was chosen for fabrication of microﬂuidic chips due to its useful
properties for the electrochemical biosensors. Firstly, it is easy to replicate the moulding of
microﬂuidic channel feature in the range of micrometre size. The fabrication process can be
implemented quickly and inexpensively. PDMS microﬂuidic chips are ﬂexible and mechani-
cally strong. Additionally, they are transparent, so it easy to notice air bubbles that might
occur during my experiment. The most important property of PDMS is that it is highly
gas permeable, hence oxygen can pass through the material leading to suﬃcient supply for
oxygen consuming chemical reactions. The overall process of PDMS-based microﬂuidic de-
vice fabrication is summarised in Figure 3.16 and this section will further explain each step
in detail.
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Figure 3.16: Schematic illustration of the procedure for fabricating a microfluic device using soft
lithography
Photolithography was used to make a pattern of the designed channels as a moulding
master on a silicon wafer. The process of soft lithography is illustrated in Figure 3.16;
a mixture of PDMS (Sylgard 184, Dow Corning, USA) prepolymer and curing agent was
prepared in the ratio 10:1 by weight, and was stirred vigorously until well mixed. The
mixture were degassed using a vacuum desiccator in order to remove air bubbles. Next, the
mixture was cast onto the patterned SU-8 master, and then degassed, again to avoid air
bubbles for 10-15 minutes. The master ﬁlled with PDMS was cured in an oven at 65℃ for 1
hour. Then the cured PDMS was cut along the edge of the mould using a scalpel blade and
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was peeled oﬀ from the master. To make the ﬂuidic inlet, outlet, and the biosensor insertion
point, holes were punched in the patterned PDMS chip using a blunted 23G hypodermic
needle. The punched PDMS chip was placed on a semi-cured PDMS base before bonding the
two parts together by heating in the oven at 65℃ overnight. As mentioned the advantages
of PDMS, however there are some disadvantages such as its hydrophobicity which can lead
to analyte adsorption on its surface and would occur a leak when the needle electrode was
placed too hard on the PDMS chip.
2 cm
1 cm
(a) (b)
Figure 3.17: A PDMS-based microfluidic device (a) schematic of the design of the microfluidic
device with a channel height of 100 µm, showing the positions of the inlet, the outlet and sensor
housing and (b) photo of the PDMS chip with channels filled with blue dye to make them clearly
visible
The schematic of a microﬂuidic design used in this study is shown in Figure 3.17a .
The microﬂuidic channels were designed using AutoCAD software and were typically 100
µm high. The chamber used to house the biosensor was 500 µm in width and 1000 µm in
length.
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3.9 Materials and Reagents
In this thesis all chemical reagents were of analytical (AnalaR) grade or better. DI water was
from a SELECT FUSION Water Puriﬁcation system (PURITE Ltd, UK), Reverse osmosis,
and ﬁnal polishing stage typically 18.2 MΩ.cm. All glassware (grade A) were cleaned using
a dishwasher ( Miele Professional, USA) to remove organic and inorganic residues.
3.9.1 Ferrocene monocarboxylic Acid
Ferrocene monocarboxylic acid (Fc) was used as a redox couple in CV in order to assess
the surface of the electrodes. Solutions consisted of sodium citrate (0.1 M, Sigma-Aldrich),
ferrocene monocarboxylate (1.5 mM, Fluka), ethylenediaminetetra acetic acid (EDTA, 1
mM, Fluka), sodium chloride (150 mM, Sigma-Aldrich). In addition, 400 µl of 5-chloro-
2-methyl-4-isothiazoline-3-one (Kathon CG, SUPELCO Analytical, USA) was added per
litre as an antibacterial agent. The pH of the solution was adjusted to pH 7.0 using 1 M
hydrochloric acid (HCl).
3.9.2 Potassium ferrocyanide
Potassium ferrocyanide (K4Fe(CN)6, Sigma-Aldrich) was also used as a redox species in
electrochemistry to assess the eletrode performance. 1 mM K4Fe(CN)6 was dissolved in 0.1
M potassium chloride (KCl).
3.9.3 m-phenylenediamine
m-phenylenediamine (mPD, ﬂakes, ≥99% obtained from Sigma-Aldrich) was dissolved in
0.01 M PBS for the electropolymerisation process. A stock of 100 mM fresh mPD solution
was used to block other electroactive species which could be oxidised at 0.7 V ( the potential
used to oxidise H2O2).
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3.9.4 Substrate Standards
D-(+)-glucose (99.5%) and sodium L-lactate (98%) were obtained from Sigma-Aldrich. Both
glucose and lactate standard solutions were dissolved into 0.01 M PBS for biosensor char-
acterisations. D-glucose solutions were allowed to stand overnight in the fridge to allow
mutarotation (a transformation from α-glucose to β-glucose) to occur.
3.9.5 1-ethyl-3-(3-dimethylaminoprophy) carbondiimide hydrochlo-
ride and N-hydroxyl succinimide solution
1-ethyl-3-(3-dimethylaminoprophy) carbondiimide hydrochloride (EDC) and N-Hydroxylsuc-
cinimide (98% NHS) were purchased from Sigma-Aldrich. EDC (30 mg/ml) and NHS (30
mg/ml) were dissolved in 0.01 M PBS (pH 7.4). This solution was used to activate the
carboxylic groups of graphene oxide.
3.9.6 Chitosan
Chitosan (from crab shells, deacetylation percentage of > 75% practical grade) was pur-
chased from Sigma-Aldrich. 1 g chitosan was dissolved in 100 ml of 1% acetic acid in DI
water. This mixture was stirred overnight to dissolve it completely. At the end, the solution
was ﬁltered with a syringe ﬁlter (PVDF with 0.45 µm pore size, Whatman). The pH of the
solution was adjusted to pH 5.0 using 1 M sodium hydroxide (NaOH).
3.9.7 T1 solution
1 litre of T1 solution was prepared with 147 mM sodium chloride (NaCl), 4 mM potassium
chloride (KCl), and 2.3 mM calcium chloride (CaCl2) in DI water and 400 µl of 5-chloro-
2-methyl-4-isothiazoline-3-one (Kathon CG, SUPELCO Analytical, USA) was added as an
antibacterial agent. All of these chemical were obtained from Sigma-Aldrich.
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3.9.8 Phosphate buffered saline
Phosphate buﬀered saline (PBS) was used for the preparation of all substrate standards and
background of biosensor calibrations. One tablet of PBS (Sigma-Aldrich) was dissolved in
200 ml of DI water to yield 0.01 M phosphate buﬀer, 2.7 mM KCl and 137 mM NaCl pH
7.4.
For 0.1 M PBS (pH 7.4), which was used as a supporting electrolyte for electrochemical
oxidation studies of all DNA bases at physiological pH, the solution was prepared with
77.4 mM sodium phosphate dibasic (Na2HPO4), 21.2 mM sodium phosphate monobasic
(NaH2PO4), and 150 mM NaCl in DI water. The pH was adjusted to pH 7.4.
3.9.9 Acetate buffer
Acetate buﬀer (ACB) was used for the preparation of all DNA-base solutions, nucleotide
solutions and in the process of sensor calibrations for carboplatin detection. 0.1 M acetate
buﬀer solution (pH 4.5) was prepared by dissolving 0.1 M acetic acid (Sigma-Aldrich) and
0.1 M sodium acetate trihydrate (Fluka) in DI water.
3.9.10 Guanine and adenine solutions
Guanine and adenine were purchased from Sigma-Aldrich. The stocks of 1 mM adenine and
1 mM guanine were prepared in 0.1 M phosphate buﬀer (pH 7.4) and served as supporting
electrolytes for the electrochemical oxidation of DNA base studies. In case of guanine
solution, due to diﬃculties in making a homogeneous solution, an alkaline solution of 1 M
NaOH (Sigma-Aldrich) was added in order to ensure it became a homogeneous solution.
3.9.11 Single-stranded DNA
Deoxyribonucleic acid sodium salt from calf thymus (type I, highly polymerised, ﬁbrous
preparation, Sigma-Aldrich) was used to prepare single-stranded DNA (ssDNA) solution
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for carboplatin-DNA damage studies. 3 mg of the calf thymus DNA ﬁbrous was treated
with 0.5 ml pure perchloric acid (Sigma-Aldrich) and stirred for 10 minutes until dissolved.
Then 0.5 ml of 9 M NaOH was added to neutralise the solution followed by 9 ml of a
supporting electrolyte, which was 0.1 M acetate buﬀer (pH 4.5).
3.9.12 Guanosine 5’-monophosphate and adenosine 5’-monophosphate
solutions
Guanosine 5’-monophosphate disodium salt hydrate (GMP, from yeast, 99%) and adenosine
5’-monophosphate (AMP, MW= 347.22 from yeast, sodium 99 %, premium grade) were
obtained from Sigma-Aldrich. Both stocks of 1 mM GMP and 1 mM AMP were dissolved
in ACB as supporting electrolytes for use in a beaker experiment. In the case of testing in
vitro using an autocalibration system, 1.5 mM AMP was dissolved in 0.1 M ACB and T1
solution in the ratio of 3:1. For example, for 20 ml of 1.5 mM AMP, 10.42 mg of AMP was
dissolved in 15 ml of 0.1 M ACB and 5 ml T1 solution.
Chapter 4
Development of Graphene-based
Electrochemical Biosensors
The aim of this chapter is to describe the development of a novel electrochemical biosensor
using graphene oxide as a supporting material. Diﬀerent methods of graphene oxide-based
enzyme immobilisation on a needle microelectrode surface were studied. Glucose oxidase
and lactate oxidase were employed as model enzyme systems. Biosensors were characterised
electrochemically both in a stirred beaker and using an automated calibration device to
investigate how performance, such as sensitivity, stability, reproducibility, and response
time, can be enhanced. Finally, I will describe the use of the biosensors on a microﬂuidic
platform with a microdialysis probe at the end of this chapter.
4.1 Enzymes
Enzymes are biological molecules that are an important component of a biosensor. They
consist of chains of amino acid folded into a complex 3-dimensional shape and act as cat-
alysts, increasing the chemical reaction rate without being consumed by the process. An
enzyme usually contains one or more active sites, which are responsible for its speciﬁcity.
Thus, enzymes provide extraordinary speciﬁcity to a substrate. This section will give more
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information on two enzymes used in this study, namely glucose oxidase and lactate oxidase.
Glucose Oxidase
Glucose oxidase (GOx) is an oxido-reductase enzyme that catalyses the oxidation of glucose.
It is widely used to determine the amount of glucose in body ﬂuids for diagnostics and is
used as an additive in the food industry. GOx is typically extracted from Aspergillus niger.
As seen in Figure 4.1, the three-dimensional structure of GOx is a homodimetric protein
with an active site located in a deep pocket where glucose binding occurs. The structure is
made of two subunits (molecular weight of 80 kDa each) shown as dark and light blue regions
in Figure 4.1 and each subunit is non-covalently bound with a ﬂavin adenine dinucleotide
(FAD) coenzyme (pink), which acts as an electron carrier during catalysis [135]. The FAD
is situated approximately 8.7 Å within the glycoprotein shell that acts as a barrier to the
electron transfer between the active site of the enzyme and the electrode surface [136]. The
unit cell dimensions of GOx are 6.75 × 6.75 × 21.54 nm [137]. GOx has a negative charge
at pH 7.4 owing to its isoelectric point of 4.2 [119].
Figure 4.1: Structure of glucose oxidase at 1.9 Å resolution. The light and dark blue regions
represent the two subunits and the pink regions represent the FAD coenzymes. Image taken from
Wang et al. [135]
GOx catalyses the oxidation of β-D-glucose to D-gluconolactone and hydrogen perox-
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ide (H2O2). The mechanism of this reaction with glucose is given below.
GOx(FAD) + β-D-glucose −→ GOx(FADH2) +D-gluconolactone (4.1)
GOx(FADH2) +O2 −→ GOx(FAD) +H2O2 (4.2)
In these reactions, β-D-glucose acts as an electron donor and oxygen acts as an electron
acceptor. The H2O2 produced as a product is easily measured electrochemically. The H2O2
can be oxidised at the electrode surface when a constant potential of +0.7 V is applied, as
shown in equation 4.3.
H2O2 −→ 2H
+ +O2 + 2e
− (4.3)
In equation 4.3 two electrons are produced by the oxidation of H2O2, which are detected
by the working electrode as shown in Figure 4.2. The amount of H2O2 detected is directly
proportional to the glucose concentration in the sample.
+ 0.7 V
Figure 4.2: Schematic representation of the detection of glucose using glucose oxidase as a catalyst
to generate H2O2, which is oxidised at the WE.
Lactate Oxidase
Lactate oxidase (LOx) is a member of the α-hydroxyacid-oxidase ﬂavoenzyme containing
ﬂavin mononucleotide (FMN) that catalyses speciﬁcally the oxidation of lactate using molec-
ular oxygen to produce pyruvate and hydrogen peroxide. LOx is extracted from Aerococcus
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viridans. The molecular weight of LOx is 41 kDa and its dimensions are 19.11×19.11×19.45
nm [138]. The structure of LOx is shown in Figure 4.3 at 2.1 Å resolution, demonstrating its
four monomers in diﬀerent colours. LOx has four monomers per asymmetric unit, which is
called a tetramer. Each subunit contains a FMN molecule bound non-covalently. LOx has
an isoelectric point of 4.6 [139] so it has a net negative charge under neutral pH conditions.
Figure 4.3: Structure of lactate oxidase tetramer at 2.1 Å resolution with each monomer shown
in a different colour. Image taken from Umena et al. [138]
LOx catalyses the oxidation of L-lactate into pyruvate and H2O2 produced. As de-
scribed in the following equations, the ﬁrst step is reduction of the enzyme to convert
L-lactate to pyruvate (equation 4.4) and the second step is oxidation of the enzyme by
oxygen to form H2O2 (equation 4.5).
LOx(FMN) + L-lactate −→ LOx(FMNH2) + pyruvate (4.4)
LOx(FMNH2) +O2 −→ LOx(FMN) +H2O2 (4.5)
Similar to detection of glucose, the H2O2 generated from the above reaction is oxidised
when a potential at +0.7 V is applied. This leads to the production of two electrons, which
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are detected at the working electrode surface as shown in equation 4.3. The concentration
of H2O2 is directly related to the concentration of lactate.
4.2 Enzyme Kinetics
Enzyme kinetics is the study of chemical reactions in which enzymes are used as a catalyst.
As stated above, the catalyst increases the rate of the chemical reaction without itself
being used up by the process. When considering a simple enzyme-catalysed reaction, the
transformation of substrate (S) into product by the enzyme (E) is described below:
E + S
k1−−⇀↽−
k
−1
ES (4.6)
ES
k2−→ E + product (4.7)
In this scheme, the ﬁrst step represents the substrate binding to the enzyme to form the
enzyme-substrate complex (ES). Once ES has been formed, it proceeds to the product with
the regeneration of the enzyme (equation 4.7).
In enzyme kinetics, Michaelis-Menten is a well-known model, which is used to explain
the relationship between the rate of the enzymatic reaction and the substrate concentration.
The Michaelis-Menten formula is presented in equation 4.8:
V =
Vmax · [S]
Km + [S]
(4.8)
where V is the reaction rate, Vmax is the maximum reaction rate, [S] is the substrate
concentration, and Km represents the Michaelis-Menten constant, which is the substrate
concentration at which the reaction rate is half of Vmax.
From equation 4.8 it can be seen that if [S] « Km then Km+ [S] ≈ Km, and so
V =
Vmax · [S]
Km
(4.9)
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If [S] » Km then Km+ [S] ≈ [S] and so
V = Vmax (4.10)
As illustrated in the above equations, at low substrate concentration the reaction rate in-
crease linearly with the substrate concentration. However, at high concentration, the rate
approaches the maximum rate, Vmax, at which the curve reaches a plateau as shown in Fig-
ure 4.4). This indicates that almost all active sites of the enzyme are occupied and therefore
there is no further change in the reaction rate with increasing substrate concentration.
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Figure 4.4: Schematic of Michaelis-Menten curve presenting the relationship between reaction
rate and substrate concentration
The value of Km relates inversely to the aﬃnity of the enzyme for the substrate, which
is the strength of the binding between the two. For smaller Km values, the reaction rate will
reach Vmax more quickly indicating a higher aﬃnity for the substrate (stronger binding).
However, some enzymes do not follow Michaelis-Menten kinetics, including allosteric
enzymes, which contain multiple active sites or subunits. These enzymes produce a sigmoid
shape in a plot of the relationship between V and [S]. This can occur as a result of cooperative
binding of the substrate to the active site, which is where the binding of a substrate can
aﬀect the binding of subsequent substrate molecules to the same enzyme. Additionally, in
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some cases, enzyme activity can also be aﬀected by binding of regulatory molecules to non-
catalytic sites. The Hill equation is often used to describe the activity of enzymes which do
not obey Michaelis-Menten kinetics [140]. This is shown in equation 4.11.
I =
Vmax
1 + (Km/[S])α
(4.11)
where I represents a measure of the reaction rate and α represents the deviation from the
Michaelis-Menten equation. It is noted that when α = 1, this equation becomes the classical
Michaelis-Menten equation, shown in equation 4.8.
The Hill equation is widely used to ﬁt the calibration curves for various biosensors. In
particular, GOx biosensor kinetic has a sigmoid shape response curve that is better ﬁtted
by use of the Hill equation [64]. The mechanistic reason for this experimental observation
is currently not clear. This expression will be used to ﬁt the calibration curves of glucose
and lactate biosensors in this chapter.
4.3 Hydrogen Peroxide Oxidation at a Platinum Surface
As mentioned earlier the presence of the analyte is detected indirectly through the oxidation
of H2O2, which is a product of the reaction catalysed by both GOx and LOx. Thus, the
ability of the electrode to respond to H2O2 is an important factor for biosensor fabrication.
As previously study [132], the results clearly showed that platinum (Pt) has a high sensitivity
towards H2O2 when compared to gold and therefore was employed in this thesis as a working
electrode to detect H2O2 electrochemically.
The overall mechanism of H2O2 oxidation at a Pt surface is shown in equation 4.12.
Pt+H2O2 −→ Pt+ 2H
+ + 2e− +O2 (4.12)
The equation is made up of two processes. Firstly, in the absence of H2O2 when a potential
of +0.7 V vs Ag|AgCl is applied to the Pt electrode the reaction at the surface of the Pt
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electrode is given by equation 4.13:
Pt+ 2H2O −→ Pt(OH)2 + 2H
+ + 2e− (4.13)
When H2O2 is present in the solution the following reaction occurs:
Pt(OH)2 +H2O2 −⇀↽ Pt+ 2H2O +O2 (4.14)
From the cyclic equation 4.14, Pt(OH)2 is regenerated and converted to Pt species, from
which two electrons are produced continuously to the Pt surface. This reaction occurs as
long as H2O2 is still available.
Equation 4.14 can be broken down into two reactions, which are adsorption and re-
duction, as illustrated in equations 4.15 and 4.16, respectively.
Pt(OH)2 +H2O2 −⇀↽ Pt(OH)2.H2O2 (4.15)
Pt(OH)2.H2O2 −→ Pt+ 2H2O +O2 (4.16)
As described in these equations, H2O2 is adsorbed onto the Pt(II) binding sites of
Pt(OH)2 to produce the Pt(OH)2.H2O2 complex. Following this, the complex breaks down
to produce Pt by internal electron transfer and also releases H2O and O2. This mechanism
is analogous to the Mechaelis-Menten enzyme mechanism, and the ability of Pt(OH)2 sites
to catalyse the conversion of H2O2 to H2O can be a limiting factor. It means that the sites
can be saturated with H2O2 leading to the rate of reaction reaching a maximum known as
Vmax. In addition, other completing reactions can occur at the Pt surface, which could lead
to fewer points where H2O2 can bind and be detected, resulting in a lower sensitivity to
H2O2.
According to Hall et al. [141], there are two inhibiting side reactions, which can inhibit
the oxidation of H2O2 at a Pt surface. The ﬁrst competing reaction involves competitive
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binding of the reaction product O2 to Pt(OH)2 as shown in equation 4.17 below:
Pt(OH)2(hydroxide group) +O2 −⇀↽ Pt(OH)2.O2 (4.17)
As shown in Figure 4.5, this complex with O2 can be a problem at low concentrations of
H2O2. The complex occupies the active Pt(OH)2 sites but it does not produce the inactive
Pt species, hence the adsorption reaction (equation 4.15) can no longer occur leading to loss
of H2O2 sensitivity.
Figure 4.5: Surface species for hydrogen peroxide oxidation on a platinum surface. Image taken
from Hall et al. [141].
The other competing reaction involves the reversible reaction of the protonated com-
plex as seen in equation 4.18.
Pt(OH)2.H2O2 +H
+ −⇀↽ Pt(OH)2.H2O2.H
+ (4.18)
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This is not a problem at low concentrations of H2O2 since the concentration of Pt(OH)2.H2O2
is also low. However, as the concentration of Pt(OH)2.H2O2 increases, the concentration of
the protonated complex increases and as this complex can not undergo reaction 4.16, the
current is reduced.
4.4 Development of Graphene Oxide-based Biosensors
Immobilisation of enzyme on an electrode surface is an important process and is one of
the most challenging tasks in biosensor fabrication. In particular, there are still major
limitations in immobilising either GOx or LOx on solid electrodes, such as the poor electrical
connection between the active site of the enzyme and the electrode surface and loss of enzyme
from the electrode surface. As mentioned previously, graphene oxide has been reported to
have the potential for enhancing the performance of electrochemical biosensors. This is
due to oxygen-containing groups at the edge of the graphene oxide (GO), which makes it a
suitable material for biomolecule immobilisation.
In this thesis, GO synthesised using the modiﬁed Hummer method was employed for
the development of a novel graphene based biosensor as it has a high loading of oxygen
functional groups. The GO-based biosensors were fabricated by the following methods:
• cross-linking using GO-poly(ethylene glycol)diglycidyl ether (PEGDE) hydrogel (sec-
tion 4.4.1)
• electrodeposition using GO-chitosan (section 4.4.2)
• dip-coating of GO-chitosan (section 4.4.3)
• chemical-linking of GO-chitosan self-assembled layers (section 4.4.4)
GOx and LOx were employed as model enzymes. The fabricated biosensors were
characterised electrochemically by carrying out a calibration in a beaker and by using an
automated LabSmith calibration board. The sensitivity determined by the slope of the
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calibration curve, the response time, and the enzyme kinetics were investigated for the
diﬀerent enzyme immobilisation methods. The procedure of each method will be described
as well as the results of the biosensor characterisation.
4.4.1 Cross-linking Using GO-PEGDE Hydrogel
Recently our group has fabricated hydrogel glucose biosensors using a method adapted from
that reported by Vasylieva et al. [142]. In the method, GOx is trapped on the electrode
surface in a matrix, which is formed by the reaction of the epoxy groups in PEGDE with
the amine groups on the enzyme. This is done by dipping the electrode in the PEGDE-GOx
solution, and increasing the temperature to 55℃ for 2 hours to accelerate the cross-linking
reaction, thus forming a stable immobilised ﬁlm with the enzymatic activity still preserved.
Method
In this study I adapted the method developed in the group by adding GO during the enzyme
immobilisation process. These biosensors were fabricated using the following steps.
1. As mentioned previously, all sensors were coated with mPD using electropolymerisa-
tion (see section 3.5) to improve the selectivity of the biosensor.
2. 2 mg/ml GO was dispersed in 0.01 M PBS (pH 7.4) and sonicated for 1 hour to obtain
a homogeneous solution. The GO solution was incubated with EDC/NHS coupling
agent (see section 3.9) in the ratio of 1:1 for 30 minutes in order to activate the carboxyl
groups on the GO sheets, and facilitates bonding with the primary amine groups of
the enzyme, as described in Figure 4.6.
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Figure 4.6: The process of immobilising enzyme on GO using 1-ethyl-3-(3-dimethylaminoprophyl)
carbondiimide hydrochloride (EDC) as a carboxyl activating agent to facilitate bonding with the
primary amine groups of enzyme.
3. 6 mg of GOx was dissolved in 50 µl of the activated GO, and incubated for 30 minutes
after which 50 µl of PEGDE solution was added to form a ﬁnal 60 mg/ml GOx solution.
The GOx-GO-PEGDE solution was mixed well and then 5 µl of the GOx-GO-PEGDE
nanocomposite solution was placed on a glass slide.
4. A micro-manipulator was used to dip coat the electrode to improve the reproducibility
of this step. The mPD-coated needle electrode was slowly brought down towards the
solution until the solution came up to touch the needle and was held in place for 20 s.
The composition of the PEGDE solution in 0.01 M PBS (pH 7.4) is shown in Table
4.1.
Table 4.1: Chemical compositions of PEGDE hydrogel solution
Reagent Concentration
Bovine serum albumin 30 mg/ml
Poly(ethylene glycol) diglycidyl ether (PEGDE) 60 mg/ml
Glycerol 2%
5. The modiﬁed microelectrodes were then secured upside down in order to keep the ﬁlm
as thin as possible and were incubated in an oven at 55℃ for 2 hours. After this time,
the biosensors were left at room temperature for 5 minutes before being stored at 4℃
overnight. For lactate biosensors, LOx was employed instead of GOx. For comparison,
glucose biosensors were also fabricated by dissolving GOx (60 mg/ml) directly into
the hydrogel solution without GO and dip coating using the same procedure.
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Biosensor Charaterisation
To characterise the biosensors, calibrations were carried out in a beaker containing 10 ml of
0.01 M PBS (pH 7.4) under well stirred conditions as described in section 3.7. To assess the
functionality of the enzyme trapped on the surface the glucose and lactate biosensors were
calibrated until a plateau (Vmax) was observed. The analyte response for each concentration
step was measured by subtracting the background current from the steady-state current
measured after analyte exposure. Figure 4.7 shows a typical calibration in a beaker.
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Figure 4.7: Calibration of a glucose biosensor in a beaker. (a) Raw data trace of step changes in
glucose concentration. (b) Raw data trace of a step change. T90 is the 90% response time, which is
the time it takes to obtain 90% current response from the time of addition. (c) Calibration up to
60 mM glucose. Vmax and Km values shown on graph are obtained from the curve fitting with the
Hill equation in Igor Pro. Markers indicate the mean ± standard deviation obtained from the raw
data as indicated by "mean ± SD" in (a). Inset shows initial pseudo-linear calibration. Its slope
indicates the sensitivity of the glucose response.
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Figure 4.8 shows examples calibration curves of glucose and lactate biosensors, which
were obtained by characterising the biosensors using a beaker calibration. The graphs show
the change in current at increasing substrate concentration. Vmax is seen as a plateau of
the trace and Km is the substrate concentration at half Vmax as indicated on the graphs.
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Figure 4.8: Typical GO-hydrogel nanocomposite biosensor calibration curves. These calibrations
were achieved in a beaker. Biosensors were held at a constant potential of +0.7 V. The green curve
represents the lactate response, the red curve represents the glucose response, both fabricated using
GO-hydrogel nanocomposite dip coating. The blue and orange curves represent glucose and lactate
responses of hydrogel biosensors without GO, respectively. The calibration curves were fitted with
the Hill equation. Dotted lines indicate Vmax and Km for each biosensors. In these cases α = 1.28
± 0.04 (green curve), α = 4.13 ± 0.10 (yellow curve), α = 1.06 ± 0.04 (red curve) and α = 1.14 ±
0.12 (blue curve).
As seen in the examples, the calibration curves were ﬁtted with the Hill equation
using Igor Pro. The Vmax and Km for the lactate biosensor which was fabricated by using
GO-PEGDE hydrogel dip coating (green trace) was 2.63 ± 0.02 nA and 0.56 ± 0.01 mM,
respectively. For the equivalent without GO (orange), the lactate response showed Vmax
and Km of 1.5 ± 0.003 nA and 0.38 ± 0.003 mM, respectively. For the glucose biosensors,
the Vmax was 1.14 ± 0.03 nA, and Km was 9.60 ± 0.48 mM when GO was added to the
hydrogel (red). However, without GO (blue) the Vmax and Km were 0.76 ± 0.03 nA and
3.73 ± 0.31 mM, respectively. An overview of the average lactate and glucose biosensor
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responses is shown in Table 4.2.
Table 4.2: Glucose and lactate GO-hydrogel composite biosensor responses
Biosensors Vmax (nA) Km(app) (mM) T90 (s) Sensitivity (nA/mM)
Glucose with GO (n=10) 1.44 ± 1.04 6.99 ± 2.32 5.08 ± 2.14 0.138 ± 0.09
Glucose without GO (n=3) 0.55 ± 0.19 3.59 ± 0.32 11.58 ± 3.83 0.09 ± 0.05
Lactate with GO ( n=2) 2.34 ± 0.42 0.85 ± 0.41 4.35 ± 0.22 1.62 ± 0.75
Lactate without GO†( n=30) 1.40 ± 1.30 0.38 ± 0.09 5.10 ± 2.60 1.19 ± 1.09
Note: † These results were obtained from Gowers [143]. Values are mean ± standard deviation.
These results show that addition of GO nanoparticles to the hydrogel solution increases
the sensitivity of the biosensors slightly. In addition, the Km exhibited is closer to that of the
free enzyme, which for glucose is 30 mM according to the Genzyme data sheet. For lactate
biosensors, with GO-hydrogel solution, the Km was 0.85 mM, which is really close to that of
free LOx, which is reported as 0.7 mM on the Genzyme data sheet. The response time (T90)
for glucose biosensors was almost 2 times faster than the case without GO. Although overall
the results show that the GO-hydrogel glucose biosensors have a slightly better performance
than without the GO, the results were variable and the improvement in sensitivity is only
slight.
4.4.2 Electrodeposition Using Graphene Oxide-chitosan
Electrochemical deposition or electrodeposition is a useful technique, which is used for coat-
ing a thin layer on a conductive surface to modify its properties. In principle, it works by
passing a current from an external source through an electrochemical cell, which causes a
ﬂow of electrons to ions in a solution leading to the generation of a thin ﬁlm on the surface.
This technique has received considerable attention for enzyme immobilisation in biosen-
sor fabrication. In this study, chitosan was chosen as a supporting material to immobilise
enzymes using electrodeposition as well as to incorporate GO for biosensor performance
enhancement.
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Chitosan
Chitosan is an abundant natural polymer, which is found in insect and crustacean exoskele-
tons. It is typically synthesised by the deacetylation of chitin, (1,4)-2-acetoamide-2-deoxy-
β-D-glucan. The structure of chitosan is illustrated in Figure 4.9. Chitosan is an excellent
candidate to be used as a substrate for biosensor fabrication due to its attractive properties.
For example the primary amine groups on chitosan are critical for binding biomolecules like
enzyme, protein and DNA. In particular, its solubility depends on the pH, which allows the
chitosan hydrogel to be electrically assembled onto a conductive surface using electrodepo-
sition [144, 145]. Chitosan is also biocompatible, commercially available, and inexpensive.
Figure 4.9: Chemical structure of chitosan
Considering the pH-responsive solubility of chitosan, at moderately acidic pH (pH
< 6), chitosan exists as a water-soluble polyelectrolyte since the primary amine groups of
chitosan become protonated and form positively charged ammonium groups. When the pH
of the solution is increased near or above its pKa value, which is about 6.3 [144, 146], the
amino groups are deprotonated, resulting in chitosan becoming insoluble as shown in Figure
4.10. As a result, it has been reported that chitosan can be deposited onto an electrode
surface using electrodeposition [20, 145].
pKa~ 6.3
+  2nH+
soluble insoluble
Figure 4.10: Chemical structure of chitosan showing pH-induced transition
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It is hypothesised that combining the beneﬁt of GO and chitosan can enable more
eﬃcient enzyme immobilisation and can increase the possibility for more enzyme loading at
the electrode surface since enzyme can be immobilised covalently to the carboxyl groups of
GO and to the primary amine groups of chitosan. Therefore, glucose and lactate biosen-
sors were fabricated using the electrodeposited nanocomposite of GO-chitosan for enzyme
immobilisation on the working electrode surface.
Method
In this work, chitosan (deacetylation percentage of > 75%, practical grade, Sigma-Aldrich)
was prepared by dissolving in 1% acetic acid as described in section 3.9. 2.5 mg of GO
was dissolved in 5 ml of the chitosan solution to form 0.5 mg/ml GO-chitosan solution, and
sonicated for 30 minutes to obtain a homogeneous solution. The pH of the GO-chitosan
solution was adjusted to pH 5.0 by adding 1.0 M NaOH. Then, 5 mg/ml of GOx was prepared
in the GO-chitosan solution. The GOx was incubated in the solution at room temperature
for 30 minutes. The mPD-coated Pt microelectrode was immersed in the GOx-GO-chitosan
solution for 5 minutes before a current density of 20 A/m2 [147], which is equivalent to
current (I)=39.29 nA for a 50 µm diameter Pt microelectrode, was applied using a current
source. For lactate biosensors, LOx was prepared in the same concentration as for GOx and
the biosensors were fabricated using the same procedure. Figure 4.11 shows a typical trace
during current application during GOx-GO-chitosan electrodepostion obtained.
4.4. Development of Graphene Oxide-based Biosensors 85
-1.2
-1.0
-0.8
-0.6
-0.4
-0.2
P
o
t
e
n
t
i
a
l
 
/
 
V
2015105
time / min
Figure 4.11: A typical trace seen during chitosan electrodeposition on the microelectrode surface
using a current density of 20 A/m2 for 15 minutes. The working electrode was held at 0 nA for 5
minutes and then the current was applied to the electrode for 15 minutes for electrodeposition to
occur. The electrode was held at 0 nA for a further 2 minutes to allow the film to stabilise.
During the current application between the Pt working electrode (cathode) and the
stainless steel auxiliary electrode (anode), the electrodes became negatively and positively
charged, respectively. Electrons ﬂowed through the cathode and reduction of H2O occured
at the cathode surface while oxidation of H2O occured at the anode as shown in equations
4.19 and 4.20, respectively.
Cathode : 2H2O + 2e
− −→ H2 + 2OH
− (4.19)
Anode : 2H2O −→ O2 + 4H
+ + 4e− (4.20)
From the above reactions it can be seen that the pH of the region of chitosan near the
cathode surface gradually increased due to the production of hydroxide ions (OH−) were
produced. The generation of OH− at the cathode neutralised the chitosan and induced its
localised sol-gel transition. When the pH was higher than the pKa value of chitosan (pKa =
6.3) [144], chitosan became insoluble leading to the localised deposition of chitosan hydrogel
ﬁlm on the surface as described in the following reaction.
Chitosan−NH+3 +OH
− −→ Chitosan−NH2 +H2O (4.21)
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This led to entrapment of enzyme-GO with the chitosan on the surface as shown in
Figure 4.12. Proton consumption occurs causing a pH gradient to be generated at the inter-
facial region of the Pt electrode (the cathode) and the solution. As the pH of the chitosan
surrounding the Pt electrode increases, it is deprotonated and becomes insoluble (pH >
pKa) resulting in an enzyme-GO-chitosan being electrodeposited on the cathode surface.
Chitosan is not deposited on the auxiliary electrode surface because the pH surrounding the
auxiliary electrode is lower than 6.3 (soluble condition).
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2H+
pH gradient
soluble chitosan chains
(low pH)
insoluble chitosan !lm
(high pH)
e-
Figure 4.12: Mechanism of cathodic electrodeposition of enzyme-GO-chitosan composite. Elec-
trolysis of water generates a localised high pH that induces chitosan to undergo a sol-gel transition
to form a hydrogel film at the working electrode (Pt).
After coating, the biosensors were kept in a fridge at 4℃ overnight. The fabricated
biosensors were characterised in a well-stirred beaker and also using the automated LabSmith
calibration board to investigate the stability of the biosensors during continuous calibration
in a ﬂow system through a PDMS microﬂuidic chip for 24 hours.
Biosensor Characterisation
In GOx-GO-chitosan electrodeposition, the duration of current application is a key factor
as it aﬀects the thickness of the chitosan ﬁlm. This was optimised by making sensors at 5,
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10, 12, 15 and 20 minute deposition times. To compare these biosensors, calibration was
carried out in a beaker under stirred conditions. The relationship between the sensitivity of
the biosensors and the time of electrodeposition is shown in Figure 4.13.
slope = 1.32      0.048 x 10-4
Figure 4.13: Electrodeposition of GOx-GO-chitosan at different electrodepostion periods. The
Figure shows the glucose sensitivity, taken as the initial pseudo-linear calibration slope (± error),
for 5 different electrodeposition times. The line is a curve fit using the sigmoid function in Igor
Pro.
As shown in Figure 4.13, it was found that increasing the time of electrodeposition
increases the sensitivity of the biosensor. The results showed a plateau of sensitivity at
15 minutes of current application with a sensitivity value of 1.6 × 10−4 nA.mM−1.µm−2.
Therefore, a period of 15 minutes for GOx-GO-chitosan electrodeposition was chosen for
enzyme immobilisation in glucose biosensor fabrication, and also for fabrication of lactate
biosensors.
Examples of the calibration curves obtained for glucose and lactate biosensors made
using 15 minute electrodeposition are shown in Figure 4.14.
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Figure 4.14: Typical calibration curves of GO-chitosan biosensors fabricated using electrodepo-
sition (15 minutes). Calibrations were carried out in a beaker. Biosensors were held at a constant
potential of +0.7 V. The green curve represents the lactate response, the red curve represents the
glucose response, and the blue curve represents glucose response of chitosan glucose biosensor with-
out GO combination. The calibration curves were also fitted with the Hill equation. Dotted lines
indicate Vmax and Km for each biosensors. In these cases α = 3.22 ± 0.49 (green curve), α = 1.00
± 0.13 (blue curve) and α = 1.84 ± 0.09 (red curve).
In these examples, the calibration curves were ﬁtted with the Hill equation using Igor
Pro. For the lactate biosensor in Figure 4.14, which was fabricated by using GO-chitosan
electrodeposition the Vmax and Km were 0.84 ± 0.01 nA, and 0.29 ± 0.02 mM, respectively.
For the glucose biosensor with GO (red curve), the Vmax was 0.88 ± 0.01 nA and the Km
was 2.15 ± 0.08 mM, while without GO biosensor (blue curve), the Vmax and Km were 2.30
± 0.08 nA and 1.96 ± 0.24 mM, respectively. An overview of the responses of lactate and
glucose biosensors which were fabricated by electrodeposition is shown in Table 4.3.
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Table 4.3: Glucose and lactate chitosan biosensor responses with and without GO
Biosensors Vmax (nA) Km(app) (mM) T90 (s) Sensitivity (nA/mM)
Glucose with GO (n=9) 1.20 ± 0.46 2.71 ± 1.36 5.12 ± 1.09 0.29 ± 0.12
Glucose without GO (n=2) 2.52 ± 0.47 2.89 ± 1.18 5.72 ± 0.60 0.54 ± 0.15
Lactate with GO ( n=5) 0.97 ± 0.36 0.26 ± 0.037 6.47 ± 1.47 1.41 ± 0.67
Overall in the construction of glucose biosensors by chitosan electrodeposition, the
performance of glucose biosensors seems to be worse when GO is combined with the chitosan
solution. The Vmax and sensitivity of glucose biosensors fabricated by electrodeposition
using GO combined with chitosan solution was lower than without GO. The values of Km
and the response time were quite similar between the two cases. As seen in Table 4.3 for
chitosan enzyme immobilisation the Km of the enzymes is much smaller than that reported
for the free enzyme and indeed for the PEGDE ﬁlms. T90 was broadly similar to that for the
PEGDE biosensor with the exception of the glucose PEGDE biosensor without GO, which
was higher, however this was n=2. At ﬁrst sight it appears that sensitivity with chitosan
(at 0.29 nA/mM) is greater than that for PEGDE (at 0.138 nA/mM). However, closer
examination of the data shows that this is because Km of the enzyme is lower with chitosan,
while Vmax is basically the same. Hence the chitosan electrode delivers the response over a
narrower concentration range.
On-chip Stability Study
The stability of glucose biosensors, which were fabricated using GOx-GO-chitosan electrode-
position and GOx-chitosan electrodeposition (without GO) was investigated by using the
microﬂuidic automated calibration platform (LabSmith) as described earlier in section 3.7.
This device allowed the system to be calibrated continuously every hour. The stability of
the glucose biosensors was studied for 24 hours. The biosensor was placed in the housing
chamber of a PDMS microﬂuidic chip described earlier in section 3.8. The calibration was
carried out with 5 diﬀerent glucose concentrations, which were 1 mM, 0.75 mM, 0.50 mM,
0.25 mM and 0 mM, at a ﬂow rate of 2 µl/min. An example of the raw data for the 5-
90 Chapter 4. Development of Graphene-based Electrochemical Biosensors
step calibration is illustrated in Figure 4.15. The results are shown in Figure 4.16a for the
GOx-GO-chitosan biosensor, and in Figure 4.16b for the GOx-chitosan biosensor.
Glucose concentration                   1 mM                                  0.75 mM                             0.5 mM                                 0.25 m M                                   0 mM 
Figure 4.15: An example of raw data for a 5-point glucose calibration. In this example, the
glucose biosensor was fabricated using electrodeposition of GO-chitosan and was calibrated from
0-1 mM on-chip using an automated calibration board to control the flow rate of the solutions.
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(a) GO-chitosan glucose biosensor
(b) Chitosan glucose biosensor without GO
Figure 4.16: Glucose biosensor calibrated on-chip from 0 -1 mM using an automated calibration
board (a) glucose biosensor fabricated by electrodeposition of chitosan with GO and (b) glucose
biosensor fabricated by chitosan electrodeposition without GO.
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As seen in Figure 4.16, glucose biosensor calibrations were carried out continuously
for 24 hours. The sensitivity of the GO-chitosan electrodeposited biosensor (Figure 4.16a)
was more stable over 6 hours compared to without GO. Comparison of the calibration
curve slope over 24 hours for the GO-chitosan and chitosan without GO glucose biosensors
shows similar results with the drops in sensitivity from the ﬁrst hour to the 24th hour being
approximately 27.39% and 24.31%, respectively. Although the sensitivity of the GO-chitosan
electrodeposited biosensor decreased only slightly during 6 hours, its sensitivity then fell over
the remaining 24 hours. In contrast, the glucose biosensor without GO showed an initial fall
in sensitivity, which then stabilised over the remaining time. In practical use, for short term
monitoring, the GO-chitosan biosensor would be more suitable, while the glucose biosensor
without GO would be better for glucose detection for longer monitoring times.
4.4.3 Dip Coating of GO-chitosan
Method
Glucose biosensors were fabricated by dip coating using the same GO-chitosan nanocom-
posite solution containing 5 mg GOx dissolved in 1 ml of 0.5 mg/ml GO-chitosan. 5 µl of
the GOx-GO-chitosan solution was placed on a glass slide. In a similar way to the hydrogel
dip coating, the mPD-coated needle electrode was slowly brought down towards the solution
until the solution came up to touch the needle and was held in place for 5 minutes as shown
in Figure 4.17. The electrodes were not connected at this step. The modiﬁed electrode was
then kept at 4℃ overnight before use.
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Figure 4.17: Dip coating the needle electrode surface in enzyme solution using a micro-
manipulator.
Biosensor Characterisation
An example of the result of a beaker calibration is shown in Figure 4.18. In this example,
the calibration curve was ﬁtted with the Hill equation using Igor Pro. The Vmax and Km for
this glucose biosensor were 2.04 ± 0.03 nA and 1.48 ± 0.09 mM, respectively. An overview
of the responses glucose biosensors fabricated using this method is shown in Table 4.4.
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Figure 4.18: Typical calibration curve of a glucose biosensor fabricated using the dip-coating
method. The calibration was carried out in a beaker. The biosensors was held at a constant
potential of +0.7 V. The calibration curve was fitted with the Hill equation. Dotted lines indicate
Vmax and Km. In this case α = 2.19 ± 0.31.
Table 4.4: Glucose biosensor responses of GO-chitosan dipped biosensors
Biosensors Vmax (nA) Km(app) (mM) T90 (s) Sensitivity (nA/mM)
Glucose with GO (n=3) 2.58 ± 0.57 1.15± 0.29 4.33 ± 0.66 1.26 ± 0.51
As seen in Table 4.4, these biosensors exhibited much higher sensitivity and higher
Vmax as compared to biosensors fabricated using the electrodeoposition method (Table 4.3).
In addition, the time response is still fast. However, the Km value is approximately half of
that for the electrodeposition case, meaning that the biosensor saturated quickly at about
8 mM. This indicates the high aﬃnity of the enzyme for the substrate. To investigate the
stability of these biosensors, a glucose biosensor was calibrated for 24 hours in a PDMS mi-
croﬂuidic chip using the autocalibration board. The results of the on-chip glucose calibration
are shown in Figure 4.19.
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Figure 4.19: Glucose biosensor on-chip was calibrated from 0-1 mM using the automated cal-
ibration board. The glucose biosensor was fabricated by dip-coating of chitosan combined with
GO.
Figure 4.19 illustrates the glucose response over for 24 hours in a microﬂuidic platform.
The sensitivity of the GO-chitosan glucose biosensor decreased dramatically over the ﬁrst
three hours, 18 hours, and then stabilised after 18 hours. Comparing the ﬁrst calibration and
the last calibration, the slope dropped by approximately 78%. However, it should be noted
that the residual sensitivity of 0.27 nA/mM is still comparable with the initial sensitivity
of other methods. Although the sensitivity of the glucose biosensors, which were fabricated
using dip-coating of a combination of GO and chitosan oﬀered a high initial sensitivity,
these biosensors were unstable in the ﬂow system over 24 hours. Therefore, this method
may not a good alternative for glucose biosensor construction for real-time glucose detection
in clinical use.
4.4.4 Chemical-linking of GO-chitosan Self-assembled Layers Method
This section will describe the construction of glucose biosensors by coating with layers
of chitosan and GO, which was adapted from Huimin et al. [148]. In this method, they
immobilised trypsin with layer-by-layer coating of GO and chitosan on a glass ﬁbre by
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employing the beneﬁt of the positive charge of chitosan and negative charge of GO. However,
for a glucose biosensor it may be diﬃcult to immobilise GOx on the GO sheet without any
coupling agent due to the fact that both GOx (pI=4.2) and GO are negatively charged at
pH 7.4. Therefore, chemical linking was used for construction of the biosensors.
The immobilisation method was developed based on the combination of both layer-by-
layer assembly of chitosan and GO and also the use of coupling agents, which were 1–ethyl–3–
(3–dimethylaminoprophyl) carbondiimide hydrochloride (EDC) and N-hydroxysuccinimide
(NHS) as covalent chemical linkers. In this method, GO and chitosan were still deposited
in alternate layers on the needle electrode surface. The GO-chitosan layer deposition was
driven by electrostatic force on the surface as chitosan was positively charged and GO was
negatively charged at pH 7.4 condition. GOx could then be immobilised onto the GO-
chitosan layer using the EDC/NHS as coupling agents to bond the carboxyl groups of GO
and the primary amine groups of GOx as described in the previous section (Figure 4.6).
Method
In this procedure, 2 mg/ml GO were dissolved in DI water and adjusted to pH 8.0 using
a diluted ammonia aqueous solution (3M). Chitosan solution was prepared as described in
section 3.9. 5 µl of the chitosan solution was placed on a glass slide. The mPD-coated
needle electrode was dipped in the chitosan drop for 5 minutes and subsequently dipped
for a further 5 minutes into 5 µl of the GO solution, which had been placed on a glass
slide. The two-layer modiﬁed microelectrode was then secured upside down in order to keep
the ﬁlm as thin as possible and allowed to dry at room temperature for 1 hour. The GO-
chitosan layer modiﬁed electrode was then immersed into EDC/NHS solution to activate
the carboxyl groups of GO sheet layer for 1 hour. Subsequently, the activated GO-chitosan
electrode was incubated in 10 mg/ml GOx in 0.01 M PBS solution (pH 7.4) for 2 hours
at room temperature. In this step, an amine group was introduced into the GO sheet
through EDC/NHS mediated reaction between carboxylic acid and ethylenediamine to form
a positively charged GO sheet. Then the negatively charged GOx were assembled on the
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surface of GO-NH+3 as previously described in Figure 4.6. The overall procedure is shown
in Figure 4.20. The glucose biosensor was kept in a fridge at 4℃ overnight before use.
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Figure 4.20: Schematic procedure of a needle electrode modified by layer deposition of chitosan
and GO and finally enzyme on the GO layer using 1–ethyl–3–(3–dimethylaminoprophyl) carbondi-
imide hydrochloride (EDC) and N-hydroxysuccinimide (NHS) as carboxyl activating agents for
bonding with the primary amine groups of the enzyme
Biosensor Characterisation
Figure 4.21 shows an example of a glucose biosensor calibration curve. The calibration was
carried out in a beaker and the graph shows the change in current at increasing substrate
concentration.
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Figure 4.21: Typical calibration curve of GO-chitosan biosensor fabricated using layer of chitosan
and GO and chemical linking method. The calibration was carried out in a beaker. Biosensors
were held at a constant potential of +0.7 V. The calibration curve was also fitted with the Hill
equation. Dotted lines indicate Vmax and Km. In this case α = 1.45 ± 0.05.
The calibration curve shown in Figure 4.21 was ﬁtted with the Hill equation using Igor
Pro. The Vmax and Km for this glucose biosensor were 2.00 ± 0.02 nA and 4.36 ± 0.108
mM, respectively. An overview of average glucose biosensor responses is shown in Table 4.5.
Table 4.5: Glucose biosensor responses of chemical linked GO-chitosan biosensors
Biosensors Vmax (nA) Km(app) (mM) T90 (s) Sensitivity (nA/mM)
Glucose with GO (n=8) 2.31 ± 0.94 7.03 ± 5.26 3.92 ± 0.71 0.23 ± 0.17
Overall, these results showed that glucose biosensors were successfully fabricated using
chemical linking combined with the layers of chitosan and GO. The glucose biosensors were
fast to respond to changes in glucose concentration. Their sensitivity is not as good as
that of the dip-coating of GO-chitosan method (section 4.4.3) but is better than that of
cross-linking using GO-PEGDE hydrogel method. These biosensors were also be tested for
stability under ﬂow for 24 hours. The results are shown below.
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Figure 4.22: Glucose biosensor was calibrated on-chip from 0-1 mM using the automated cali-
bration board. The glucose biosensor was fabricated using layer of chitosan and GO and chemical
linking method
Figure 4.22 shows glucose responses over for 24 hours in a microﬂuidic platform. The
drop in sensitivity of the glucose biosensor was slightly reduced compared with previous
methods. The sensitivity of the calibration at 1st hour is reduced by approximately 10.61%
by the 24th hour. Although the glucose biosensors fabricated using this method the exhibited
currents almost 10 times lower than that for other methods, there were quite stable under
ﬂow during repeated calibrations. Therefore, this method is a good alternative for the
glucose biosensor construction for real-time glucose detection in clinical use.
4.5 Comparison of Performance Characteristics in Re-
sponse to Glucose Concentration
This section summarises and compares the performance characteristics of GO-based glucose
biosensors, which were reported previously in the result tables, including Vmax, Km(app),
T90, sensitivity and stability. All four methods used to fabricate glucose biosensors in
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this chapter were compared, including cross-linking GO-PEGDE hydrogel (GOx-EDC-GO-
PEGDE)dip|mPD|Pt, electrodeposition using GO-chitosan (GOx-GO-chitosan)EDP |mPD|Pt,
dip coating using the same solution as for the electrodeposition (GOx-GO-chitosan)dip|mPD|Pt,
and chemical-linking to GO-chitosan self-assembled layers GOx/EDC-(GO-chitosan)dip|mPD|Pt.
Histograms summarising the four charateristics of GO-based glucose biosensors for each
method are shown in Figure 4.23.
The results for Vmax are shown in Figure 4.23a. Vmax typically represents the max-
imum reaction rate when all the enzyme in the system is occupied by the substrate. The
results show that the (GOx-GO-chitosan)dip yielded the highest value (mean 2.58 nA),
which was slightly higher than for GOx/EDC-(GO-chitosan)dip (mean 2.31 nA) as well
as for (GOx-EDC-GO-PEGDE)dip (mean 1.44 nA). However, it was signiﬁcantly higher
than for (GOx-GO-chitosan)EDP (mean 1.20 nA). This is possibly because the (GOx-GO-
chitosan)dip was based on the dipping technique, which might allow immobilisation of more
enzyme in the layers than using electrodeposition techniques. As a results, Vmax for the
(GOx-GO-chitosan)dip is the highest of the four fabrication techniques.
Km(app) (Figure 4.23b) indicates the aﬃnity of substrate for the enzyme, which af-
fects the reaction rate. A lower value of Km represents a higher aﬃnity. The GOx/EDC-
(GO-chitosan)dip shows the highest value of Km (mean 7.03 mM), which is not statistically
diﬀerent from the (GOx-EDC-GO-PEGDE)dip (6.99 mM). However, the value of Km for the
(GOx-EDC-GO-PEGDE)dip is signiﬁcantly higher than that for the (GOx-GO-chitosan)EDP
and for the (GOx-GO-chitosan)dip, which are equivalent to 2.71 mM and 1.15 mM, respec-
tively.
In case of T90 (Figure 4.23c), the results show that there is no signiﬁcant diﬀerence
between the four fabrication techniques (all in the range of 4-5.5 s). This means that the
biosensors can quickly respond to change in the glucose concentration.
Finally, the sensitivity (the slope of the calibration curve) is illustrated in Figure
4.23d. It represents the current detected for a given substrate concentration. A higher
sensitivity means the biosensor is better able to detect lower substrate concentrations. The
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results reveal that the (GOx-GO-chitosan)dip method gives the highest sensitivity (mean 1.4
nA/mM), which is signiﬁcantly higher than for the other fabrication techniques.
Overall in a beaker the (GOx-GO-chitosan)dip method can provide good performance
in terms of Vmax, T90 and sensitivity for detecting glucose. Typically, the baseline dialysate
levels in the brain in the range 300-2000 µM glucose and 400-2000 µM lactate [149] and
200-5000 µM glucose and 200-several µM lactate [40]. These biosensors can be used to
measure the metabolite levels, especially for detection in the brain. The higher enzyme
loading enabled by the chitosan and the dipping-coat technique results in biosensors with
a superior performance than the other three fabrication techniques. However, it should be
noted that the Km of the (GOx-GO-chitosan)dip highest for this method, which means that
the enzyme becomes saturated quickly and at lower glucose concentrations. The GOx/EDC-
(GO-chitosan)dip, on the other hand, can provide similar performance in terms of Vmax
and T90 but with a better Km. However, a trade-oﬀ exists because the sensitivity of the
GOx/EDC-(GO-chitosan)dip is much lower than for the (GOx-GO-chitosan)dip. The stability
of the biosensors is an important characteristic for a successful biosensor for clinical use. The
stability of the biosensors was studied for 24 hours under ﬂow conditions using a microﬂuidic
platform and were already shown previously. The results will be was compared in the
following section.
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Figure 4.23: Comparison of four methods used for GO-based glucose biosensor fabrication in terms of performance characteristics. Histograms
represent mean ± standard deviation. Data for (GOx-EDC-GO-PEGDE)dip |mPD|Pt obtained from Table 4.2 (n=10), (GOx-GO-chitosan)EDP |mPD|Pt
obtained from Table 4.3 (n=9), (GOx-GO-chitosan)dip|mPD|Pt obtained from Table 4.4 (n=3) and GOx/EDC-(GO-chitosan)dip |mPD|Pt obtained from
Table 4.5 (n=8). (a) Vmax, (b) Km, (c) T90 and (d) sensitivity. Significance: * P<0.05, ** P<0.01, *** P<0.001, NS=not significant. Test with
unpaired statistic t-test using GraphPad software.
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Stability Over 24 Hours
To be useful as biosensors in the intensive care unit or in other clinical monitoring situations
it is vital that the biosensors show good stability in the relevant concentration range. If
complete stability is not possible, which is usually the case, then the sensitivity can be
tracked during the monitoring period using an automated calibration board (LabSmith). In
this section I will track the long-term performance of the diﬀerent GO-chitosan biosensors
using repeated calibrations every 3 hours over 24 hours of continuous use.
The glucose biosensors were intended to be inserted into a PDMS microﬂuidic chip
therefore, damage to the enzyme layer could occur. To compare the stability of these
biosensors over time, the results of continuous calibrations using the automated calibration
board (LabSmith) for each method, which were shown previously were plotted against time
of calibration as illustrated in Figure 4.24.
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Figure 4.24: Comparison of the stability of glucose biosensors for a 24-hour period during repeated calibration using the automated calibration board.
The relationship between the current signal and glucose concentration is plotted for the different fabrication methods using (a) (GOx-GO-Chitosan)dip
method, (b) (GOx-GO-Chitosan)EDP method, and (c) GOx/EDC-(GO-Chitosan)dip method. (d) The sensitivities of each method were plotted against
time of calibration (d). For (b) the calibration at the 18th hour and (c) the calibration at the 3rd hour were lost due to bubbles occurring in the analysis
chip.
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As shown in Figure 4.24, in continuous use both (GOx-GO-Chitosan)EDP (Figure
4.24d blue) and GOx/EDC-(GO-Chitosan)dip (Figure 4.24d green) displayed satisfactory
stability over a 24-hour period, which is suﬃcient for clinical monitoring. In contrast,
the sensitivity of the (GOx-GO-Chitosan)dip glucose biosensor (Figure 4.24d red) dropped
dramatically over 18 hours because the enzymes were washed out during ﬂowing the solution
in the PDMS chip. This indicates that these enzymes were not bonded strongly on the
electrode surface by using the dip-coating GO-chitosan method. After assessment of the
three methods for enzyme immobilisation, it can be concluded that both the method of
electrodeposition using GO-chitosan and the method of chemical-linking on layers of GO-
chitosan have potential for fabrication of glucose biosensors for real-time glucose detection
within a microﬂuidic platform.
4.6 Interference Study
In practical use, the eﬀect of interferences on the detection of glucose and lactate biosensors is
a crucial issue. In this study, all sensors were coated with mPD using electropolymerisation
as described in section 3.5. This section will investigate the potential of the mPD ﬁlm
to protect the Pt electrode from interferent species, which could be oxidised at the high
potential applied. These species include serotonin, dopamine and ascorbic acid.
This experiment was conducted in a beaker containing 0.01 M PBS (pH 7.4) under
stirred conditions. All chemicals under investigation, which were 5-hydroxytryptamine (sero-
tonin, 5-HT), ascorbic acid (AA) and dopamine (DA) were purchased from Sigma-Aldrich
and solutions were prepared fresh. The glucose biosensor was initially coated with mPD by
electropolymerisation followed by (GOx-GO-Chitosan)EDP (see section 4.4.2). The results
are compared with a bare electrode. Three possible interferences including 5 µM 5-HT, 5
µM DA, and 500 µM AA in PBS were tested. The results are shown in Figure 4.25.
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Figure 4.25: Interference study of mPD-coated Pt microelectrode compared to a bare Pt mi-
croelectrode. The red trace represents a glucose biosensor fabricated using GOx-GO-chitosan
electrodeposition method on top of the mPD-coated electrode and the blue trace represents a
Pt electrode without mPD coating on its surface.
The results showed that no interference was observed on the mPD-coated biosensor
from DA, 5-HT and AA. This is most likely due to the selectivity of the mPD electropoly-
merised ﬁlm. However, the biosensor successfully detects H2O2 which is both small and
neutral. DA and 5-HT are positive, AA is negative and all are larger than H2O2 in size. In
contrast, at the bare Pt electrode, the interference was seen clearly as the current increased
upon addition of each species. This indicates that the mPD ﬁlm prevents the problem of
interference even after the electrodeposition process.
4.7 Automated Clinical Microdialysis Analysis Platform
As a ﬁnal proof-of-concept experiment a GOx/EDC-(GO-Chitosan)dip|mPD|Pt biosensor
was placed in a microﬂuidic chip (see section 3.8) connected to a modiﬁed computer con-
trolled autocalibration system and a microdialysis probe. As mentioned previously in section
3.7, regular calibration is crucial to ensure that the results obtained are accurate, thus an
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automated calibration system was employed to calibrate the biosensor. This system was
controlled using uProcess software (LabSmith) by running the custom-written command
script to automatically create step changes in concentration.
Modified Autocalibration System Incorporating Microdialysis Probe
The autocalibration system described in section 3.7 was modiﬁed to allow computer con-
trolled switching between dialysate from the microdialysis probe and the calibration system.
It was important that this new device maintained constant ﬂow through the microdialysis
probe and that it avoided introduction of bubbles into the analysis chip during switching.
Control scripts were written in uProcess.
The experimental setup can be seen in Figure 4.26. The automated calibration system
consists of two syringe pumps, one containing 5 mM of glucose standard solution and one
containing T1 solution (see section 3.9) used as a physiological solution. The biosensor was
calibrated automatically at 2 µl/min in the range from 0 to 5 mM. As described before in
section 3.7, the solutions from both syringe pumps were mixed at the interconnect. In this
system, the substrate is diluted depending on the mixing ratio between the two solutions,
which is determined by varying the respective ﬂow rates of the two pumps, thus creating
a multi-step calibration. The glucose sensor was placed in a PDMS analysis chip and
connected to a potentiostat, which was used to apply a constant potential of +0.7 V to the
sensor in order to allow the oxidation of H2O2 to occur.
108 Chapter 4. Development of Graphene-based Electrochemical Biosensors
(b)  Calibration on board (c)  Dialysate analysis
T1
Standard solution
waste
2 μl/min
Dialysate
waste
T1
Standard solution
waste
2 μl/min
Dialysate
waste
T1
Standard solution
waste
Dialysate
waste
(a)  Re!ll pumps
2 μl/min
Dialysate
T1
Standard solution
waste
waste
syringe pump reservoir Analysis chipInterconnectValve
Figure 4.26: Schematic of the experimental setup for detector of dialysate in a beaker. This setup
was used to calibrate on-chip biosensors.The cross indicates the biosensor.
A microdialysis (MD) probe (CMA 70, MDialysis, Sweden) was immersed in a beaker
containing 30 ml of T1 solution under stirred conditions. The outlet of the MD probe was
extended using low-volume ﬂuorinated ethylene propylene (FEP) tubing (0.12 mm inner
diameter, Royem Scientiﬁc, UK) and connected to the automated calibration board. The
inlet of the MD probe was continuously perfused with T1 solution at 2 µl/min ﬂow rate using
a portable syringe pump (CMA 107, Mdialysis, Sweden) and was connected connecting to
the automated calibration board. The T1 solution from the syringe pump ﬂows continuously
during the experiment in order to allow glucose molecules to diﬀuse through the membrane
and to travel in the dialysate stream through the probe outlet to the analysis chip. To vary
the glucose concentration in the beaker, aliquots of glucose standard solution were added
using a Gilson pipette.
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Figure 4.26 shows the calibration board setup to reﬁll the pumps, carry out a calibra-
tion to analyse dialysate levels. The dialysate continuously ﬂows to the LabSmith board
without interruption and the direction is controlled by the three-port two position valve.
The valve can be switched to the direction of the waste reservoir during pump reﬁll and
calibration. In the dialysate analysis chip, the dialysate ﬂows directly towards the analysis
system, and the alternative path is blocked (red cross) to ensure that only the dialysate
stream ﬂows towards the analysis chip. The results are shown in Figure 4.27.
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Figure 4.27: Dialysate calibration curve of on-chip novel GO-based glucose biosensor. Calibra-
tions were carried out using an automated calibration board with integrated PDMS microfluidic
chip housing the glucose biosensor. The glucose biosensor was fabricated using chemical linking of
GOx on the layers of GO and chitosan. The glucose biosensor was held at a constant potential
of +0.7 V. (a) the red trace represents the calibration curve obtained using calibration on-board,
and (b) the purple trace represents the changes measured in the dialysate when aliquots of glucose
standards were injected into the beaker in which the MD probe was placed. The concentrations
refers to beaker concentrations not dialysate concentrations.
For the on-chip calibration, a 4-point glucose concentration was carried out with levels
corresponding to 0, 2.5, 3.75, and 5 mM. In Figure 4.27a, the sensitivity of the glucose
biosensor in the microﬂuidic chip was 0.087 ± 0.005 nA/mM. The purple line ( Figure 4.27b)
shows the data obtained when the MD probe was placed in beaker and glucose standard
concentrations was added giving total of 0, 0.2, 0.4, 0.8, 1.2, and 1.6 mM. The sensitivity of
the dialysate calibration curve was 0.073 ± 0.003 nA/mM. The slope of the calibration curve
was lower in this case than that of the on-chip calibration. This is because when a perfused
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microdialysis probe is immersed in a beaker, the analyte concentration in the dialysate will
be less than that in the beaker due to the fact that there is not complete diﬀusion through
the membrane into the moving liquid stream. Although a low ﬂow rate of only 2 µl/min
was used, the dialysate concentration was still less than the beaker concentration. This is
determined by the recovery of the MD probe (R) which can be calculated by equation 4.22.
R =
[Glucose]MD
[Glucose]beaker
× 100 (4.22)
Where [Glucose]MD is the concentration of glucose in the dialysate and [Glucose]beaker
is the concentration of glucose in the beaker.
In this case, the recovery was found to be 72.29 ± 2.43 %. Therefore the recovery of
a microdialysis probe would aﬀect glucose concentration detected in the dialysate stream.
The percentage recovery depends on a number of factors including the ﬂow rate of the T1
perfusion solution through the MD probe, the membrane length, the membrane molecular
weight cut-oﬀ and the intensity of stirring in the beaker [150]. In this study, the values of
these parameters were 2 µl/min, 10 mm length, and 20 kDa, respectively.
4.8 Conclusion
In summary, this chapter shows the development of GO-based biosensors that employed GOx
and LOx as model enzyme systems. Four methods of GO-based enzyme immobilisation on
a needle microelectrode surface were investigated, including cross-linking using GO-PEGDE
hydrogel, electrodeposition using GO-chitosan, dip-coating with GO-chitosan solution and
chemical linking of GOx on chitosan-GO layers.
GO was successfully employed to prepare a biocompatible coating on the surface of
needle electrodes via these methods. Fabrication by chemical linking was found to be the
best overall method for immobilisation of GOx. These novel GO-based biosensors could
be used successfully in a microﬂuidic platform. It was demonstrated that the GO-chitosan-
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based glucose biosensor fabricated by chemical linking showed potential for on-line detection
during several hours continuous monitoring.
This chapter has introduced an automated calibration board, which can be used with
on-chip biosensors. The system allows calibration to be carried out at regular intervals.
This system was used to study the stability of these GO-based biosensors for 24 hours. In
addition, eﬀect of interferent species which could be oxidised at the high potential applied
has been investigated. Coating the electrode surface with a mPD ﬁlm using electropoly-
merisation before the enzyme immobilisation step was found to give good protection against
interferences.
Finally, the capability of detecting physiologically relevant concentrations of glucose
in the dialysate using a GO-based glucose biosensor was validated in vitro by placing the
MD probe into a beaker under vigorously stirred conditions.
Chapter 5
Development of on-line Microfluidic
Detector for Dopamine
This chapter describes the use of reduced graphene oxide as a material to modify a platinum
(Pt) needle electrode for fabrication of electrochemical sensors to detect neurotransmitters
such as dopamine. Electrochemical detection of dopamine using a bare Pt needle electrode
is compared to that using a reduced graphene-modiﬁed needle electrode and a graphene
oxide-modiﬁed electrode. Also, the stability of these sensors and the interference of ascorbic
acid is discussed. Then, the selected electrode is calibrated using the LabSmith automated
calibration board given as an example of using the biosensors for online neurochemical
detection through microdialysate.
5.1 Introduction
Dopamine (DA) is one of the most important catecholamines and acts as a signiﬁcant
neurotransmitter. It consists of a catechol structure, a benzene ring with two hydroxyl
groups, and a terminal amine group as shown in Figure 5.1.
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Figure 5.1: Schematic chemical structure of dopamine.
DA is produced in the brain and the adrenal gland from the precursor chemical L-
DOPA. In the brain the dopaminergic cell bodies are in the substantia nigra and the ventral
tegmental area in the midbrain. Neurons in the substantia nigra project to terminals in
the striatum whereas the ventral tegmental area neurons project to terminals in both the
nucleus accumbens and the frontal lobe, as shown in Figure 5.2a. DA is synthesised in the
presynaptic terminals from L-DOPA and packed into vesicles. When the terminal receives
an electrical impulse from the cell body, a release event can be triggered (depending on
the chemical state of the presynaptic terminal). The vesicle forms a fusion pore with the
presynaptic membrane, which grows to allow DA to be released into the synapse (Figure
5.2b). This process is termed as exocytosis. Recently, new information about the kinetics
of exocytotic events have been revealed by the Ewing group [151]. They introduced the
concept of extended kiss-and-run fusion between the cell membrane and the vesicle for
release events as a major method of exocytosis. They observed the presence of feet on
the descending part of the amperometric peak after evoking neurotransmitter release by
chemical stimulation of the cell at carbon ﬁbre microelectrodes. This evidence indicates
leakage of neurotransmitters through a fusion pore at a late stage of vesicle fusion, which
is hypothesised to be the formation of a stable pore during closing of the vesicle following
partial release events through extended kiss-and-run. The results are also supported by the
study of Amatore et al. [152] which has recently reported that it is not possible for full
fusion to occur during the time course of exocytosis.
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Figure 5.2: Schematic DA transmission (a) DA pathway, and (b) DA during synaptic transmission.
DA plays an important role in the central nerve system. It controls several functions
to keep the normal body functioning, including initiation of movement, memory, learn-
ing, motivation and reward. Its dysregulation can lead to neurological disorders, such as
Parkinson’s disease (too little DA), depression, and hyperkinesia (too much DA) [153–156].
In the late 1970s, Adems and coworkers pioneered using electrochemical techniques
to monitoring neurotransmitters in vivo. This led to a dramatic increase in the use of
electrochemical techniques in a wide range of neuroscience applications from resolution of
single exocytotic events [151] to monitor neurotransmitter ﬂuctuations in awake and behav-
ing animals [157]. Generally, these techniques detect neurotransmitters through their redox
reaction at a carbon-based electrode. The dynamic chemical ﬂuctuation of the neurotrans-
mitters, which can indicate behaviour and disease pathology, are hence reﬂected as changes
in oxidation current. The most commonly used electrochemical method for DA detection
is fast scan cyclic voltammetry (FSCV), which is frequently coupled to microelectrodes to
allow neurotransmitter dynamics to be measured with millisecond temporal resolution. Car-
bon ﬁbre microelectrodes (CFEs) fabricated by sealing a single ﬁbre in a glass capillary was
introduced by Ponchon et al. [158]. CFEs are commonly used for DA detection because
of their small size, reliable fabrication, and good electron transfer properties. In FSCV
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detection, DA is easily oxidised to dopamine-o-quinone (DOQ,) which can be reduced back
to dopamine as illustrated in Figure 5.3.
time
+V
-V
(a) (b) (c)
current
potential
Dopamine - o - quinone
NH3+
HO OH
NH3+
O
O+ 2e-
- 2e-
Dopamine
+  2H+
CFE
Figure 5.3: Reaction of DA at an electrode surface when potential is applied (b). The waveform
as a function of time as shown in (a) and the resulting voltammogram in (c). Adapted from Phillips
and Wightman [10].
As seen in Figure 5.3, oxidation of dopamine occurs at the electrode surface when an
adequate potential is applied. For the oxidation reaction, the dopamine is converted to DOQ
and two electrons are released. These two electrons are detected as current. As the potential
is swept back, the DOQ at the electrode surface accepts electrons and is reduced back to
dopamine producing a current in the opposite direction. The ﬂux of electrons (current) is
directly related to the amount of dopamine that undergoes electrooxidation. In FSCV there
is also a considerable charging current that must be removed by subtraction of background
scans.
Over the past decades, the design of other microsensors for neurotransmitter detection
has grown. Much research has been focused on using various carbon-based materials due
to their low cost, good electrochemical properties and biological compatibility [159–161].
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According to Swamy et al. [162], carbon nanotube (CNT)-modiﬁed CFEs for detection of
dopamine and serotonin in vivo were ﬁrst achieved by dip coating a CFE in a CNT-Naﬁon
suspension. They reported that the modiﬁed electrode showed an increase in sensitivity and
greater resistance to fouling. However, such electrodes are diﬃcult to make reproducibly.
Initially, this was ascribed to problems of CNT orientation limiting access to the tube ends.
However, more recent work suggests that the electron transfer rates at the side walls are
also fast [163]. Much attention has been paid to graphene as an alternative supporting
electrode material for neurotransmitter detection. For instance, Ping et al. [164] fabricated
a screen-printed graphene electrode to detect neurotransmitters using cyclic voltammetry
and diﬀerential pulse voltammetry. The results revealed that the electrochemical oxidation
signals of DA, ascorbic acid (AA), and uric acid (UA) can be identiﬁed as three distinct
peaks. In addition, Gao et al. [165] reported that modifying a glassy carbon electrode by
covalently bonding GO for DA detection could enhance the faradaic response of DA, whereas
the response of AA was suppressed.
Microdialysis is widely used for the study of neurochemical changes in vivo. Mi-
crodialysis is beneﬁcial for the measurement of brain extracellular neurotransmitters as it
is relatively easy to implement to sample various neurotransmitters and it gives the good
chemical resolution as the dialysate is removed from the brain and can therefore be analysed
externally by various techniques [12]. This technique can be coupled to microﬂuidic devices,
which are capable of handling the small sample volumes produced allowing for electrochem-
ical detection of the analyte with good time resolution. Most recently 1-minute on-line time
resolution using capillary electrophoresis has been shown [58].
In this study, both graphene oxide (GO) and reduced graphene oxide (rGO), which
have been chemically synthesised by the modiﬁed Hummer method (see in Chapter 2)
will be investigated for DA detection. The experiment was conducted using the needle
microelectrodes in order to enable us to incorporate the electrodes with the microﬂuidics for
the ﬁnal on-line detection system. Graphene was used as an electrode material to modify
the needle electrode based on the layer-by-layer method. The following section will provide
further detail about the methodology.
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5.2 Methodology for Modifying Pt Electrode Using Layer-
by-Layer
In this chapter, the combined needle electrodes (see section 3.4) were employed. Three types
of sensors were fabricated to investigate their performance for electrochemical detection of
DA. These electrodes were a bare Pt electrode, a GO-modiﬁed Pt electrode, and a rGO-
modiﬁed Pt needle electrode. These sensors were developed by the layer-by-layer (LBL)
assembly approach by alternately depositing layers of the carbon material and chitosan [148].
The approach of LBL deposition is driven by the electrostatic force on the surface as chitosan
is positively charged and GO is negatively charged at pH 7.4.
Prior to modiﬁcation, Pt needle electrodes were cleaned by polishing with three sizes
of alumina slurries as described earlier in section 3.4. The polished electrodes were dipped
in 1 M sodium hydroxide (ACS reagent >97%, Sigma-Aldrich) for 15 minutes, and rinsed
well with DI water. Then the Pt electrodes were dipped in 5 µl of chitosan solution (see
section 3.9) on a glass slide for 5 minutes to adsorb a layer of positively-charged chitosan
and rinsed with DI water for 30 seconds. Subsequently they were dipped in 5 µl of the
rGO solution (0.5 mg/ml in DI water) for 5 minutes to adsorb a layer of negatively-charged
rGO and were then rinsed in DI water for 30 seconds. This coating cycle was repeated for
3 more times in total as illustrated in Figure 5.4. The modiﬁed electrodes were dried at
room temperature for 15 minutes before being used. The GO-based sensors were fabricated
based on the procedure above but 2 mg/ml of GO in DI water was used instead of the rGO
solution.
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Figure 5.4: Procedure for modifying Pt electrode with rGO using layer-by-layer deposition.
5.3 Electrochemical Characterisation
The three diﬀerent types of electrodes, namely a bare Pt electrode, a Pt electrode coated
with GO-chitosan layers (GO-chitosanLBL|Pt), and a Pt electrode coated with rGO-chitosan
layers (rGO-chitosanLBL|Pt), were characterised electrochemically using cyclic voltammetry
(CV) to investigate the electrochemical behaviour of the sensors. The CV experiments were
performed either in 1.5 mM ferrocene monocarboxylic acid (Fc) or in 1.5 mM DA, both
in a beaker. Additionally, I also tested the performance of the fabricated sensors using an
automated calibration (LabSmith) board, where the sensors were incorporated into a PDMS
microﬂuidic chip. The results are shown in the following sections.
To investigate the surface characteristics of the three diﬀerent sensors, CV was per-
formed using 1.5 mM Fc in the potential range of -0.1 V to 0.5 V at a scan rate of 10 mV/s.
This experiment was assessed in a beaker with a Ag|AgCl reference electrode and using
the stainless steel of the needle shaft as an auxiliary electrode. The cyclic voltammograms
obtained are shown in Figure 5.5.
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rGO-chitosan Pt electrode
GO-chitosan Pt electrode
bare Pt electrode
r = 25 μm
Pt electrode
rGO-chitosan Pt  electrode
Figure 5.5: CV was carried out in 1.5 mM Fc for the 3 electrodes all with a base radius of 25 µm.
The red trace is for a bare Pt electrode, the blue trace is for Pt coated with chitosan-rGO, and the
green trace is for Pt coated with chitosan−GO, all at a scan rate of 10 mV/s. Ag|AgCl was used
as a reference electrode in each case.
The results in Figure 5.5 show that the GO-chitosanLBL|Pt (green) yields the lowest
steady-state current (2 nA). The bare Pt (red) and rGO-chitosanLBL|Pt (blue) electrodes
show higher currents at approximately 8.5 nA and 16.2 nA, respectively.
The measured current of the bare Pt electrode (50 µm diameter) agrees with the pre-
dicted current (Iss) for a disc electrode as described previously in section 3.1.1 (equation 3.5,
Iss = 8.29 nA). The current for the rGO-chitosanLBL|Pt is twice this value. We can consider
two possible versions of coating the carbon material on the electrode surface. Firstly, the Pt
wire makes electrical contact through the chitosan with rGO covering the whole electrode
surface (400 µm in outer diameter). In this case, the predicted current should be 7 times
higher than that of the bare Pt electrode, giving a current of about 60 nA. The second
hypothesis is that there is only contact with rGO covering the 50 µm diameter Pt wire,
making for example a hemisphere mound as described in equation 5.1.
I =
4πnFDCr
2
(5.1)
Using the above equation the calculate current, I = π/2 × 8.29 nA, which is 13.03
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nA. This current value is quite close to the result obtained (16.2 nA), indicating that the
electrode modiﬁed by rGO is much more likely to be a hemisphere mound just on the Pt
electrode.
To investigate the electrochemical behaviour of the electrodes in the presence of neu-
rochemical species, DA was used as an example. 1.5 mM 3,4-dihydroxylphenethylamine
(Dopamine, Sigma-Aldrich) was dissolved in PBS. CV was carried out in the potential
range from -0.1 V to 0.6 V at a scan rate of 10 mV/s in the 1.5 mM DA solution. The
results are illustrated in Figure 5.6.
rGO-chitosan Pt electrode
GO-chitosan Pt electrode
bare Pt electrode
Figure 5.6: CV was carried out in 1.5 mM DA using the three electrodes all with a base radius of
25 µm. The red trace is for a bare Pt electrode, the blue trace is for Pt coated with chitosan-rGO,
and the green trace is for Pt coated with chitosan−GO, all at a scan rate of 10 mV/s. Ag|AgCl
was used as a reference electrode in all cases. Markers indicate values of potential at half limiting
current.
Figure 5.6 shows that the currents obtained from the rGO-chitosanLBL|Pt and the
bare Pt electrode are about 32 and 17 nA, respectively. These currents are consistent with
the picture seen for Fc. This is because the electrochemical oxidation of DA involves 2e−
rather than the 1e− for Fc as given in equation 5.2.
dopamine −⇀↽ DOQ+ 2e
− + 2H+ (5.2)
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Two electrons are generated from DA oxidation, which results in the steady-state current
of all electrodes being two times higher than the currents for Fc oxidation.
Comparison between Figure 5.5 (Fc) and Figure 5.6 (DA) shows that, in addition to
the diﬀerence in the limiting current due to the number of e−, the DA trace on Pt is diﬀerent
from that of DA on rGO as well as to that of Fc on either surface. This is because the kinetics
of DA oxidation on Pt are slow as the DA needs to be orientated well with respect to the
electrode surface for e− transport to occur. Typically, for carbon surfaces such as carbon
ﬁbres DA in fact pre-adsorbs onto the surface leading to preconcentration [17, 160]. From
Figure 5.6 it would appear that this has happened for the rGO electrode.
At equilibrium condition, [DA2+] and [DA] at the electrode surface are the same as
their values in bulk solution, so the equilibrium potential of the electrode depends on the
standard electrode potential of the reaction. The half-wave potential, E1/2, is related to the
peak potentials for the oxidation and reduction reactions by the expression:
E1/2 =
Eoxp + E
red
p
2
(5.3)
As seen in Figure 5.6, the E1/2 for DA was shifted towards the DA redox potential at
the rGO-chitosanLBL|Pt. This indicates that rGO-chitosanLBL|Pt exhibited more reversible
electrochemistry than bare Pt electrode. In contrast, the cyclic voltammogram of the GO-
chitosan|Pt electrode showed very low currents indicating little reversible electrochemistry,
so this case was not investigated further. Table 5.1 shows the E1/2 for DA detection obtained
in this work compared to that at other carbon-based electrodes in the literature.
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Table 5.1: Comparison of E1/2 for DA detection at different types of carbon-based electrodes.
Electrode Method E1/2 (V) Ref.
CFE FSCV +0.15 [166]
CNT modiﬁed CFE FSCV +0.075 [166]
Glassy carbon electrode CV +0.175∗ [164]
rGO-chitosanLBL|Pt CV +0.13† this work
Pt CV +0.21† this work
Note: For FSCV and CV: take mid-point between oxidation and reduction peaks as this is invariant
with scan rate. ∗ Adjusted from saturated calomel electrode (SCE) to Ag|AgCl. † as shown CV at
a microelectrode used the values refer to markers shown in Figure 5.6.
5.3.1 Stability Study
Stability is an important parameter to consider for neurochemical detectors. The stability of
traditional electrodes cannot be achieved due to surface fouling caused by the adsorption of
oxidised products of the biological species. To overcome these problems, the performance of
electrodes modiﬁed with rGO were investigated for detection of the neurochemical species.
In this study, the bare Pt electrode and the rGO-chitosanLBL|Pt were characterised using
CV. The CV was performed at 10 mV/s scan rate in a beaker containing 1.5 mM DA and
0.15 mM DA every 20 minutes for 5 time-points, from 0 to 80 minutes.
The results for the bare Pt electrode are shown in Figure 5.7a and the normalised
current is shown in Figure 5.7d (red curve). It showed good performance at the beginning,
but it rapidly deteriorated. Actually, on closer inspection of the voltammograms this curve
really collapses as the limiting current was reducing and becoming less reversible. Figure
5.7b shows the results for the rGO-chitosanLBL|Pt electrode at high DA concentration (1.5
mM). There was a gradual reduction in the limiting current, which might be due to a loss
of the electrode surface area by absorption of oxidised DA. The solid blue curve in Figure
5.7d shows that this electrode responded better than the bare Pt electrode, but it shows
that there was some loss in current by 80 minutes. However, in tissue DA concentration
is actually much lower than tested here. If testing is conducted in solutions 10 times less
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concentrated (0.15 mM), the voltammograms showed much better stability over time and
no change in the electrode kinetics was observed (Figure 5.7c). Additionally, they showed
more reversible than that of the case at 1.5 mM DA. As seen in Figure 5.7d (dotted blue) a
slight drop in the limiting current was observed, but it was negligibly small. We can predict
from this that at likely in vivo levels of 20 nM to less than 1 µM, the rGO-chitosanLBL|Pt
electrode would be very stable over time.
Therefore, it can be concluded that Pt electrodes do not show good performance for
DA detection, whereas the performance of rGO-based electrodes is much better with little
fouling at low and physiological concentrations of DA.
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Figure 5.7: Stability comparison between bare Pt electrode and rGO-chitosanLBL|Pt. The insets are repeated CVs at (a) bare Pt electrode, (b)
rGO-chitosanLBL|Pt in 1.5 mM Dopamine and (c) rrGO-chitosanLBL|Pt in 0.15 mM dopamine. The ratio of the initial plateau current to the current
at 5 different times (d).
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5.3.2 Interference Study of Ascorbic Acid
The presence of interference during electrochemical monitoring is an important problem.
Ascorbic acid (AA) coexists with DA in the extracellular ﬂuid of the central nervous system
and its concentration is much higher than DA. Resolution of DA in the presence of AA at
the traditional electrode is diﬃcult due to both AA and DA being oxidised at almost the
same potential, sometimes resulting in overlap of the voltammetric responses [164]. In this
thesis, the inﬂuence of AA interference on the bare Pt electrode and the rGO-chitosanLBL|Pt
was investigated using CV. This was conducted in a solution containing 1.5 mM AA or 1.5
mM DA and assessed in a beaker. The results for a bare Pt and rGO-chitosanLBL|Pt are
illustrated in Figure 5.8 and 5.9, respectively.
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Figure 5.8: Cyclic voltammograms of a bare Pt electrode in (a) 1.5 mM AA (red) and (b) 1.5
mM DA (green) at 10 mV/s scan rate. Ag|AgCl was used as a reference electrode.
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Figure 5.9: Cyclic voltammograms of a rGO-chitosanLBL|Pt in (a) 1.5 mM AA (red) and (b) 1.5
mM DA (green) at 10 mV/s scan rate. Ag|AgCl was used as a reference electrode.
As seen in Figure 5.8, the cyclic voltammogram (green) showed irreversible behaviour
for DA at the bare Pt electrode and it is rather hard to observe for AA. It is noted that the
oxidation of AA on Pt surface can occur when the Pt surface is very clean, however the Pt
electrode is poisoned easily. For rGO-chitosanLBL|Pt (Figure 5.9), both DA and AA cyclic
voltammograms showed more reversibility than for the bare Pt electrode and it can be seen
that AA was oxidised before DA.
For completeness, a potential problem with mixed solutions is the chemical reaction
between AA and DA. It is known that the oxidation of AA is slower than that of DA as
shown in the following equations:
ascorbic acid
slow
−−→ dehydroascorbic acid+ 2e− + 2H+ (5.4)
dopamine
fast
−−→ DOQ+ 2e− + 2H+ (5.5)
DOQ+ ascorbic acid −→ dopamine + dehydroascorbic acid (5.6)
As the oxidation of DA is fast DOQ is produced, which can react in the presence of AA
(which is slow to be oxidised), producing more DA (as shown in equation 5.6) which can also
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be oxidised and contribute to signal detected. The catalytic current therefore depends on
the concentration of both AA and DA. Hence, if the sensor is capable of separating AA and
DA oxidation potential, it will be very useful as a neurochemical detector. This is because
the signal detected would be due only to DA oxidation, eliminating the AA interference
issue.
In my case, if both DA and AA are in the same beaker, the problem above will occur.
At a Pt electrode, the DA is oxidised before the AA, so the oxidised DA (DOQ) reacts in
the presence of AA leading to the risk of getting a catalytic current for DA. However, for
the rGO-chitosanLBL|Pt electrode oxidation of AA occurred before DA, so that oxidised AA
(dehydroascorbic acid) is in a presence of DA, which is much less of a problem. This indicates
that the developed electrode using rGO showed a better performance for DA detection when
compared to the bare Pt electrode.
5.4 Autocalibration of DA
In this study, the bare Pt and the rGO-chitosanLBL|Pt electrode were incorporated into a
PDMS microﬂuidic chip. The LabSmith autocalibration board was employed to control the
ﬂow rate of the DA solution to 2 µl/min at 5 diﬀerent dopamine concentrations from 0 mM
to 2 mM in order to study the sensors under continuous ﬂow conditions. A potential of 0.7
V versus Ag|AgCl reference electrode was applied to the sensors. The resulting calibration
curve is shown in Figure 5.10.
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Figure 5.10: Calibrations were carried out in an automated calibration board. Sensors were held
at a constant potential of +0.7 V vs Ag|AgCl reference electrode. The blue trace shows the DA
response at rGO-chitosanLBL|Pt, and the red trace show the response at a bare Pt sensor. Markers
indicate mean ± SD obtained from the inlet. Points fitted with line equation.
As seen in Figure 5.10, the sensitivity of rGO-chitosanLBL|Pt was 1.60 nA/mMwhereas
that of bare Pt was 0.05 nA/mM. Therefore, the sensitivity of the rGO-chitosanLBL|Pt was
around 32 times higher than that of the bare Pt sensor.
5.5 Conclusion
In conclusion, rGO-based sensors showed good performance for neurochemical detection.
The results indicate that the carbon material provides good performance characteristics in
terms of fast electron transfer and good stability in comparison with the metal electrode.
Additionally, the rGO-based sensor worked well in a microﬂuidic chip, which can be used
as an on-line neurochemical detector. As mentioned previously carbon ﬁbre electrodes have
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been reported that they have shown good performance, but they are very fragile which is
easier to be broken when being incorporated with a microﬂuidic chip. Hence, rGO modiﬁed
Pt needle microelectrodes may provide a promising alternative for development of sensors
for neurochemical detection.
Chapter 6
Carbon-based Sensors for Carboplatin
Detection
This chapter describes the detection of the interaction between deoxyribonucleic acid (DNA)
and carboplatin (a platinum-based anticancer drug) using a carbon-based sensor to develop
a device capable of monitoring cancer chemotherapy in real time. The chapter begins with
the electrochemical determination of the purine bases (guanine and adenine) as well as
nucleotides adenosine 5’-monophosphate (AMP) and guanosine 5’-monophosphate (GMP)
using carbon-based electrodes using diﬀerential pulse voltammetry (DPV). This is followed
by the determination of carboplatin-nucleotide interaction using both bare multiwalled car-
bon nanotube-epoxy composite (MWCNT-epoxy composite) electrodes and DNA-modiﬁed
MWCNT-epoxy composite electrodes. In this chapter, all experiments were conducted in
a beaker under stirred conditions. Results from experiments in a microﬂuidic chip are
presented in Chapter 7.
6.1 Introduction
Cancer is a major public health problem and is one of the leading causes of death in the
world. According to the American Cancer Society, there were 8.2 million deaths caused
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by of cancer in 2012 worldwide [167] (about 22,000 cancer deaths a day). Cancer is a
group of diseases which is characterised by the uncontrolled growth and spread of abnormal
cells. If the spread of these abnormal cells is not controlled it can lead to death. Cancer is
caused by external factors including tobacco, infectious organisms and an unhealthy food
and also by internal factors, for example inherited genetic mutations, hormones, and immune
conditions. There are diﬀerent approaches for cancer treatment depending on the type of
cancer including surgery, radiation, chemotherapy, hormone therapy and immune therapy.
Chemotherapy is the most common treatment for cancer tumours. This involves
treatment with chemical substances, especially one or more anti-cancer drugs, which are
used to kill cancer cells and to inhibit the growth of the toxic tumours (malignant tissue)
in order to prevent their spread to other organs. Platinum-based anti-cancer drugs such as
oxaliplatin, nedaplatin, lobaplatin, heptaplatin and carboplatin have been widely needed
for chemotherapy [168]. Among these drugs, carboplatin is widely used for the treatment of
a variety of malignancies. However, although carboplatin is an eﬀective anti-cancer drug, it
causes many side eﬀects. This is because the anti-cancer drug works on active cells that are
growing and dividing into more of the same type of cell and as a result it cannot distinguish
between cancer cells and healthy cells such as blood cells, skin cells, hair follicles and the
cells inside the digestive system. Consequently, carboplatin aﬀects not only the cancer cell
growth but also blocks the growth of healthy rapidly dividing cells, leading to side eﬀects
such as mouth and throat sores, diarrhea, nausea and vomiting, blood disorders, nervous
system eﬀects, appetite loss and hair loss [169, 170].
The problem with carboplatin is that its therapeutic index (the ratio between toxic
dose and eﬀective dose) is low. Consequently, avoiding toxicity by controlling the systemic
dose is diﬃcult. An alternative approach is to consider delivering the drug to a targeted
speciﬁc area (the tumour) at a high dose and to monitor the surrounding healthy tissue for
the ﬁrst arrival of the drug. This could be achieved either by detecting carboplatin or the
DNA damage caused by carboplatin in real time. Moreover, this approach could enhance
the eﬀectiveness of chemotherapy and also reduce the cost of drug administration as the
drug would be injected directly into the cancer cells.
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In this study the interaction of carboplatin and DNA nucleotides was investigated by
the electrochemical detection of DNA damage. The mechanism of DNA damage caused by
carboplatin will be described in the next section. Before describing the damage mechanism,
a background on DNA and carboplatin will be given.
Deoxyribonucleic Acid (DNA)
DNA is the molecule that is responsible for the storage and expression of genetic information
used in development, functioning, and reproduction for living organisms. DNA is found
inside the nucleus of every cell. DNA comprises two long polynucleotide strands twisted in
opposite directions into a double helix. Each nucleotide consists of three main components:
a phosphate group, a deoxyribose sugar, and a nitrogenous base (adenine, guanine, cytosine
or thymine). Based upon its molecular structure the four DNA bases (also called nucleic acid
bases) are separated in two groups: purines (adenine and guanine) and pyrimidines (cytosine
and thymine). The genetic information is coded by the four bases and the sequence of these
bases determines the code needed to build and maintain an organism.
Adenine Thymine
Guanine Cytosine
DNA
Sugar-phosphate backbone
Hydrogen bond
S
P
Nucleotide
P
S Deoxyribose sugar
Phosphate group
base
Figure 6.1: Structure of DNA. DNA is a double helix formed by two strands of polynucleotides
with sugar-phosphate backbones. The paired nucleic acid bases are joined across the helix by
hydrogen bonds.
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As seen in Figure 6.1, nucleotides are linked together with a sugar and a phosphate
group representing the DNA backbone and the paired bases are linked across the helix
like rungs of a ladder by hydrogen bonds in a speciﬁc manner with adenine paired with
thymine and cytosine with guanine. In the process of cell division, DNA is able to clone
itself by DNA replication. The DNA helix splits to become two single strands that serve as
templates. The DNA sequences on these single strands are replicated for building two new
DNA helices. Therefore, if the structure of the DNA is damaged the process of cell division
may be inhibited or perturbed leading to the occurrence of abnormal cell functioning or cell
death.
The proposed electrochemistry of guanine and adenine [171, 172] is described in the
mechanisms illustrated in Figure 6.2.
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Figure 6.2: Schematics of the oxidation mechanisms of (a) guanine and (b) adenine.
As seen in Figure 6.2a, the electro-oxidation process of guanine involves four electrons
and four protons in two steps. Three-step mechanism associated with the total loss of six
electrodes and six protons occurs in the electrochemical oxidation of adenine (Figure 6.2b).
Every step of both mechanisms includes two electrons and two protons process and the ﬁrst
oxidation step is the rate determining.
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Carboplatin
Carboplatin is a platinum-based drug, which has become widely used in chemotherapy
treatment and has proven activity against a variety of solid tumours including ovarian,
testicular, head and neck and lung cancers (both non-small-cell and small-cell) [173–178].
It is a derivative of cisplatin and has a similar mechanism of action with less toxicity than
the parent compound. More recently it is used in combination with paclitaxel [179]. The
chemical structures of the platinum-based drugs are shown in Figure 6.3. Both cisplatin
and carboplatin have a platinum atom in the centres but carboplatin has the bidentate
dicarboxylate in cyclobutane dicarboxylic acid (CBDCA) in place of the two chloride ligands
in cisplatin.
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(b) Carboplatin
Figure 6.3: Chemical structures of the platinum anti-cancer drugs (a) cisplatin and (b) carboplatin
The anticancer properties of cisplatin were ﬁrst discovered in 1965 by Barnett Rosen-
berg and his colleagues [180] as they demonstrated the eﬀects of electric ﬁelds on bacterial
growth. In their research they found that when an electric ﬁeld was applied through plat-
inum electrodes, which were immersed in Escherichia coli bacteria the process of cell division
of the bacteria was inhibited and the bacteria formed ﬁlaments up to 300 times longer than
their normal length. It was deduced that this ﬁnding did not relate to the electrical ﬁeld
but the product of the reaction between the platinum electrodes and components of the
solution containing the bacteria. The product was later identiﬁed to be cisplatin (cis -
[PtCl2(NH3)2]). Due to the anti-proliferative ability of cisplatin, this group worked further
on testing cisplatin for cancer treatment in mice with malignant tumours to prove that the
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platinum drug was an eﬀective anti-tumour agent. In 1978 cisplatin was approved for use
in testicular and ovarian cancers by the U.S. Food & Drug Administration (FDA) [181].
This led to an increasing number of research papers on the platinum-based drug for cancer
treatment and also to the synthesis of new compounds of platinum-based drugs. However,
although cisplatin is an eﬀective anti-cancer agent, it was necessary to limit the clinical
applications of cisplatin due to its severe side eﬀects including gastrointestinal eﬀects, renal
toxicity and neurotoxicity [173].
Further research has led to the development of the next generation of platinum-based
drug in order to reduce these side eﬀects. In the late 1980s carboplatin was introduced and
has obtained popularity in clinical treatment as it is considered to be the therapeutic equiv-
alent of cisplatin but with less toxicity than its parent compound (cisplatin). Additionally,
it oﬀers easy outpatient therapy as the need for hydration or the use of anti-emetics is min-
imised and it has a reduced incidence of nephrotoxicity, neurotoxicity, and ototoxicity [173].
Due to the fact that carboplatin has been widely used and have been eﬀective in the treat-
ment of solid-tumour cancer, research has focused on determination of carboplatin-DNA
interaction, which causes DNA damage. To understand the mechanism the interaction of
DNA and carboplatin will be described in the next section.
6.2 Carboplatin-DNA Interaction
It is known that carboplatin has the capability of stopping tumour growth by binding to
DNA and causing cell death. It is believed that carboplatin can generate lesions in DNA
through DNA adduct formation with platinum resulting in inhibition of replication and
transcription processes leading to cell death.
Many studies have reported that this compound predominantly interacts with DNA at
purine (guanine and adenine) nucleotides to form the Pt-DNA monoadducts and it is found
to frequently react with adenine groups to form Pt-DNA intra- and interchain diadducts
[168, 182–184]. Hah et al. [183] determined the kinetics of carboplatin-DNA binding using
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accelerator mass spectrometry. They found that the adducts formed by this platinum-based
drug can be monoadducts and intra- and interstrand diadducts as illustrated in Figure 6.4.
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Figure 6.4: Schematic formation of adducts between DNA and carboplatin adapted from [183].
The carboplatin-DNA interaction can form monoadducts and intra- and interstrand diadducts.
Similarly, Jangir et al. [184] studied carboplatin interaction with calf-thymus DNA
using Fourier transform infrared spectroscopy (FTIR). They reported that carboplatin
binds with DNA through guanine N7 and adenine N7 by observing a shift in their vi-
brational bands after incubation of the DNA with carboplatin in diﬀerent ratios. In ad-
dition, Sousa et al. [168] has recently explained further the mechanism of action inside
the cell. As carboplatin comes across the cell membrane it is activated by hydrolysis of
1,1-cyclobutanedicarboxylate and becomes positively charged. This allows carboplatin to
interact with nucleophilic molecules (negatively charged) within the cell, including DNA.
This results in the formation of adducts of platinum through covalent binding of carboplatin
to the N7 position of purine bases. This suggests that purine bases play a signiﬁcant role
in carboplatin interaction.
6.3 Electrochemical Sensors for Drug-DNA Damage De-
tection
Several analytical techniques have been used to detect the interaction of anticancer drugs
with the structure of DNA. These include high-performance liquid chromatography (HPLC),
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which is the most widely used method [185, 186], inductively coupled plasma-mass spec-
trometry [187], capillary electrophoresis [188], and Fourier transform infrared spectroscopy
(FTIR) [184], which is not sensitive enough for quantitative determination of drugs. These
methods involve large instruments with high costs and require highly trained personnel for
the testing. They are also not suitable for on-line detection at the patient bedside. There is
a need for rapid, continuous and low-cost techniques for analysis of drug-DNA interaction.
Electrochemical techniques have high sensitivity, low cost, and can be small. Typically once
the method is established they do not require a great deal of user expertise. This has made
electrochemical devices an attractive choice for point-of-care applications.
DNA is an electroactive compound that can be detected electrochemically in various
polarography and voltammetry modes. Electrochemical sensors can be used for the detec-
tion of drugs interacting with the structure of DNA as the DNA-trapped compounds can
be detected via changes in the electrochemical DNA signal or directly if they are electroac-
tive molecules [189, 190]. Diﬀerent types of materials have been employed to monitor the
interaction between platinum-based anticancer drugs and DNA, for example, glassy carbon
electrodes [182], hanging mercury drop electrodes [191], screen printed electrodes [192] and
graphite electrodes [193]. More detail for using these diﬀerent types of electrode is explained
in the following paragraph.
Oliveira-Brett et al. [182] developed a DNA-modiﬁed glassy carbon electrode to elec-
trochemically detect carboplatin in the serum of ovarian cancer patients who were under-
going chemotherapy using diﬀerential pulse voltammetry (DPV). A DNA-modiﬁed glassy
carbon electrode was prepared by covering the electrode with a thick layer of DNA and was
conditioned in single strand DNA (ssDNA) until the oxidation current for the DNA bases
was stable. The detection was carried out in ssDNA solution by adding the patient serum
with diﬀering concentrations of carboplatin. The result revealed that the oxidation current
of the nitrogenous bases (guanine and adenine) decreased with increasing carboplatin con-
centration. It was also noted that carboplatin at low concentration interacted preferentially
with adenine rather than guanine. Krizkova et al. [191] studied the interactions between
DNA and cisplatin using a EDTA metallothionein modiﬁed hanging mercury drop electrode.
138 Chapter 6. Carbon-based Sensors for Carboplatin Detection
The result showed that decrease of guanine peak height is well detectable and also suggested
that the modiﬁed electrode could be a new tool for investigation of the interaction of DNA-
cisplatin due to responding only in the presence of cispaltin-DNA adduct. Marrazza et
al. [192] developed a disposable DNA electrochemical sensor using graphite screen-printed
electrodes. The graphite screen-printed electrode was modiﬁed by adsorption of short DNA
sequences with two immobilisation techniques which are using avidin-biotinylated oligonu-
cleotide and using a constant potential. The results revealed that both techniques showed
good performance for daunomycin (anti-cancer drug) detection. Additionally, Brabec Vik-
tor [193] reported the determination of [Pt(dien)(H2O)]2+ (platinum-based anticancer drug)
using a paraﬃn wax-impregnated graphite electrode, which was modiﬁed by linearised plas-
mid DNA using adsorptive accumulation for 2 minutes at +0.5 V. The detection was carried
out using DPV to determine the interaction of the platinum drug in solution with the DNA
conﬁned on the surface of the electrode. The result showed a decrease in the intrinsic
electrooxidation response caused by the interaction of [Pt(dien)(H2O)]2+ within a short re-
action time (2-10 minutes) and detection at submicromolar levels of the drug were reported.
This DNA wax-impregnated graphite sensor is a potential candidate for detecting platinum
compounds but it suﬀers from the problem that it can only be used once as repetitive mea-
surement requires to be repeated the surface of the electrode to be renewed and the process
of immobilising DNA layer.
Over the past decades, the design of DNA biosensors that exploit interactions between
the surface-conﬁned DNA and target drugs have been developed for rapid drug screening.
Nanotechnology has played an important role for the development of these challenging tools.
Since carbon nanotubes were discovered in 1991 by Iijima [98] this carbon material has been
considered highly attractive, especially in DNA-sensing technology owing to its remarkable
properties such as promoting electron transfer reactions, increased surface area, enhance-
ment of signals and its ability to maintain biocompatibility. [194–196]. Additionally, Ya-
pasan [197] demonstrated using single-walled carbon nanotube (SWCNTs)-modiﬁed graphite
electrodes to detect cisplatin and oxaliplatin interacting with calf thymus double-stranded
DNA using DPV. They found that SWCNT-modiﬁed graphite electrodes gave higher oxi-
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dation currents for guanine than unmodiﬁed graphite electrodes. In both cases there was a
clear decrease in the guanine oxidation signal after immersion in the drug solution. They
suggested that using SWCNT-modiﬁed electrodes could provide reproducible and sensitive
detection since their high electrical conductivity leads to enhanced signals and DNA could
be immobilised onto the SWCNT-modiﬁed surface. Recently, the use of multi-walled car-
bon nanotube (MWCNT)-chitosan modiﬁed pencil graphite electrodes to electrochemically
monitor mitomycin C - DNA interaction was reported by Sengiz et al. [196]. They revealed
that the pencil graphite electrode, which was modiﬁed with MWCNT-chitosan compos-
ite exhibited good performance for detection of the interaction between mitomycin C and
DNA, giving higher signals for guanine and mitomycin C oxidation in comparison with the
unmodiﬁed pencil graphite electrode.
These studies indicate that DNA electrochemical sensors have great potential and
could be used in the development of a rapid and cost-eﬀective technique for anti-cancer
drug detection. The development of DNA electrochemical sensors with high potential for
fabrication of sophisticated devices for low-cost routine clinical practice has become a subject
of great research [198]. Nevertheless, at the time of writing there is no study using a carbon
nanotube-epoxy composite to determine the carboplatin-DNA adducts and certainly not
being used for on-line detection using microdialysis as a sampling probe. In this study,
a sensor for investigation of carboplatin-DNA adducts using a MWCNT-epoxy composite
electrode will be reported.
6.4 Objective
The objective of this study is to develop a method to detect the chemotherapeutic agent
carboplatin in tissue at low therapeutic concentrations. The use of microdialysis as a means
to sample the tissue extracellular concentration enables the objective to be simpliﬁed to the
measurement of carboplatin in a microlitre per minute aqueous ﬂow stream. Ideally, this
will take place in a microﬂuidic chip. Initially, diﬀerent types of electrodes were tested with
the free purine bases to conﬁrm that they could be detected using DPV in a beaker.
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6.5 Preliminary on Free Purines Base Detection
Preliminary experiments were carried out in a beaker containing 20 ml of 0.1 M phosphate
buﬀer saline (PBS, pH 7.4 see section 3.9) using an Ag|AgCl (3 M NaCl) reference electrode
and a coiled Pt wire auxiliary electrode with a range of carbon or carbon-modiﬁed electrodes.
The electrochemical behaviour of guanine and adenine were studied by injecting aliquots of
guanine and adenine solutions into 0.1 M PBS to give ﬁnal concentrations in the range from
0 µM to 200 µM. For this calibration experiment all measurements were performed using
DPV (see section 3.1.2) in the potential range of 0 to 1.4 V and with a pulse amplitude
of 50 mV, a pulse width of 70 ms and a scan rate of 5 mV/s. DPV was carried out using
Echem software (eDAQ, UK) and using a PowerLab of 8SP (ADinstruments).
Initially, the electrochemical behaviour of guanine and adenine was investigated using
a glassy carbon electrode (6 mm diameter) as a working electrode. Before use, the glassy
carbon electrode was polished using alumina slurries in the order 1 µm, 0.3 µm and 0.05
µm, and sonicated in DI water to remove any particles in the same way as for the combined
needle electrode as described in Chapter 3. The results of guanine and adenine oxidation
are shown in Figures 6.5 and 6.6, respectively.
6.5. Preliminary on Free Purines Base Detection 141
Figure 6.5: Differential Pulse Voltammograms (DPVgrams) obtained with a glassy carbon elec-
trode in guanine in the range from 0 to 60 µM in 0.1 M PBS pH 7.4. Pulse amplitude 50 mV, pulse
width 70 ms and scan rate 5 mV/s.
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Figure 6.6: DPVgrams obtained with a glassy carbon electrode in adenine in the range from 0 to
60 µM in 0.1 M PBS pH 7.4. Pulse amplitude 50 mV, pulse width 70 ms and scan rate 5 mV/s.
As seen in Figures 6.5 and 6.6, clear oxidation peaks were observed for guanine and
adenine at peak potentials of +0.70 V and +1.04 V, respectively. The oxidation peak
current for both guanine and adenine increased when the concentration of free purine bases
increased. These results agree well with the oxidation peak potentials obtained by Oliveira-
Brett et al. [199] using a 3 mm diameter glassy carbon electrode of +0.70 V for guanine
and 0.96 V for adenine, respectively. The peak width for the three guanine concentrations
was 80 mV, whereas the peak width for adenine showed a increase with increasing adenine
concentration, with peak widths of 120, 145, and 165 mV at 20, 40, and 60 µM adenine,
respectively.
In section 3.1.2, we saw that for a reversible couple DPV theory which the width
at half-height of peak, W1/2=3.52RT/nF ≈ 90.4 mV at 298 K for 1e−. The peak widths
obtained from this result do not correspond to a 4e− transition as shown in Figure 6.2.
Instead it is more likely to correspond to 2e− with some irreversibility, which broadens the
peak. Indeed, in the ﬁgures presented in the Oliveira-Brett paper [199] the peak widths
6.5. Preliminary on Free Purines Base Detection 143
obtained were 83 mV and 91 mV for 20 µM guanine and 20 µM adenine, respectively, which
do not agree with their preferred 4e− mechanisms.
The purpose of this study, however, was to fabricate a device for on-line detection
of carboplatin whereby the sensor is integrated into a microﬂuidic chip. To meet these
requirements a much smaller electrode is required than what can be fabricated from the
rather brittle glassy carbon. Therefore, to meet these sensor requirements, a few types of
working electrode materials were explored in this study including a platinum (Pt) needle
electrode (fabricated as described in section 3.4, used in Chapter 5), a reduced graphene
oxide (rGO) coated Pt needle electrode, and a multiwalled carbon nanotube (MWCNT)-
epoxy electrode (see section 3.3). In this chapter, the rGO-Pt electrode was fabricated by
dip coating of rGO solution. A bare Pt needle electrode was dipped in 5 µl of 1 mg/ml rGO
dissolved in dimethylformamide (ACS reagent, > 99.8% Sigma-Aldrich) for 5 minutes and
was heated at 55℃ for 1 hour before use.
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Figure 6.7: DPVgrams obtained with a 50-µm-diameter Pt electrode in (a) guanine and (b)
adenine and with a rGO-Pt electrode in (c) guanine and (d) adenine in concentrations from 0 to
100 µM in 0.1 M PBS pH 7.4. Pulse amplitude 50 mV, pulse width 70 ms and scan rate 5 mV/s.
Preliminary testing of the free purine base responses at these electrodes showed that
the oxidation peaks for both guanine and adenine were not observed at either the Pt or the
rGO-Pt needle electrodes. The results for the Pt and rGO-Pt electrodes are shown in Figure
6.7. The Pt result is not surprising because it is not good for electroactive species. The
result for rGO-Pt is surprising as in Chapter 5 it showed a good response for dopamine. This
might because the rGO was directly coated on the Pt electrode without chitosan leading to
ease to loss rGO layer from the electrode surface. In contrast, both purine bases showed
clear oxidation peaks at the MWCNT-epoxy electrode. These results are shown in Figure 6.8
for guanine and in Figure 6.9 for adenine. The oxidation potential of the purine bases were
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observed at +0.69 V for guanine and at +0.98 V for adenine at MWCNT-epoxy composite
electrode and these peak potentials were quite stable with increasing concentration of the
purine bases.
Figure 6.8: DPVgrams obtained with a MWCNT-epoxy composite electrode in guanine solution
in the concentration 0 to 200 µM in 0.1 M PBS at pH 7.4. Pulse amplitude 50 mV, pulse width 70
ms and scan rate 5 mV/s.
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Figure 6.9: DPVgrams obtained with a MWCNT-epoxy composite electrode in adenine solution
in the concentration 0 to 200 µM in 0.1 M PBS at pH 7.4. Pulse amplitude 50 mV, pulse width 70
ms and scan rate 5 mV/s.
Adenine at glassy carbon electrode
Adenine at MWCNT-epoxy composite 
electrode
Guanine at glassy carbon electrode
Guanine at MWCNT-epoxy composite 
electrode
Figure 6.10: Comparison of the oxidation potential for guanine and adenine for both a glassy
carbon electrode and a MWCNT-epoxy composite electrode.
A comparison of the peak potential data from Figures 6.5 and 6.6 for the glassy
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carbon electrode and Figures 6.8 and 6.9 for the MWCNT-epoxy composite electrode is
shown in Figure 6.10. The results clearly show the stability of the peak potential at the
MWCNT-epoxy composite electrode with increasing purine base concentration. This pro-
vides direct evidence that both guanine and adenine are electrochemically more reversible
at the MWCNT-epoxy composite electrode than at the glassy carbon electrode.
Overall, these results showed clearly that it is diﬃcult to detect the oxidation of
purine bases at either a Pt electrode or at a rGO-Pt electrode. On the other hand, MWCNT-
epoxy composite electrodes showed good performance for electrochemical detection of purine
oxidation. The MWCNT-epoxy composite electrodes also have the advantage that they can
be made small enough to be placed in a microﬂuidic chip, which was one of the objectives
set out at the beginning of this chapter. Hence, they were used for carboplatin detection in
the rest of this study.
6.6 Fabrication of a DNA-modified MWCNT-epoxy Com-
posite Electrode
DNA biosensors were prepared to investigate the carboplatin binding to DNA. A method
ﬁrst reported by Oliveira-Brett et al. [182] was adapted in order to make it suitable for
DNA immobilisation on a MWCNT-epoxy electrode. In this study, DNA sodium salt from
calf thymus (type I, highly polymerised, ﬁbrous preparation, Sigma-Aldrich) was used to
prepare the DNA stock solution. 3 mg of the DNA was dissolved in 80 µl of 0.1 M acetate
buﬀer (ACB) pH 4.5. A MWCNT-epoxy composite electrode (1 mm diameter) was used,
the surface of which was modiﬁed with DNA using dip coating. 5 µl of the DNA solution
was placed onto a glass slide. A MWCNT-epoxy composite electrode was slowly brought
down to the solution and was held for 30 s using a micro-manipulator. The DNA-modiﬁed
electrode was then secured upside down in order to keep the layer of DNA as thin as possible
and was allowed to dry at room temperature.
Oxidation peaks of the DNA bases were investigated at the DNA-modiﬁed MWCNT-
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epoxy composite electrode. DPV was performed in a beaker containing 0.1 M ACB under
stirred conditions. As seen in Figure 6.11, no oxidation peaks were observed for the DNA
bases at the DNA-modiﬁed MWCNT-epoxy composite electrode in buﬀer solution. This
agrees with the ﬁnding of Oliveira-Brett et al. [182] using a glassy carbon electrode. Oliveira
Brett [200] suggests that this is because the structure of DNA makes it diﬃcult for electrons
to transfer from the inside of the double-stranded DNA to the electrode surface, presumably
because the distance for electron tunnelling is too large.
1.2
1.1
1.0
0.9
0.8
0.7
0.6
c
u
r
r
e
n
t
 
/
 
µ
A
1.21.00.80.60.4
Potential / V vs Ag|AgCl
Figure 6.11: DPVgrams obtained at a DNA-modified MWCNT-epoxy composite electrode. DPV
was carried out in a beaker containing 0.1 M ACB at pH 4.5 under stirred conditions with a pulse
amplitude of 50 mV, a pulse width of 70 ms and a scan rate of 5 mV/s.
6.7 Detection of Single-Stranded DNA (ssDNA)
As DNA damage caused by carboplatin could not be detected when the DNA was immo-
bilised on the electrode surface, the next step was to test with ssDNA in solution. The
binding of carboplatin with ssDNA is measured as a decrease in the oxidation current of
ssDNA. Therefore, initially the electrochemistry of ssDNA was studied.
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Bare MWCNT-epoxy Composite Electrode
A bare MWCNT-epoxy composite electrode was used to investigate the oxidation of ssDNA.
A ssDNA solution was prepared by denaturation of DNA using perchloric acid as described
in section 3.9. DPV was carried out in the range from 0 V to +1.4 V in a beaker containing
10 ml of ssDNA solution under stirred conditions. The electrode was held in the ssDNA
solution at 0 V for 2 minutes before each scan. The results are illustrated in Figure 6.12.
The oxidation peaks of guanine (Ep=0.87 V) and adenine (Ep=1.08 V) can be seen clearly,
in contrast to the scan observed for the DNA modiﬁed MWCNT-epoxy electrode in ACB
(Figure 6.11). However, the ssDNA electrochemistry of the bare MWCNT-epoxy composite
electrode was not stable, with the oxidation currents increasing continuously from the 1st
to the 6th DPV scan and beyond (data not shown). This lack of stability means that the
electrode was not suitable for use in detecting the carboplatin-DNA interaction.
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Figure 6.12: DPVgrams during conditioning of a bare MWCNT-epoxy composite electrode in
ssDNA . The DPVgrams show the 1st-6th scans and the dotted line indicates a DPVgram obtained
in 0.1 M ACB at pH 4.5. Pulse amplitude 50 mV, pulse width 70 ms and scan rate 5 mV/s.
As an alternative, Piedade et al. [201] suggested using the combination of DNA on
the electrode surface with ssDNA. The DNA-modiﬁed electrode had to be conditioned in
ssDNA solution before use in order to reach the maximum activity and to obtain repro-
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ducible DPVgrams. The procedure was adapted for use with the MWCNT-epoxy composite
electrodes in the following sections.
DNA-coated MWCNT-epoxy Composite Electrode
To condition the DNA-modiﬁed electrodes in ssDNA, a DNA-modiﬁed MWCNT-epoxy
composite electrode (see section 6.6) was immersed in 0.1 M ACB (pH 4.5) and a constant
potential of +1.4 V was applied for 5 minutes, which promotes the ssDNA incorporation in
the following step. Then the DNA-modiﬁed electrode was transferred to a ssDNA solution
and DPV was carried out in the range of 0 V to +1.4 V until stable peaks were observed.
For each scan, the electrode was ﬁrst held at 0 V in the ssDNA solution for 2 minutes under
stirred conditions. This conditioning process was repeated until stable surface modiﬁcation
was obtained. Following this step, the conditioned DNA-modiﬁed electrode was cleaned in
0.1 M ACB by applying 0 V for 5 minutes. The electrochemical behaviour of the DNA-
modiﬁed electrode in ssDNA is shown in Figure 6.13.
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Figure 6.13: DPVgrams during conditioning of a DNA modified MWCNT-epoxy composite elec-
trode in ssDNA. The DPVgrams show the 1st-10th scans and the dotted line indicates a DPVgram
obtained in 0.1 M ACB at pH 4.5. Pulse amplitude 50 mV, pulse width 70 ms and scan rate 5
mV/s.
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As seen in Figure 6.13, the oxidation peaks of both guanine and adenine were clearly
observed. In addition, the oxidation currents of these purine bases increased in each scan
until saturation was reached. Oxidation currents began to stabilise at the 3rd scan and
saturated at the 10th scan. This is because ssDNA penetrates further into the DNA layer
and forms triple-helix DNA between the DNA ﬁlm and the ssDNA until it is limited by
diﬀusion [201] leading to the increase and the saturation of the oxidation peak currents.
Thus, DNA-modiﬁed MWCNT-epoxy composite electrodes, which have been conditioned in
ssDNA are candidates for use in detection of carboplatin.
Although DNA-modiﬁed MWCNT-epoxy composite electrodes, which have been con-
ditioned in ssDNA provide stable oxidation peaks for both guanine and adenine, the oxi-
dation currents were quite small and the method to fabricated these electrodes required a
succession of time consuming steps. In the next section, the DNA-modiﬁed MWCNT-epoxy
composite electrode exposed directly to guanosine 5’-monophosphate (GMP) or adenosine
5’-monophosphate (AMP) was investigated.
6.8 Electrochemistry of GMP and AMP
Oliveira-Brett et al. [182] suggested that the use of the nucleotides AMP and GMP could
be used instead of ssDNA, allowing the oxidation signals to be observed more clearly and
with the advantage that they are much less expensive than ssDNA.
Therefore, GMP and AMP were used instead of ssDNA for determination of carbo-
platin binding to DNA. The DNA-modiﬁed MWCNT-epoxy composite electrode was condi-
tioned either in a solution of 1 mM GMP or of 1 mM AMP in 0.1 M ACB (see section 3.9).
To investigate the oxidation peaks of the purine bases, DPV was carried out in a beaker
containing 10 mL of 1 mM GMP or 1 mM AMP under stirred conditions and performed in
the potential range of 0 to 1.5 V with a pulse amplitude of 50 mV, a pulse width of 70 ms
and a scan rate of 5 mV/s. The DNA-modiﬁed MWCNT-epoxy composite electrode was
maintained in the nucleotide solution at 0 V for 2 minutes before DPV was performed.
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DNA-modified MWCNT-epoxy Composite Electrodes
The results for the oxidation of GMP and AMP at the DNA-modiﬁed electrodes are shown
in Figure 6.14 and Figure 6.15, respectively.
acetate buer
Figure 6.14: DPVgrams of a DNA-modified MWCNT-epoxy composite electrode in 1 mM GMP.
Pulse amplitude 50 mV, pulse width 70 ms and scan rate 5 mV/s. The dotted line indicates the
DPVgram obtained using 0.1 M ACB at pH 4.5 as the supporting electrolyte.
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Figure 6.15: DPVgrams of a DNA-modified MWCNT-epoxy composite electrode in 1 mM AMP.
Pulse amplitude 50 mV, pulse width 70 ms and scan rate 5 mV/s. The dotted line indicates the
DPVgram obtained using 0.1 M ACB at pH 4.5 as the supporting electrolyte.
As illustrated in Figures 6.14 and 6.15, the oxidation peaks of both GMP and AMP
were clearly observed and with higher signals than for ssDNA. The GMP was oxidised
at +1.05 V vs Ag|AgCl (Figure 6.14), while the AMP oxidation peak was observed at
+1.35 V for the DNA-modiﬁed electrodes (Figure 6.15). It is noted that both cases showed
reproducible oxidation peaks for the initial DPV scans. This agrees with the ﬁndings of
Piedade et al. [201] with DNA-modiﬁed glassy carbon electrodes, for which the oxidation
peaks of both GMP and AMP were stable for the ﬁrst scans at +1.05 V and +1.3 V,
respectively.
Bare MWCNT-epoxy Composite Electrodes
Given the high eﬃciency of MWCNT-epoxy composite electrodes for many complex electro-
analytical reactions, I thought it was valuable to investigate the oxidation of the nucleotide
bases directly on a bare MWCNT-epoxy composite electrode. Interestingly, the data shown
in Figures 6.16 and 6.17 for GMP and AMP, respectively was obtained, showing stable peaks
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with the peak heights of 0.53 µA and 0.7 µA, respectively.
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Figure 6.16: DPVgrams of a bare MWCNT-epoxy composite electrode in 1 mM GMP. The dotted
line indicates a DPVgram obtained using 0.1 M ACB at pH 4.5 as a supporting electrolyte. Pulse
amplitude 50 mV, pulse width 70 ms and scan rate 5 mV/s.
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Figure 6.17: DPVgrams of a bare MWCNT-epoxy composite electrode in 1 mM AMP. The dotted
line indicates a DPVgram obtained using 0.1 M ACB at pH 4.5 as a supporting electrolyte. Pulse
amplitude 50 mV, pulse width 70 ms and scan rate 5 mV/s.
Surprisingly, as seen in these results, stable oxidation currents were observed within a
few DPV scans at the bare MWCNT-epoxy composite electrode for both 1 mM AMP and 1
mM GMP. These DPVgrams show prominent oxidation peaks at +1.0 V for GMP (Figure
6.16) and at +1.30 V for AMP (Figure 6.17). These oxidation potentials were in almost the
same position as those observed for the DNA-modiﬁed electrode.
Importantly, the results are inconsistent with those reported at a bare glassy carbon
electrode in [201]. To verify whether the stable oxidation of the nucleotides obtained was
due to this protocol or to the properties of the MWCNT composite, a bare glassy carbon
electrode was used to investigate the oxidation peaks of GMP and AMP. The results are
illustrated in Figure 6.18 for GMP and Figure 6.19 for AMP.
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scan number
Figure 6.18: DPVgrams of a bare glassy carbon electrode in 1 mM GMP. Pulse amplitude 50 mV,
pulse width 70 ms and scan rate 5 mV/s. The dotted line indicates a DPVgram obtained using 0.1
M ACB at pH 4.5 as the supporting electrolyte.
1st scan
2 nd scan
7th scan
Figure 6.19: DPVgrams of a bare glassy carbon electrode in 1 mM AMP. Pulse amplitude 50
mV, pulse width 70 ms and scan rate 5 mV/s. The dotted line indicates a DPV obtained using 0.1
M ACB at pH 4.5 as supporting electrolyte.
As seen in Figures 6.18 and 6.19, the results showed that the oxidation peaks of both
nucleotides were not stable or reproducible with a glassy carbon electrode. For AMP, the
oxidation peak obtained at the glassy carbon electrode diminished with successive scans (see
6.8. Electrochemistry of GMP and AMP 157
Figure 6.19). This agrees with the ﬁnding of [201] and is the reason why Oliveira-Brett’s
group modiﬁed the glassy carbon electrode with DNA followed by conditioning with ssDNA.
To summarise these result, a comparison of the DPVgrams in Figures 6.14 and 6.15
for the DNA-modiﬁed MWCNT-epoxy composite electrode and Figures 6.16 and 6.17 for
the bare MWCNT-epoxy composite electrode is shown in Table 6.1.
Table 6.1: Comparison of DPV results between the DNA-modified MWCNT-epoxy composite
electrodes and the bare MWCNT-epoxy composite electrodes in GMP and AMP solutions.
DPV results
DNA-modiﬁed electrode Bare electrode
GMP AMP GMP AMP
Peak height / µA 0.22 0.51 0.53 0.70
Peak width / mV 90 125 100 120
Peak potential vs Ag|AgCl 1.05 1.34 1.02 1.33
S/N∗ 23.67 60.42 44.74 101.12
Note: For 1 mM GMP and 1 mM AMP in 0.1 M ACB at pH 4.5. S/N is Ipeak/noise. N∗ is the
standard deviation of the current values for scan the 2nd-5th for a 100 mV window before the peak.
Table 6.1 clearly shows that the bare MWCNT-epoxy composite electrode performed
better than the DNA-modiﬁed MWCNT-epoxy composite electrode. For the bare electrode,
both the GMP oxidation peak height and the S/N were twice as large as for the DNA-
modiﬁed electrode. The peak widths are not consistent with a 4e− transition as described
in the oxidation mechanisms of the DNA bases in section 6.1 (Figure 6.2). The peak widths
suggest there is only a 1e− transition in the oxidation mechanism of both GMP and AMP.
The data ﬁgures for both GMP and AMP shown in [201] are consistent with a 1e− transfer
rather than the 4e− or 6e− mechanism given in the text.
These interesting observations suggest that it may be possible to use a bare electrode
instead of a DNA-modiﬁed electrode. Using a bare MWCNT-epoxy composite electrode can
reduce the time required for the process of DNA immobilisation on the electrode surface as
well as the conditioning with ssDNA solution. Due to these beneﬁts, a bare MWCNT-epoxy
composite electrode is the best candidate in the absence of carboplatin. In the next section,
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the performance of both electrodes was compared in the presence of carboplatin.
6.9 Determining Carboplatin Interaction with Nucleotide
Bases
To determine the interaction of carboplatin with nucleotide bases the performance of two
electrodes was evaluated. These electrodes were the bare MWCNT-epoxy composite elec-
trode, which was selected as the best candidate in the previous section, and the DNA-
modiﬁed MWCNT-epoxy composite electrode. Both were investigated in case the DNA-
modiﬁed electrode was a better detector for carboplatin. DPV was performed in the po-
tential range of 0 to 1.5 V at a pulse amplitude of 50 mV, a pulse width of 70 ms and a
scan rate of 5 mV/s using Echem software (eDAQ, UK). The experiment was conducted
following the steps shown below.
1. The electrode was placed in 1 mM GMP or 1 mM AMP in 0.1 M ACB (pH 4.5).
DPV was performed until a stable oxidation peak was obtained. Typically this took
5 scans for a DNA-modiﬁed MWCNT-epoxy composite electrode and 11 scans for a
bare MWCNT-epoxy composite electrode.
2. Aliquots of carboplatin (1 mM in 0.1 M ACB, pH 4.5) was added under stirred con-
ditions.
3. This was left for a period of 2 minutes to allow the reaction between carboplatin and
the nucleotides to go to completion, after which the electrode was held at 0 V for 2
minutes and the DPV analysis scan was run.
4. Step 2 and 3 were repeated.
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DNA-Modified MWCNT-epoxy Composite Sensor
The results from the DNA-modiﬁed sensor are illustrated in Figure 6.20 for AMP, and in
Figure 6.21 for GMP. For AMP, a decrease in the oxidation peak current was observed with
increasing carboplatin concentration. Presumably, this indicates that the decrease of the
AMP oxidation peak height relates to the sequential formation of complex of carboplatin
and AMP. The electrode detected only unbound AMP in the solution, and did not detect
the carboplatin bound the AMP. For GMP, the oxidation current seemed to be unchanged
with increasing concentrations of carboplatin.
Figure 6.20: DPVgrams obtained with a DNA-modified MWCNT-epoxy composite electrode for
the addition of 0 to 280 µM carboplatin to 1 mM AMP in 0.1 M ACB, pH 4.5. Pulse amplitude
50 mV, pulse width 70 ms and scan rate 5 mV/s.
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Figure 6.21: DPVgrams obtained with a DNA-modified MWCNT-epoxy composite electrode for
the addition of 0 to 320 µM carboplatin to 1 mM GMP in 0.1 M ACB, pH 4.5. Pulse amplitude
50 mV, pulse width 70 ms and scan rate 5 mV/s.
Bare MWCNT-epoxy Composite Electrode
The DPVgrams for a bare MWCNT-epoxy composite electrode are shown in Figure 6.22 for
AMP and in Figure 6.23 for GMP. There was a marked decrease in the oxidation current
for AMP with increasing the carboplatin concentration from 0 to 160 µM. However, the
current seems to saturate at higher concentrations of carboplatin.
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Figure 6.22: DPVgrams obtained with a bare MWCNT-epoxy composite electrode for the addition
of 0 to 280 µM carboplatin to 1 mM AMP in 0.1 M ACB, pH 4.5. Pulse amplitude 50 mV, pulse
width 70 ms and scan rate 5 mV/s. The dotted line indicates a DPVgram obtained in ACB.
In Figure 6.23, the GMP oxidation current also showed a decrease with increasing
carboplatin concentration, but the DPVgrams are more complex with a post peak trough
that diminishes with increasing carboplatin concentration. There are two possibilities for
the result. Firstly, blocking on the electrode surface by the product of GMP oxidation.
It might absorb on the surface and having less GMP molecules in the solution, leading to
the decrease of the peak current after the oxidation peak. However, the trough would also
occur because it can regenerate of other molecules during the process and the electrode was
cleaned every scan.
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Figure 6.23: DPVgrams obtained with a bare MWCNT-epoxy composite electrode for the addition
of 0 to 360 µM carboplatin to 1 mM GMP in 0.1 M ACB, pH 4.5. Pulse amplitude 50 mV, pulse
width 70 ms and scan rate 5 mV/s.
A comparison of the reduction in the peak current from Figure 6.22 for AMP and
Figure 6.23 for GMP is shown in Figure 6.24. The results clearly show that for AMP there
was initially a steep reduction in the peak current, which reached a saturation plateau at 280
µM, while there was a steady increase in the current reduction caused by the carboplatin-
GMP interaction with much lower signals than for AMP.
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AMP
GMP
Figure 6.24: Comparison of the reduction in peak height with addition of carboplatin for AMP and
GMP using bare MWCNT-epoxy composite electrodes. The yellow trace is the data from AMP
and the dark blue trace is the data of GMP. The traces were fitted with the Michaelis-Menten
equation in Igor Pro.
To determine the nucleotide preferential interaction of carboplatin (the strength of
binding) we can consider Kd, which is the dissociation constant. A reversible binding equi-
librium is shown in equation 6.1.
M + L⇌ML (6.1)
where M is a free macromolecule, L is a free ligand, and ML is a macromolecule-ligand
complex.
For the above equation, Kd is given by equation 6.2.
Kd =
[M ][L]
[ML]
(6.2)
It is noted that the lower the Kd, the tighter the binding. When considering the mass
balance of M, it is M0= M+ ML. Equation 6.2 is simpliﬁed by substituting M for M0 - ML
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as shown in equation 6.3, which is now in the same form as the Michealis-Menten equation
for enzyme kinetics.
[ML] =
[M0][L]
Kd + [L]
(6.3)
In this case, the binding reaction of carboplatin (CP) to AMP is shown below:
AMP0 + CP ⇌ AMPCP + AMPfree (6.4)
where [ML] ≡ AMPPt, [L] ≡ [CP], and [M0] ≡ [AMP0], which its mass balance [AMP0] is
equal to [AMPfree] + [AMPCP] . Therefore, the equation for this case is given in equation
6.5.
[AMP0]− [AMPfree] =
[AMP0][CP ]
Kd + [CP ]
(6.5)
In Figure 6.24, the Kd value of carboplatin interacting with AMP was 124.9 ± 17.3
µM. For GMP, saturation was not reached with the carboplatin concentration used, so it
is more diﬃcult to accurately determine Kd. To indicate the diﬀerence in Kd more clearly,
it is conventional to plot the data on a semi-log graph with logarithm (log) of carboplatin
concentration on the x-axis as shown in Figure 6.25.
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Figure 6.25: Comparison of the peak reduction for AMP and GMP at a bare MWCNT-epoxy
composite electrodes as a function of the logarithm of the carboplatin concentration. The yellow
trace is the data from AMP and the dark blue trace is the data of GMP. The traces were fitted
with sigmoidal curves in Igor Pro.
As seen in Figure 6.25, Kd is the log of the carboplatin concentration at which the
fraction saturation is a half. The results show that the sigmoidal curve of GMP (dark blue)
was shifted progressively to the right and therefore its Kd value was higher (lower aﬃnity)
than that of AMP. This provides evidence that carboplatin has more of an eﬀect on AMP
compared with GMP, particularly at low concentrations of carboplatin. Similar results were
found by Oliveira-Brett et al. [182]. They found that at low concentrations carboplatin
showed a preferential interaction with AMP and it saturated at 80 µM in 1 mM AMP using
a DNA-modiﬁed glassy carbon electrode. They observed that the interaction of carboplatin
with GMP was much less at low concentrations and that the peak reduction for GMP
increased steadily even at higher concentrations. In my study, the saturation plateau for
the interaction of carboplatin with AMP was at a higher concentration than that reported
by [182].
Overall, studies with both the DNA-modiﬁed MWCNT-epoxy composite electrode
and the bare MWCNT-epoxy composite electrode showed that carboplatin interacts prefer-
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entially with AMP rather than GMP. A MWCNT-epoxy composite electrode without DNA
coating exhibited better results than that with the DNA modiﬁcation as the decrease in
oxidation currents with increasing carboplatin concentration was clearly observed for both
GMP and AMP. To fabricate a device for on-line determination of carboplatin interact-
ing with DNA, a bare MWCNT-epoxy composite electrode was employed to monitor the
presence of the carboplatin-AMP interaction. This will be described in the next chapter.
6.10 Conclusion
In summary, this chapter reported the investigation of the oxidation of free guanine and
free adenine at diﬀerent electrodes using DPV. The MWCNT-epoxy composite electrodes
showed the best results for detecting the oxidation signal of the free purine bases at diﬀerent
concentrations and also had the advantage that they can be made small enough to be placed
in a microﬂuidic chip. In contrast, no oxidation signals were observed at Pt electrodes or
at rGO-modiﬁed Pt electrodes. The oxidation peaks for both GMP and AMP were tested
at both DNA-immobilised MWCNT-epoxy composite electrodes and bare MWCNT-epoxy
composite electrodes compared with bare glassy carbon electrodes. Both bare MWCNT-
epoxy composite electrodes and DNA-immobilised MWCNT-epoxy composite electrodes
showed stability of AMP and GMP oxidation currents.
Finally, the capability of both DNA-immobilised MWCNT-epoxy composite electrodes
and bare MWCNT-epoxy composite electrodes for detecting of carboplatin interacting with
nucleotides was examined. At the bare MWCNT-epoxy composite electrode, the decrease of
the oxidation current of both GMP and AMP was clearly observed, whereas the oxidation
of GMP at the DNA-modiﬁed MWCNT-epoxy composite electrode exhibited only a slight
decrease. Therefore, bare MWCNT-epoxy composite electrodes showed better performance
than DNA-modiﬁed MWCNT-epoxy composite electrodes.
Chapter 7
Carbon-based Sensors for on-line
Carboplatin Detection
This chapter describes the fabrication of a device for detection of carboplatin in a dialysate
stream. The aim of this device is to allow detection of carboplatin in healthy tissue when
carboplatin is being infused into the centre of a tumour, thus reducing the risk of toxic
side eﬀects to the tissue surrounding the tumour. Such a system needs to be small in
order for it to be convenient for use in an operating theatre. In Chapter 6, I showed that
sensitive carboplatin detection could be achieved using of a bare MWCNT-epoxy composite
electrode. This sensor is now adapted for analysis of dialysate in T1 perfusion solution
and is combined with a microﬂuidic platform employing a microﬂuidic chip and LabSmith
components to build a new bioanalytical device. This chapter will conclude with proof-of-
concept data.
7.1 Methodology Development
In this chapter, a microﬂuidic chip was used to house a bare MWCNT-epoxy composite
electrochemical sensor for detection of carboplatin. In all measurements described in this
chapter, a bare MWCNT-epoxy composite electrode (see Chapter 6) was employed as the
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working electrode (WE). To ﬁt into a microﬂuidic chip, an Ag|AgCl wire (50 µm diameter)
was incorporated within a 27G hypodermic needle (400 µm OD, see section 3.4) to be used
as the reference electrode (RE). The stainless steel shaft of the needle served as the auxiliary
electrode (AE). The needle RE/AE was used instead of the coiled Pt electrode and Ag|AgCl
in 3 M NaCl solution used in the previous chapter. Diﬀerential pulse voltammetry (DPV)
was performed with a pulse amplitude of 50 mV, a pulse width of 70 ms and a scan rate of
5 mV/s at room temperature (typically 294 K). The MWCNT-epoxy composite electrode
incorporated in the PDMS microﬂuidic chip is illustrated in Figure 7.1.
WE RE/AE
inlet outlet
3 cm
5 cm
(c)                                                                                                             (d)
(a)
(b)
RE/AE
WE
outletinlet
 1cm
 1cm
 1cm
Figure 7.1: A PDMS-based microfluidic device for carboplatin detection. (a) MWCNT-epoxy
composite electrode used as WE. (b) an Ag|AgCl wire for RE incorporated within a 27G hypodermic
needle used as AE. (c) schematic of the design of the microfluidic device with a channel height of
150 µm and a channel width of 500 µm, showing the positions of the inlet, the outlet, the RE/AE
electrode and the WE (d) photo of the PDMS chip incorporating these electrodes.
Figure 7.1c shows a schematic of design of the PDMS chip used in all experiments in
this chapter, indicating the position of the electrodes. The channel height was 150 µm and
the width was 500 µm. A photo of a PDMS chip is presented on the right (Figure 7.1d),
showing the RE/AE needle electrode (right electrode) and the MWCNT-epoxy composite
WE (left electrode). The inlet of the microﬂuidic chip was connected to the LabSmith
autocalibration system.
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Before use, each bare MWCNT-epoxy composite electrode was preconditioned in a
beaker containing 0.1 M acetate buﬀer (ACB) at pH 4.5. In this step, DPV was carried out
in the range from 0 V to 1.6 V at a scan rate of 5 mV/s to investigate the cleanliness of the
electrode surface. Then, the electrode was cycled using CV in the range from 0.3 V to 1.6
V in ACB solution until a steady cyclic voltammogram was obtained in order to reduce the
background current and to obtain reproducible experimental results.
Before using the preconditioned MWCNT-epoxy composite electrode to detect carbo-
platin using a microﬂuidic chip, the electrode was also conditioned in AMP solution. For
tissue measurement, the microdialysis (MD) probe must be perfused with T1 solution (a
physiological solution) to sample the carboplatin dispersing into the healthy tissue for exter-
nal analysis. Therefore, in this chapter T1 solution was used to prepare the AMP solution
for use in the detection of the carboplatin-AMP interaction. The overall concept is shown
in Figure 7.2.
Carboplatin
Carboplatin
in dialysate
T1
Healthy tissue
Tumour
Carboplatin
efflux
Outlet
Analysis chip
MD probe 2
MD probe 1
Figure 7.2: Schematic of the carboplatin detector device coupled to MD sampling probe with
retrodialysis of carboplatin using another MD probe during chemotherapy.
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Carboplatin Carboplatin
in dialysate
1 cm
Tumour
Healthy tissue
MD probe 2MD probe 1
Figure 7.3: Schematic shown the approximate distance between two probes during the carboplatin
detection.
For carboplatin detection in tissue, MD probe 2 is placed as close as possible to the
tumour as seen in Figure 7.3, to predict the time for carboplatin diﬀuses through tissue it
is given by Einstein Smoluchowski equation:
L = (2Dt)1/2 (7.1)
where L is the distance of carboplatin diﬀusion from the injection point to the MD probe
for analysis, D is the diﬀusion coeﬃcient, and t is the time of analyte diﬀustion to the MD
probe.
t ≈
L2
2D
(7.2)
As assumed, the distance between both MD probes (L) is 1 cm and diﬀusion coeﬃcient
of carboplatin (D) is 27.0 × 10−6 cm2s−1 (assuming unity partition coeﬃcient) [202], so the
predicted time will be 1.85 × 104 s. However, as mentioned before in tissue we also have
convective ﬂow due to lymphatic, so this is much faster than the predicted time.
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7.1.1 Study of the Ratio of AMP and T1
1 mM AMP was prepared in T1 solution (unbuﬀered, 147 mM NaCl, 4 mM KCl and 2.3
mM CaCl2 in DI water, pH measured at 5.3 presumably due to dissolved CO2). After the
preconditioning step in 0.1 M ACB (pH 4.5) DPV was carried out in the range from 0 V
to 1.3 V in a beaker of the 1 mM AMP solution under stirred conditions. The results are
shown in Figure 7.4 (blue trace) compared to the oxidation peak obtained in 1 mM AMP
dissolved in 0.1 M ACB at pH 4.5 (red trace).
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Figure 7.4: Differential pulse voltammograms (DPVgrams) showing the oxidation of AMP. The
blue trace is a DPVgram obtained in 1 mM AMP in T1 solution and the red trace is a DPVgram
obtained in 1 mM AMP in 0.1 M ACB at pH 4.5. Pulse amplitude of 50 mV, pulse width of 70 ms
and a scan rate of 5 mV/s.
As seen in Figure 7.4, no oxidation peak was observed when AMP was dissolved in
T1 solution, whereas an oxidation peak was clearly seen when AMP was prepared in 0.1 M
ACB (AMP/ACB). The reasons for this diﬀerence are not clear. The diﬀerence in the pH of
the solution is a possibility but AMP dissolved in PBS at pH 7.0 does give a small oxidation
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peak (data not shown). However, it is necessary to use unbuﬀered T1 as the perfusate in
tissue, so ACB buﬀer at pH 4.5 would need to be added downstream of the MD probe. An
autocalibration board (see section 3.7) was used to investigate the eﬀect of the ratio of ACB
to T1 solution.
T1
  2 mM  AMP/ACB
waste
Syringe pump Reservoir Analysis chip with sensor InterconnectValve
Figure 7.5: Schematic of the autocalibration board for investigating the ratio of AMP/ACB and
T1. This setup would be used for on-chip calibration of sensors.
Figure 7.5 shows the schematic of the experimental setup. The autocalibration system
consists of two syringe pumps one that contains 2 mM AMP/ACB and one that contains
T1 solution. Three diﬀerent ratios were created by altering the ﬂow rates of the two pumps,
as shown in Table 7.1. The total ﬂow rate of the ﬁnal solution ﬂowing pass the WE was 2
µl/min. The results are shown in Figure 7.6.
Table 7.1: The ratios of ACB and T1 solution.
Flow rate (µl/min)
Final [AMP] (mM) % buﬀer
ACB T1
2 0 2 100
1.5 0.5 1.5 75
1 1 1 50
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Figure 7.6: DPVgrams showing the oxidation peak of AMP with different ratios of ACB and T1
solution created using an autocalibration board. DPV was performed in the range from 0.9 V to
1.5 V and the electrode was held at 0 V for 2 min before starting each scan. Pulse amplitude was
50 mV, pulse width was 70 ms and scan rate was 5 mV/s. The blue traces are DPVgrams obtained
at a 1:1 ratio, the green traces are DPVgrams obtained at a 1.5:0.5 ratio and the red traces are
DPVgrams obtained at a 2:0 (in the absence of T1 solution). Overlay of three scans for each ratio.
As shown in Figure 7.6, the oxidation peaks of AMP were clearly observed both for
the 2:0 ratio case (red) and for the 1.5:0.5 ratio case (green) for all three scans. In contrast,
in the case of the 1:1 ratio (blue) the oxidation peak was observed in the ﬁrst scan but by the
third scan it had disappeared. The pH of this solution was still buﬀered at 4.5, conﬁrming
that the loss of the peak is not due to pH. The ratio of 1.5:0.5 (ACB : T1 solution) was
chosen to study carboplatin-DNA adduct detection in the following experiments.
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7.1.2 Detection of Carboplatin Using a MWCNT-epoxy Composite
Electrode
A preliminary experiment was carried out to demonstrate that detection of carboplatin using
a MWCNT-epoxy composite electrode in the chosen 1.5:0.5 ratio of ACB:T1 was possible.
The results are shown in Figure 7.7.
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Figure 7.7: DPVgrams of a bare MWCNT-epoxy composite sensor for the addition of 0 to 120
µM carboplatin to 20 ml of 1.5 mM AMP in ACB/T1 in 1.5:0.5 ratio (AMP/ACB/T1) solution
under stirred conditions. The dotted lines show the results after addition of 1.5 mM AMP/ACB/T1
solution to dilute the carboplatin concentration in the beaker. Pulse amplitude was 50 mV, pulse
width was 70 ms and scan rate was 5 mV/s.
We can see that as expected carboplatin reduces the height of the AMP oxidation peak
in a dose-dependent manner. However, the eﬀect of carboplatin seems to be irreversible.
When the 1.5 mM AMP in ACB/T1 in 1.5:0.5 ratio (AMP/ACB/T1) solution was added
into the beaker to dilute the ﬁnal carboplatin concentration back to a lower concentration
(from 80 µM to 60 µM), the oxidation peak did not recover to the expected current. Also
when the MWCNT-epoxy composite electrode was tested in a fresh 1.5 mM AMP/ACB/T1
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solution without the drug (0 µM), the same oxidation current was observed as for the
previous concentration of carboplatin tested. The fact that the current does not increase
again in a fresh carboplatin-free solution suggests strongly that the eﬀect is due to a change
on the electrode surface.
To examine the causes of this surprising result, a stepwise protocol was followed using
the ﬂowchart shown in Figure 7.8a. The experiment was conducted in a beaker containing 1.5
mM AMP/ACB/T1 solution (0 µM carboplatin), and a beaker containing 40 µM carboplatin
in 1.5 mM AMP/ACB/T1 solution. The results are shown in Figure 7.8b.
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Figure 7.8: Investigation of the decrease in the oxidation current after carboplatin detection at a MWCNT-epoxy composite electrode. (a) Protocol
for investigation and (b) DPVgrams showing the results from each step. DPV was conducted in a beaker at a pulse amplitude of 50 mV, a pulse width
of 70 ms and a scan rate of 5 mV/s using the same MWCNT-epoxy composite electrode.
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Figure 7.9: Flow chart for abolition of AMP oxidation peak by carboplatin. Colours correspond
to those in Figure 7.8.
Following the ﬂow chart in Figure 7.9 it can be seen that exposure to carboplatin/AMP,
holding the electrode at 0 V and scanning to just below the AMP oxidation peak are not
suﬃcient to aﬀect the AMP oxidation peak. However, the oxidation peak is diminished for
the green curve, in which AMP was oxidised in the presence of carboplatin.
Interestingly after these scans the electrode was placed in 0 µM carboplatin, at this
point it was found that the RE had not been connected during holding period at 0 V for 2
minutes. In the following scan the oxidation current became much higher than for even the
initial scan. This is because when the RE is not connected, the WE potential is undeﬁned
and typically moves to the voltage of the power supply. This would be equivalent to an
electrochemical cleaning of the electrode surface. This now will be investigated in a more
controlled manner.
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7.1.3 Electrochemical Cleaning of MWCNT-epoxy Composite Elec-
trode
Given that inhibition of the AMP oxidation peak required oxidation of AMP in the presence
of carboplatin. It was unlikely that further oxidation by more positive potentials would cause
the reversal seen in Figure 7.8b, as previously variation in upper scan limit had not improved
performance. For this reason negative reducing potentials were tested.
To investigate whether applying a negative potential could be used to clean the elec-
trode surface after carboplatin detection, I tested holding the MWCNT-epoxy composite
electrode vs Ag|AgCl at diﬀerent constant holding potentials including -1 V, -2 V, -0.5 V,
-0.2 V and -0.1 V in 1.5 mM AMP/ACB/T1 solution in the absence of carboplatin for 2
minutes. Before testing the diﬀerent constant holding potentials a stable oxidation current
of AMP was obtained for the bare MWCNT-epoxy electrode in 1.5 mM AMP/ACB/T1
solution (dotted trace) shown in Figure 7.9.
For each diﬀerent holding potential the electrode was ﬁrst placed in a beaker containing
40 µM carboplatin in 1.5 mM AMP/ACB/T1 solution and DPV was performed in the range
from 0 V to 1.6 V, to demonstrate the peak inhibition. Following this, the WE was washed
with ACB to ensure no carboplatin solution remained on the electrode surface. The electrode
was then moved to the beaker containing 1.5 mM AMP/ACB/T1 (0 µM carboplatin) and
held at the chosen holding potential for 2 minutes after which DPV was performed. Figure
7.10 illustrates the results.
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Figure 7.10: DPVgrams obtained from the study of holding at different constant potentials to
clean the electrode surface. These potentials include -1 V, -2 V, -0.1 V and -0.2 V. DPV was
performed in a beaker with pulse amplitude 50 mV, pulse width 70 ms, and a scan rate of 5 mV/s.
As seen in Figure 7.10, the oxidation current recovered to close to its initial value
after holding at a constant potential of -0.1 V (dark blue trace). Thus, the constant holding
potential of -0.1 V was chosen for further experiments to clean the electrode surface after
carboplatin detection in a microﬂuidic platform.
7.1.4 Optimisation of the Analysis Protocol
The detection of carboplatin took a long time of up to 9 minutes including the cleaning step
(each scan was in the range from 0 V to 1.5 V at a scan rate of 5 mV/s). It is a challenging
task to reduce this time so that detection of carboplatin is as short as possible so that it is
more suitable for clinical use real-time detection.
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DPV   (0            1.5 V) cleaning at -0.1 V
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Figure 7.11: Timescale showing the procedure of carboplatin detection using DPV at a scan rate
of 5 mV/s. Total time was 540 s.
For 9 min per measurement, the Nyquist theorem tell us that 18 min is required to
be sure of a change. Clearly, it would be good to reduce this time as until detection of
carboplatin is conﬁrmed excess carboplatin would be diﬀusing into healthy tissue in the
setup shown in Figure 7.2. Each part of Figure 7.11 was investigated for ways to reduce the
timescale.
Static Holding Times
Firstly, the time that electrode was held at -0.1 V and then at 0 V was varied. For each
condition the experiment was conducted by following this procedure:
1. The electrode was placed in a beaker containing 1.5 mM AMP/ACB/T1 solution in
the absence of carboplatin (0 µM carboplatin) and held at 0 V for 2 minutes. DPV
was performed (0-1.5 V) shown as a black trace in Figure 7.12.
2. The electrode was placed in a beaker containing 40 µM carboplatin in 1.5 mMAMP/ACB/T1
and DPV was performed (0-1.5 V) given as green trace in Figure 7.12.
3. The electrode was washed with ACB to ensure no carboplatin solution remained on
the electrode surface.
4. The electrode was cleaned in 0 µM carboplatin by holding it at -0.1 V for the required
time.
5. The background current was allowed to stabilise at 0 V for the required time and DPV
was performed.
6. Steps 2-5 were repeated.
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Figure 7.12: DPVgrams obtained from holding at -0.1 V in different periods including 2 minutes,
30 s and 10 s in the cleansing step and holding at 0 V for stabilising baseline for 2 minutes and
without holding. DPV was performed (0 V-1.5 V) in a beaker under stirred conditions with pulse
amplitude 50 mV, pulse width 70 ms and a scan rate of 5 mV/s. The black trace is the initial
AMP oxidation peak before carboplatin testing and the green trace is AMP oxidation peak in 40
µM carboplaton in 1.5 mM AMP/ACB/T1.
Figure 7.12 shows the results for holding the electrode at -0.1 V for 2 minutes, 30 s
and 10 s, and also for holding the electrode at 0 V for stabilisation for 2 and 0 minutes. The
DPVgrams for all conditions showed enhancement of the sensitivity from the initial DPV
scan (black trace) after holding at -0.1 V in 1.5 mM AMP/ACB/T1. It can also be seen
that stabilisation at 0 V for 2 minutes was not necessary in this process. The electrode
could be held at 0 V for 10 s, but there was a slight improvement in the sensitivity when it
was held at -0.1 V for 30 s. From this result, I concluded that the stabilisation step at 0 V
was not required and the cleaning step at -0.1 V could be reduced to 30 s. Therefore, these
steps were reduced from a total of 4 minutes to only 30 s leading to a total reduction in the
procedure length of 330 s.
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DPV Scan Time
Next, a reduction in the scan potential range was tested. The scan range for DPV was
performed from 0.8 V to 1.5 V instead of from 0 to 1.5 V at a scan rate of 5 mV/s. The
results are shown in Figure 7.13.
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Figure 7.13: DPVgrams obtained when the electrode is held at -0.1 V either for 30 s or 10 s.
The potential range scanned is either 0-1.5 V or 0.8-1.5 V. DPV was performed in a beaker under
stirred conditions with a pulse amplitude of 50 mV, a pulse width of 70 ms and a scan rate of 5
mV/s.
Peak recovery after carboplatin detection was obtained when the scan potential range
was reduced from 0 - 1.5 V to 0.8 - 1.5 V as shown in Figure 7.13. For the shorter scan range,
the potential jumped from -0.1 V to 0.8 V at the beginning of the scan. Indeed when 0.9 V
was used as the DPV starting potential, a potentiostatic step interfered with the baseline in
the region of 1.0 V, which is needed to measure the DPV oxidation peak (data not shown).
For the case of holding the electrode at -0.1 V for 30 s, the result showed that the eﬀect
of carboplatin on the AMP oxidation peak was reversed and that the current peak was
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equivalent to that for when the full range was scanned (yellow trace). When the electrode
was held at -0.1 V for 10 s with a shorter scan range the oxidation peak was similar in size to
that obtained before carboplatin detection, but it did not show the enhancement. Therefore
the electrode was held at -0.1 V for 30 s for future experiment. The scan range from 0.8
V - 1.5 V was chosen for carboplatin detection in the following section. This shortened the
DPV scan time from 300 s to 140 s. Overall, the analysis time has been shortened from 560
s to 170 s. The chosen conditions are summarised in Table 7.2.
Table 7.2: Summary of the conditions chosen for detection of carboplatin at MWCNT-epoxy
composite electrodes.
Conditions chosen
Ratio of ACB and T1 1.5 : 0.5
Potential scan range 0.8 - 1.5 V
Potential holding - 0.1 V
Period of holding at -0.1 V 30 s
7.1.5 Optimal Potential for Microfluidic Chips
The next step was to take the successfully optimised beaker method and to apply it to
electrodes in a microﬂuidic chip. To conﬁrm all of the obtained conditions can also be
used under ﬂow conditions, the experiment was conducted again using the microﬂuidic
autocalibration platform instead of a beaker. The experimental setup was the same as
that shown in Figure 7.5, but in this case the two syringe pumps were ﬁlled with 1.5 mM
AMP/ACB/T1 (0 µM carboplatin), and 40 µM carboplatin in 1.5 mM AMP/ACB/T1. The
results are shown in Figure 7.14b.
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Figure 7.14: Comparison of DPVgrams obtained at a bare MWCNT-epoxy composite electrode
in a beaker and in a microfluidic chip for 0 and 40 µM carboplatin using the opimised conditions
(a) beaker data and (b) microfluidic data. DPV was performed in a PDMS chip under continuous
flow conditions at 2 µl/min with a pulse amplitude of 50 mV, a pulse width of 70 ms and a scan
rate of 5 mV/s.
As seen in Figure 7.14b, the fall in the oxidation current in 40 µM carboplatin in
1.5 mM AMP/ACB/T1 was less for the microﬂuidic system (18.83 nA) when compared
to that for the beaker setup (206.07 nA). This is probably because its peak width (0.115
V) was wider than for the beaker setup (0.080 V). However, the current for the oxidation
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AMP gave a reproducible and stable baseline, so the optimised conditions also worked
well in a microﬂuidic chip. This indicates that this method was successful for refreshing
the MWCNT-epoxy composite electrode surface after carboplatin detection at 40 µM in
1.5 mM AMP/ACB/T1. This allows the electrode to be used for carboplatin detection
in several times in a microﬂuidic chip without having to physically clean it. Therefore,
the conditions of holding the electrode at -0.1 V for 30 s in 1.5 mM AMP/AcB/T1 in the
absence of carboplatin was used to clean the electrode surface and DPV was performed in
the potential range from 0.8 V to 1.5 V.
7.2 Carboplatin Detection Using a Microfluidic Platform
Having devised a method for repeated determination of carboplatin at the same electrode
and having optimised the analysis time this was used in a microﬂuidic system. I developed
a microﬂuidic platform employing LabSmith components for carboplatin detection. In this
section, the two generations of the device are described and the results of the calibration of
carboplatin-AMP adducts obtained using the device are shown.
7.2.1 The First Generation
In the ﬁrst generation (Figure 7.15), the automated calibration system consists of three sy-
ringe pumps containing T1 solution, carboplatin dissolved in T1 solution (carboplatin/T1),
and 2 mM AMP dissolved in 0.1 M ACB. The carboplatin/T1 and T1 solutions were mixed
at the interconnect as indicated with a dotted square in Figure 7.15 to give carboplatin in T1
at concentrations from 0 to 40 µM ﬂowing at 0.5 µl/min. A 2 mM AMP/ACB solution (1.5
µl/min) was mixed with the calibration solution and fed into a long piece of coiled PEEK
tube to allow the carboplatin to interact with AMP for 2 min before the carboplatin-AMP
adducts were detected at the MWCNT-epoxy electrode. The MWCNT-epoxy composite
sensor was placed into a PDMS analysis chip and connected to the potentiostat.
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T1
   Carboplatin/T1
waste
Syringe pump Reservoir Analysis chip with sensor InterconnectValve
  2 mM  AMP/ACB
0.5 μl/min
1.5 μl/min
2.0 μl/min
variation of [carboplatin] in T1
AMP/ACB source
2 min delay
Figure 7.15: Schematic of the first generation of microfluidic platform for carboplatin detection.
The inset photo shows the needle housing the RE/AE and the WE incorporated into a PDMS chip.
The detection used the optimised parameters as shown in Table 7.2. The steps for
the carboplatin calibration using the ﬁrst generation board are shown in Figure 7.16. The
DPV results for the calibration using the ﬁrst generation microﬂuidic platform are shown
in Figure 7.17.
holding at -0.1 V for 30 s in 0 μM carboplatin
DPV scan 0.8-1.5 V at 5 mV/s
change [carboplatin]
 DPV (0.8-1.5 V) in 0 μM carboplatin
after 40 μM carboplatin
next calibration
Figure 7.16: Protocol for carboplatin calibration using the first generation of the microfluidic
platform.
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Figure 7.17: Calibrations of carboplatin-AMP interaction using the first generation of the mi-
crofluidic platform. DPV was performed in 5 different concentrations of carboplatin interacting
with 2 mM AMP/ACB under continuous flow at 2 µl/min with a pulse amplitude of 50 mV, a
pulse width of 70 ms and a scan rate of 5 mV/s. (a) 1st calibration of carboplatin-AMP interaction
and (b) 2nd calibration of carboplatin-AMP interaction. The current scale length is the same in
(a) and (b).
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As seen in Figure 7.17 the inhibition of the AMP oxidation peak with increasing
carboplatin concentration initially clearly seen. For the ﬁrst calibration the decrease in the
AMP oxidation current was clearly observable, except at 10 µM carboplatin. It was observed
that the oxidation current of AMP in the absence of carboplatin after the 1st calibration test
(dotted trace in Figure 7.17a) did not recover back to the original oxidation current when
the calibration was repeated. For the 2nd calibration (Figure 7.17b), there was a only slight
decrease in the oxidation peak with increasing carboplatin concentration. This indicates
that the WE surface was not cleaned enough after the 1st calibration.
7.2.2 The Second Generation
The second generation of the microﬂuidic platform was built by adding a syringe pump
containing 1.5 mM AMP/ACB/T1 without carboplatin to clean the electrode between the
every step of the carboplatin-AMP calibration. A 4-port valve with 2 position could then
switch between the carboplatin solution and the cleaning solution without changing the ﬂow
rate through the analysis chip as shown in Figure 7.18 (dotted blue section). This solution
ﬂowed past the sensor directly without the 2-minute delay from the coil of PEEK tubing.
During this cleaning phase the electrode was held at -0.1 V for 30 s in this solution. The
protocol for carboplatin calibration using the second generation system is shown in Figure
7.19. The results are shown in Figure 7.20.
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T1
   Carboplatin/T1
Syringe pump Reservoir Analysis chip with sensor InterconnectValve
waste
  2 mM  AMP/ACB
0.5 μl/min
1.5 μl/min
2.0 μl/min
1.5 mM  
AMP/ACB/T1
waste
4-port  valve
Figure 7.18: Schematic of the second generation microfluidic platform for carboplatin detection.
Blue dotted lines show the part modified from the first version.
holding at -0.1 V for 30 s in 1.5 mM AMP/ACB/T1
DPV scan 0.8-1.5 V at 5 mV/s
change [carboplatin]
 DPV (0.8 -1.5 V) in 0 μM carboplatin
next calibration
!nal [carboplatin]
Figure 7.19: Protocol for carboplatin calibration using the second generation of the microfluidic
platform.
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Figure 7.20: Calibrations of carboplatin using the second generation microfluidic platform. DPVs
were performed with a pulse amplitude of 50 mV, a pulse width of 70 ms and a scan rate of 5 mV/s.
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Figure 7.20 compares three successive calibrations of carboplatin (0-40 µM). A de-
crease in the AMP oxidation current was observed for all three of the calibrations. This
indicates that the system worked well with 20 µM carboplatin as the lower limit of detection.
7.3 Microdialysis Experiment
The second version of the microﬂuidic system was coupled with a microdialysis probe in order
to validate the capability of detecting physiological carboplatin during cancer chemotherapy.
In practice, it was diﬃcult to place the MWCNT-epoxy composite electrode into the hole of
the PDMS chip because it is easy to generate air bubbles inside the channel of the PDMS
and also diﬃcult to position the electrode in the channel. Consequently, the oxidation peak
of AMP was sometimes not observed during DPV scanning. Thus, in this experiment a
LabSmith injection-molded junction was adapted for use as a microﬂuidic chip. The photo
of the experimental setup is illustrated in Figure 7.21.
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MWCNT- epoxy 
composite sensor
MD probe
RE/AE
Figure 7.21: Photo of the experimental setup using the second generation microfluidic system
coupled with a microdialysis sampling probe for carboplatin detection in real time.
Similar to the method explained in section 4.7, a microdialysis (MD) probe (CMA 70,
MDialysis, Sweden) was immersed in a beaker containing 30 ml of T1 solution under stirred
conditions. The outlet of the MD probe was connected to the microﬂuidic platform and
the inlet of the MD probe was continuously perfused with T1 solution at 0.5 µl/min ﬂow
rate using a portable syringe pump (CMA 107, Mdialysis, Sweden). The T1 solution from
the syringe pump ﬂowed continuously during the experiment in order to allow carboplatin
molecules to diﬀuse through the membrane and to travel in the liquid outlet stream towards
the analysis system. The dialysate interacted with AMP in the microﬂuidic system and
ﬂowed towards the analysis chip for detection at the WE. To vary the carboplatin concen-
tration in the beaker, aliquots of 1 mM carboplatin standard solution were added using
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a Gilson pipette. The syringe pump and the beaker containing carboplatin were wrapped
with aluminium foil as carboplatin is sensitive to light. The schematic of the microﬂuidic
system with the on-chip sensor coupled with a MD probe for in vitro carboplatin detection
is shown in Figure 7.22.
T1
   Carboplatin/T1
Syringe pump Reservoir Analysis chip with sensor InterconnectValve
waste
  2 mM  AMP/ACB
0.5 μl/min
1.5 μl/min
2.0 μl/min
1.5 mM  
AMP/ACB/T1
waste
dialysate
waste
2.0 μl/min
0.5 μl/min
Figure 7.22: Schematic of the microfluidic platform for the microdialysis experiment.
In this experiment, the MWCNT-epoxy composite electrode was calibrated in the
chip using the autocalibration system before detecting the carboplatin in the dialysate
ﬂowing from the MD probe placed in the beaker. For the on-chip calibration, 5 carboplatin
concentrations were used, which were 0, 10, 20, 30 and 40 µM following the protocol set
out in Figure 7.19. The results are shown in Figure 7.23. A linear decrease in the oxidation
current of AMP was observed for 10 to 40 µM carboplatin as shown in the inset ﬁgure. For
the dialysate analysis, the DPVgrams were obtained when the MD probe was placed in a
beaker and aliquots of carboplatin were added to give ﬁnal concentrations of 10, 20 and 25
µM as shown in Figure 7.24. The decrease in the AMP oxidation peak current was clearly
observed from 10 µM to 25 µM carboplatin. This experiment is a proof for principle of the
carboplatin detection method.
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Figure 7.23: On-chip calibration of the carboplatin detection. DPV was performed with a pulse
amplitude of 50 mV, a pulse width of 70 ms and a scan rate of 5 mV/s.
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Figure 7.24: MD data using the second generation board. DPVgrams were obtained when aliquots
of carboplatin standards were injected into the beaker in which the MD probe was placed and the
dialysate interacted with the 1.5 mM AMP/ACB/T1 on board. DPV was performed with a pulse
amplitude of 50 mV, a pulse width of 70 ms and a scan rate of 5 mV/s.
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7.4 Conclusion
In conclusion, this chapter described the fabrication of a microﬂuidic board using LabSmith
components for on-line carboplatin detection and calibration. The MWCNT-epoxy compos-
ite electrode showed good performance for detection of the carboplatin in AMP solution in
a ﬂow stream. However, an issue of sensitivity loss occurred when detecting carboplatin in
a microﬂuidic chip as shown in Figure 7.14; the sensitivity in the chip was almost 10 times
smaller than in the beaker. Another the challenges was reducing the time required.
The fabricated microﬂuidic platform coupled with a MD probe was successfully used
to detect the interaction of carboplatin and AMP on-line. A decrease in the oxidation
current of AMP was clearly observed when the dialysate containing carboplatin interacted
with the AMP solution on the microﬂuidic board. This fabricated system has potential
for development of a clinical device for the detection of carboplatin in real time during
chemotherapy.
Chapter 8
Conclusions and Future Work
8.1 Overview
The aim of this thesis was to develop novel carbon based biosensors and sensors and to use
them in online systems for real-time metabolite and drug detection using microﬂuidic and
microdialysis (MD) techniques.
In Chapter 2, graphene oxide (GO) and reduced graphene oxide (rGO) were synthe-
sised by the modiﬁed Hummer method and characterised using diﬀerent techniques, includ-
ing FTIR, SEM and AFM. The results showed that the synthesised GO contained oxygen
functional groups on its surface and was 1-3 µm in width and 1-4 nm in thickness.
In Chapter 3, general methodologies are described, including fabrication of a combined
needle electrode and a multiwalled carbon nanotube (MWCNT)-epoxy composite electrode.
An autocalibration board was developed based on programmable syringe pumps and valves
(LabSmith). The system was used with the developed carbon-based biosensors and sensors
to automatically carry out regular calibrations. Using two solutions the diﬀerent concen-
trations could be generated at a constant total ﬂow rate by varying the relative ﬂow rates
of the two solutions. This enabled multipoint calibrations to be carried out automatically
under computer control.
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In Chapter 4, novel graphene-based biosensors were developed using four diﬀerent
methods of enzyme immobilisation on a needle microelectrode surface using glucose oxidase
and lactate oxidase as model enzyme systems. These include:
• cross-linking using GO-poly(ethylene glycol)diglycidyl ether (PEGDE) hydrogel
• electrodeposition using GO-chitosan
• dip-coating of GO-chitosan
• chemical-linking of GO-chitosan self-assembled layers
These graphene-based biosensors were characterised electrochemically. The biosensors were
placed in a microﬂuidic chip and the automated calibration board was used to carry out
continuous calibrations over several hours in a ﬂow stream. Although GO-based biosensors
fabricated using dip-coating of GO-chitosan gave the best sensitivity, they had poor stability
for continuous monitoring. Overall, GO-based biosensors fabricated using chemical linking
of GO-chitosan self-assembled layers showed the best performance for on-line glucose detec-
tion. Finally, proof-of-concept detection of glucose in dialysate was demonstrated using this
microﬂuidic platform coupled to a MD probe.
In Chapter 5, a rGO-based sensor was developed using layer-by-layer deposition of
chitosan and rGO for use as an on-line neurochemical detector. This carbon material pro-
vided good performance characteristics in terms of fast electron transfer and good stability
in comparison with a bare platinum electrode. rGO could be used for detection of dopamine
in biological samples and may provide a promising material for development of sensors for
neurochemical detection.
In Chapter 6, a method to detect the chemotherapeutic agent carboplatin in tissue
at low therapeutic concentrations was developed. Electrochemical determination for free
purine bases (guanine and adenine) as well as the nucleotides adenosine 5’-monophosphate
(AMP) and guanosine 5’-monophosphate (GMP) was carried out using carbon-based elec-
trodes using diﬀerential pulse voltammetry. All experiments in this chapter were carried
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out in a beaker. DNA-modiﬁed MWCNT-epoxy composite electrodes were fabricated and
used to measure AMP and GMP oxidation and compared to a bare MWCNT-epoxy com-
posite electrode. Finally, the determination of carboplatin using both bare MWCNT-epoxy
composite electrodes and DNA-modiﬁed MWCNT-epoxy composite electrodes was demon-
strated. The MWCNT-epoxy composite electrodes performed better for detection of free
purine bases compared with glassy carbon electrodes. MWCNT-epoxy composite sensors
also performed better for detection of carboplatin compared with DNA-modiﬁed MWCNT-
epoxy composite sensors.
In Chapter 7, a new bioanalytical device for detection of carboplatin in a dialysate
stream was developed to allow the online detection of carboplatin in healthy tissue when
carboplatin is being infused into the centre of a nearby tumour. A MWCNT-epoxy compos-
ite electrode was employed as a sensor, which was combined with a microﬂuidic platform
employing LabSmith components. The methodology for carboplatin detection was carefully
optimised in terms of sensitivity, analysis time and ability to use the same sensor multiple
times in the microﬂuidic system. In the proof-of-concept study, this device was coupled
with a MD probe and was used to successfully detect the addition of carboplatin to the test
beaker containing the MD probe.
8.2 Future Work
• Graphene-based biosensor for metabolite detection in real time
Graphene was successfully employed to prepare enzyme-based biosensors using needle
electrodes by several methods and they showed great promise for continuous use in a
microﬂuidic system over 24 hours. In particular, GO-based biosensors using chemical-
linking of GO-chitosan self-assembled layers performed well. However, there was an
issue of variability. To improve the reproducibility of the biosensors, it is necessary to
more precisely control the production process of GO using Hummer method, speciﬁ-
cally the chemical functionality of the GO surface and the size of GO particles. This
would greatly improve the biosensor reproducibility. Additionally, these immobilisa-
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tion methods could be used for other biomolecules such as lactate oxidase and pyruvate
oxidase and their stability could be tested in a microﬂuidic system.
• Graphene-based sensor for neurotransmitter detection
rGO-based sensors were developed using layer-by-layer deposition of chitosan and rGO
and were successfully used to detect dopamine. They showed fast electron transfer,
good stability and sensitivity compared to platinum sensors. However, this was quite a
lot of work as it took a long time to make the sensors and involved many steps. A real
improvement would be having an automatic method for making sensors by dipping and
drying them in controlled processes. This could reduce the time to make a number
of sensors and the variability between them. The stable sensitivity of rGO-based
sensors in the microﬂuidic system is an important characteristic for on-line continuous
neurochemical monitoring, so for future work investigation of the biosensor stability
over 24 hours in a ﬂow stream should be investigated. In addition, the system should
be tested with a microdialysis probe as this is how it would be used in vivo.
• Carboplatin detection in real-time
On-chip carbon-based sensors were coupled to a MD probe for detection of the pres-
ence of carboplatin in healthy tissue in real time during chemotherapy. The system
was optimised to reduce the analysis time and to allow for repeated measurement of
carboplatin using the same electrode. The system shows great potential as a new
method for monitoring local drug delivery into tumours. However, this device is lim-
ited by the loss of sensitivity that occurred in detecting carboplatin in a microﬂuidic
chip rather than in a beaker. The next stage will be to improve two aspects of this
technology. Firstly, the temporal resolution. In this thesis, sampling time was reduced
from 540 seconds to 170 seconds. A comprehensive redesign of the microﬂuidic chip
is necessary to incorporate on-chip mixing and to optimise it for this task. Secondly,
a small smoother MWCNT-epoxy composite-based sensor could be used to allow the
possibility of a faster diﬀerential pulse voltammetry scan. In this way I estimate that
the analysis time could be reduced to 40 seconds. Eventually, the study could be
extended to use this device in actual tumour tissue as a proof-of-concept clinical sys-
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tem to ensure that it is not limited by interferences during local administration of
carboplatin.
Bibliography
[1] D.A. Shifrin, M.D. Beckler, R.J. Coﬀey, and
M.J. Tyska. Extracellular vesicles: Communi-
cation, coercion, and conditioning. Molecular
Biology of the Cell, 24(9):1253–1259, 2013.
[2] U. Novak and A.H. Kaye. Extracellular ma-
trix and the brain: Components and function.
Journal of Clinical Neuroscience, 7(4):280–
290, 2000.
[3] C. Nicholson and E. Syková. Extracellular
space structure revealed by diﬀusion analysis.
Trends in Neurosciences, 21(5):207–215, 1998.
[4] E. Syková, T. Mazel, L. Vargova, I. Vorísek,
and S. Prokopová-Kubinová. Extracellu-
lar space diﬀusion and pathological states.
Progress in Brain Research, 125:155–178, 2000.
[5] E. Syková and C. Nicholson. Diﬀusion in
brain extracellular space. Physiological re-
views, 88(4):1277–1340, 2008.
[6] S. Hrabětová and C. Nicholson. Electrochem-
ical Methods for Neuroscience, chapter Bio-
physical properties of brain extracellular space
explored with ion-selective microelectrodes, in-
tegrative optical imaging and related tech-
niques. CRC Press, 2007.
[7] W.M. Saltzman. Drug delivery: Engineering
principles for drug therapy. Oxford University
Press, USA, 2001.
[8] H. Lee, L. Xie, M. Yu, H. Kang, T. Feng,
R. Deane, J. Logan, M. Nedergaard, and
H. Benveniste. The eﬀect of body posture on
brain glymphatic transport. The Journal of
Neuroscience, 35(31):11034–11044, 2015.
[9] M. Nedergaard. Garbage truck of the brain.
Science, 340(6140):1529–1530, 2013.
[10] P.E.M. Phillips and R.M. Wightman. Critical
guidelines for validation of the selectivity of in-
vivo chemical microsensors. TrAC Trends in
Analytical Chemistry, 22(8):509–514, 2003.
[11] D.W. Paul and J.A. Stenken. A review of ﬂux
considerations for in vivo neurochemical mea-
surements. Analyst, 140(11):3709–3730, 2015.
[12] D.L. Robinson, A. Hermans, A.T. Seipel, and
R.M. Wightman. Monitoring rapid chemical
communication in the brain. Chemical Re-
views, 108(7):2554–2584, 2008.
[13] M.L. Huﬀman and B.J. Venton. Carbon-ﬁber
microelectrodes for in vivo applications. Ana-
lyst, 134(1):18–24, 2009.
201
202 BIBLIOGRAPHY
[14] A. Jaquins-Gerstl and A.C. Michael. Compar-
ison of the brain penetration injury associated
with microdialysis and voltammetry. Jour-
nal of Neuroscience Methods, 183(2):127–135,
2009.
[15] A. Jaquins-Gerstl and A.C. Michael. A re-
view of the eﬀects of FSCV and microdialysis
measurements on dopamine release in the sur-
rounding tissue. Analyst, 140(11):3696–3708,
2015.
[16] J.L. Peters, L.H. Miner, A.C. Michael, and
S.R. Sesack. Ultrastructure at carbon ﬁber
microelectrode implantation sites after acute
voltammetric measurements in the striatum
of anesthetized rats. Journal of Neuroscience
Methods, 137(1):9–23, 2004.
[17] R.M. Wightman. Monitoring molecules: In-
sights and progress. ACS Chemical Neuro-
science, 6(1):5–7, 2014.
[18] A.S. Khan and A.C. Michael. Invasive conse-
quences of using micro-electrodes and micro-
dialysis probes in the brain. TrAC Trends in
Analytical Chemistry, 22(8):503–508, 2003.
[19] S. Qin, M. Van der Zeyden, W.H. Oldenziel,
T.I.F.H. Cremers, and B.H.C. Westerink. Mi-
crosensors for in vivo measurement of gluta-
mate in brain tissue. Sensors, 8(11):6860–6884,
2008.
[20] L.Z. Lugo-Morales, P.L. Loziuk, A.K. Corder,
J.V. Toups, J.G. Roberts, K.A. McCaﬀrey,
and L.A. Sombers. Enzyme-modiﬁed carbon-
ﬁber microelectrode for the quantiﬁcation of
dynamic ﬂuctuations of nonelectroactive ana-
lytes using fast-scan cyclic voltammetry. Ana-
lytical Chemistry, 85(18):8780–8786, 2013.
[21] J. Njagi, M.M. Chernov, J.C. Leiter, and
S. Andreescu. Amperometric detection of
dopamine in vivo with an enzyme based car-
bon ﬁber microbiosensor. Analytical Chem-
istry, 82(3):989–996, 2010.
[22] O.M. Schuvailo, O.O. Soldatkin, A. Lefebvre,
R. Cespuglio, and A.P. Soldatkin. Highly selec-
tive microbiosensors for in vivo measurement
of glucose, lactate and glutamate. Analytica
Chimica Acta, 573:110–116, 2006.
[23] P. Capella, B. Ghasemzadeh, K. Mitchell, and
R.N. Adams. Naﬁon-coated carbon ﬁber elec-
trodes for neurochemical studies in brain tis-
sue. Electroanalysis, 2(3):175–182, 1990.
[24] M.P. Brazell, R.J. Kasser, K.J. Renner,
J. Feng, B. Moghaddam, and R.N. Adams.
Electrocoating carbon ﬁber microelectrodes
with naﬁon improves selectivity for electroac-
tive neurotransmitters. Journal of Neuro-
science Methods, 22(2):167–172, 1987.
[25] P.J. Stout, J.R. Racchini, and M.E. Hilgers. A
novel approach to mitigating the physiological
lag between blood and interstitial ﬂuid glucose
measurements. Diabetes Technology & Thera-
peutics, 6(5):635–644, 2004.
[26] A. Kamath, A. Mahalingam, and J. Brauker.
Analysis of time lags and other sources of er-
ror of the DexCom seven continuous glucose
monitor. Diabetes Technology & Therapeutics,
11(11):689–695, 2009.
[27] A. El-Laboudi, N.S. Oliver, A. Cass, and
D. Johnston. Use of microneedle array de-
vices for continuous glucose monitoring: A
review. Diabetes Technology & Therapeutics,
15(1):101–115, 2013.
BIBLIOGRAPHY 203
[28] P.M. Wang, M. Cornwell, and M.R. Prausnitz.
Minimally invasive extraction of dermal inter-
stitial ﬂuid for glucose monitoring using mi-
croneedles. Diabetes Technology & Therapeu-
tics, 7(1):131–141, 2005.
[29] J. Trzebinski, S. Sharma, A.R. Moniz,
K. Michelakis, Y. Zhang, and A.E.G. Cass. Mi-
croﬂuidic device to investigate factors aﬀecting
performance in biosensors designed for trans-
dermal applications. Lab on a Chip, 12(2):348–
352, 2012.
[30] M.M. Ernberg and P.J. Alstergren. Microdial-
ysis of neuropeptide y in human muscle tissue.
Journal of Neuroscience Methods, 132(2):185–
190, 2004.
[31] R. Holmgaard, E. Benfeldt, J.B. Nielsen,
C. Gatschelhofer, J.A. Sorensen, C. Höﬀerer,
M. Bodenlenz, T.R. Pieber, and F. Sinner.
Comparison of open-ﬂow microperfusion and
microdialysis methodologies when sampling
topically applied fentanyl and benzoic acid in
human dermis ex vivo. Pharmaceutical Re-
search, 29(7):1808–1820, 2012.
[32] S.A.N. Gowers, V.F. Curto, C.A. Seneci,
C. Wang, S. Anastasova, P. Vadgama,
G. Yang, and M.G. Boutelle. 3D printed mi-
croﬂuidic device with integrated biosensors for
online analysis of subcutaneous human micro-
dialysate. Analytical Chemistry, 87(15):7763–
7770, 2015.
[33] C.J. Watson, B.J. Venton, and R.T. Kennedy.
In vivo measurements of neurotransmitters by
microdialysis sampling. Analytical Chemistry,
78(5):1391–1399, 2006.
[34] D.A. Jones, J. Ros, H. Landolt, M. Fillenz, and
M.G. Boutelle. Dynamic changes in glucose
and lactate in the cortex of the freely moving
rat monitored using microdialysis. Journal of
Neurochemistry, 75(4):1703–1708, 2000.
[35] T.W. Vasicek, M.R. Jackson, T.M. Poseno,
and J.A. Stenken. In vivo microdialysis
sampling of cytokines from rat hippocampus:
Comparison of cannula implantation proce-
dures. ACS Chemical Neuroscience, 4(5):737–
746, 2013.
[36] K. Caesar, P. Hashemi, A. Douhou, G. Bon-
vento, M.G. Boutelle, A.B. Walls, and M. Lau-
ritzen. Glutamate receptor-dependent in-
crements in lactate, glucose and oxygen
metabolism evoked in rat cerebellum in vivo.
The Journal of Physiology, 586(5):1337–1349,
2008.
[37] P. Tsai and T. Tsai. Simultaneous determina-
tion of berberine in rat blood, liver and bile us-
ing microdialysis coupled to high-performance
liquid chromatography. Journal of Chromatog-
raphy A, 961(1):125–130, 2002.
[38] H. Huang, Y. Zhang, R. Yang, and
X. Tang. Determination of baicalin in rat
cerebrospinal ﬂuid and blood using micro-
dialysis coupled with ultra-performance liq-
uid chromatography-tandem mass spectrome-
try. Journal of Chromatography B, 874(1):77–
83, 2008.
[39] R.T. Kennedy, C.J. Watson, W.E. Haskins,
D.H. Powell, and R.E. Strecker. In vivo neuro-
chemical monitoring by microdialysis and cap-
illary separations. Current Opinion in Chemi-
cal Biology, 6(5):659–665, 2002.
204 BIBLIOGRAPHY
[40] M.L. Rogers, P.A. Brennan, C.L. Leong,
S.A.N. Gowers, T. Aldridge, T.K. Mellor,
and M.G. Boutelle. Online rapid sam-
pling microdialysis (rsMD) using enzyme-
based electroanalysis for dynamic detection
of ischaemia during free ﬂap reconstructive
surgery. Analytical and Bioanalytical Chem-
istry, 405(11):3881–3888, 2013.
[41] U. Ungerstedt and C.H. Pycock. Functional
correlates of dopamine neurotransmission. Bul-
letin der Schweizerischen Akademie der Medi-
zinischen Wissenschaften, 30(1-3):44–55, 1974.
[42] L. Hillered, L. Persson, U. Ponten, and
U. Ungerstedt. Neurometabolic monitoring of
the ischaemic human brain using microdialysis.
Acta Neurochirurgica, 102(3-4):91–97, 1990.
[43] K.E. Price, S.S. Vandaveer, C.E. Lunte, and
C.K. Larive. Tissue targeted metabonomics:
Metabolic proﬁling by microdialysis sampling
and microcoil nmr. Journal of Pharmaceutical
and Biomedical Analysis, 38(5):904–909, 2005.
[44] M.C. Parkin, S.E. Hopwood, M.G. Boutelle,
and A.J. Strong. Resolving dynamic changes
in brain metabolism using biosensors and on-
line microdialysis. TrAC Trends in Analytical
Chemistry, 22(8):487–497, 2003.
[45] K.L. Woo and C.E. Lunte. The direct com-
parison of health and ulcerated stomach tis-
sue: A multiple probe microdialysis sampling
approach. Journal of Pharmaceutical and
Biomedical Analysis, 48(1):85–91, 2008.
[46] D.A. Richards, M.A. Silva, N. Murphy, S.J.
Wigmore, and D.F. Mirza. Extracellular amino
acid levels in the human liver during transplan-
tation: A microdialysis study from donor to
recipient. Amino Acids, 33(3):429–437, 2007.
[47] J. Chu and J.M. Gallo. Application of mi-
crodialysis to characterize drug disposition in
tumors. Advanced Drug Delivery Reviews,
45(2):243–253, 2000.
[48] C.S. Chaurasia, M. Müller, E.D. Bashaw,
E. Benfeldt, J. Bolinder, R. Bullock,
P.M. Bungay, E. DeLange, H. Derendorf,
W.F. Elmquist, M. Hammarlund-Udenaes,
C. Joukhadar, D.L. Kellogg, C. H. Nordstrom,
H. Rollema, R.J. Sawchuk, B.W.Y. Cheung,
V.P. Shah, U. Ungerstedt, D.F. Welty, and
H. Yeo. AAPS-FDA workshop white paper:
Microdialysis principles, application, and reg-
ulatory perspectives. The Journal of Clinical
Pharmacology, 47(5):589–603, 2007.
[49] L. Persson and L. Hillered. Chemical moni-
toring of neurosurgical intensive care patients
using intracerebral microdialysis. Journal of
Neurosurgery, 76(1):72–80, 1992.
[50] B.H.C. Westerink and T.I.F.H. Cremers.
Handbook of microdialysis: Methods, applica-
tions and perspectives, volume 16. Academic
Press, 2007.
[51] M. Müller. Microdialysis in clinical drug deliv-
ery studies. Advanced Drug Delivery Reviews,
45(2):255–269, 2000.
[52] M. Hammarlund-Udenaes, M. Fridén, S. Syvä-
nen, and A. Gupta. On the rate and extent
of drug delivery to the brain. Pharmaceutical
Research, 25(8):1737–1750, 2008.
[53] S. Jacobs, C.L. McCully, R.F. Murphy,
J. Bacher, F.M. Balis, and E. Fox. Extracel-
BIBLIOGRAPHY 205
lular ﬂuid concentrations of cisplatin, carbo-
platin, and oxaliplatin in brain, muscle, and
blood measured using microdialysis in non-
human primates. Cancer Chemotherapy and
Pharmacology, 65(5):817–824, 2010.
[54] G. Jin, Q. Cheng, J. Feng, and F. Li. On-
line microdialysis coupled to analytical sys-
tems. Journal of Chromatographic Science,
46(3):276–287, 2008.
[55] P. Nandi and S.M. Lunte. Recent trends in
microdialysis sampling integrated with conven-
tional and microanalytical systems for moni-
toring biological events: A review. Analytica
Chimica Acta, 651(1):1–14, 2009.
[56] K.N. Schultz and R.T. Kennedy. Time-
resolved microdialysis for in vivo neurochem-
ical measurements and other applications. An-
nual Review of Analytical Chemistry, 1:627–
661, 2008.
[57] R.A. Saylor and S.M. Lunte. A review of mi-
crodialysis coupled to microchip electrophore-
sis for monitoring biological events. Journal of
Chromatography A, 1382:48–64, 2015.
[58] H. Gu, E.L. Varner, S.R. Groskreutz, A.C.
Michael, and S.G. Weber. In vivo monitoring
of dopamine by microdialysis with one-minute
temporal resolution using online capillary liq-
uid chromatography with electrochemical de-
tection. Analytical Chemistry, 87(12):6088–
6094, 2015.
[59] H.M. Shackman, M. Shou, N.A. Cellar, C.J.
Watson, and R.T. Kennedy. Microdialysis cou-
pled on-line to capillary liquid chromatography
with tandem mass spectrometry for monitoring
acetylcholine in vivo. Journal of Neuroscience
Methods, 159(1):86–92, 2007.
[60] M.T. Bowser and R.T. Kennedy. In vivomoni-
toring of amine neurotransmitters using micro-
dialysis with on-line capillary electrophoresis.
Electrophoresis, 22(17):3668–3676, 2001.
[61] S.K. Bergström, M. Goiny, R. Danielsson,
U. Ungerstedt, M. Andersson, and K.E.
Markides. Screening of microdialysates taken
before and after induced liver damage; On-line
solid phase extraction-electrospray ionization-
mass spectrometry. Journal of Chromatogra-
phy A, 1120(1):21–26, 2006.
[62] K.L. Baker, F.B. Bolger, and J.P. Lowry. A
microelectrochemical biosensor for real-time in
vivo monitoring of brain extracellular choline.
Analyst, 140(11):3738–3745, 2015.
[63] R.D. O’Neill, G. Rocchitta, C.P. McMahon,
P.A. Serra, and J.P. Lowry. Designing sensi-
tive and selective polymer/enzyme composite
biosensors for brain monitoring in vivo. TrAC
Trends in Analytical Chemistry, 27(1):78–88,
2008.
[64] D.G. Georganopoulou, R. Carley, D.A. Jones,
and M.G. Boutelle. Development and compari-
son of biosensors for in-vivo applications. Fara-
day Discussions, 116:291–303, 2000.
[65] M.L. Rogers and M.G. Boutelle. Real-time
clinical monitoring of biomolecules. Analytical
Chemistry, 6, 2013.
[66] D.R. Thévenot, K. Toth, R.A. Durst, and G.S.
Wilson. Electrochemical biosensors: Recom-
mended deﬁnitions and classiﬁcation. Biosen-
sors and Bioelectronics, 16(1):121–131, 2001.
206 BIBLIOGRAPHY
[67] M. Miele and M. Fillenz. In vivo determina-
tion of extracellular brain ascorbate. Journal
of Neuroscience Methods, 70(1):15–19, 1996.
[68] M.G. Boutelle, L.K. Fellows, and C. Cook. En-
zyme packed bed system for the on-line mea-
surement of glucose, glutamate, and lactate
in brain microdialyzate. Analytical Chemistry,
64(17):1790–1794, 1992.
[69] M. Zhang and L. Mao. Enzyme-based am-
perometric biosensors for continuous and on-
line monitoring of cerebral extracellular micro-
dialysate. Frontiers in Bioscience: a Journal
and Virtual Library, 10:345–352, 2005.
[70] L.K. Fellows, M.G. Boutelle, and M. Fillenz.
Extracellular brain glucose levels reﬂect local
neuronal activity: A microdialysis study in
awake, freely moving rats. Journal of Neuro-
chemistry, 59:2141–2141, 1992.
[71] L.K. Fellows, M.G. Boutelle, and M. Fillenz.
Physiological stimulation increases nonoxida-
tive glucose metabolism in the brain of the
freely moving rat. Journal of Neurochemistry,
60(4):1258–1263, 1993.
[72] J. Korf, J. De Boer, R. Baarsma, K. Ven-
ema, and A. Okken. Monitoring of glucose
and lactate using microdialysis: Applications
in neonates and rat brain. Developmental Neu-
roscience, 15(3-5):240–246, 1993.
[73] M.M. Rhemrev-Boom, M.A. Jonker, K. Ven-
ema, G. Jobst, R. Tiessen, and J. Korf. On-
line continuous monitoring of glucose or lac-
tate by ultraslow microdialysis combined with
a ﬂow-through nanoliter biosensor based on
poly (m-phenylenediamine) ultra-thin poly-
mer membrane as enzyme electrode. Analyst,
126(7):1073–1079, 2001.
[74] D.A. Jones, M.C. Parkin, H. Langemann,
H. Landolt, S.E. Hopwood, A.J. Strong, and
M.G. Boutelle. On-line monitoring in neu-
rointensive care: Enzyme-based electrochem-
ical assay for simultaneous, continuous moni-
toring of glucose and lactate from critical care
patients. Journal of Electroanalytical Chem-
istry, 538:243–252, 2002.
[75] S. Deeba, E.P. Corcoles, B.G. Hanna,
P. Pareskevas, O. Aziz, M.G. Boutelle, and
A. Darzi. Use of rapid sampling microdial-
ysis for intraoperative monitoring of bowel
ischemia. Diseases of the colon & rectum,
51(9):1408–1413, 2008.
[76] G.M. Whitesides. The origins and the future
of microﬂuidics. Nature, 442(7101):368–373,
2006.
[77] I. Barbulovic-Nad, H. Yang, P.S. Park, and
A.R. Wheeler. Digital microﬂuidics for cell-
based assays. Lab on a Chip, 8(4):519–526,
2008.
[78] S.C. Hur, N.K. Henderson-MacLennan, E.R.B.
McCabe, and D. Di Carlo. Deformability-
based cell classiﬁcation and enrichment us-
ing inertial microﬂuidics. Lab on a Chip,
11(5):912–920, 2011.
[79] Samuel K Sia and George M Whitesides. Mi-
croﬂuidic devices fabricated in poly (dimethyl-
siloxane) for biological studies. Electrophoresis,
24(21):3563–3576, 2003.
[80] E.A. Ottesen, J.W. Hong, S.R. Quake, and
J.R. Leadbetter. Microﬂuidic digital pcr en-
BIBLIOGRAPHY 207
ables multigene analysis of individual envi-
ronmental bacteria. Science, 314(5804):1464–
1467, 2006.
[81] C. Zhang, J. Xu, W. Ma, and W. Zheng.
PCR microﬂuidic devices for DNA ampliﬁca-
tion. Biotechnology Advances, 24(3):243–284,
2006.
[82] N.B.Y. Tsui, R.A. Kadir, K.C.A. Chan, C. Chi,
G. Mellars, E.G. Tuddenham, T.Y. Leung,
T.K. Lau, R.W.K. Chiu, and Y.M.D. Lo. Non-
invasive prenatal diagnosis of hemophilia by
microﬂuidics digital PCR analysis of maternal
plasma DNA. Blood, 117(13):3684–3691, 2011.
[83] A.W. Martinez, S.T. Phillips, G.M. White-
sides, and E. Carrilho. Diagnostics for the de-
veloping world: Microﬂuidic paper-based ana-
lytical devices. Analytical Chemistry, 82(1):3–
10, 2009.
[84] Won Gu Lee, Yun-Gon Kim, Bong Geun
Chung, Utkan Demirci, and Ali Khademhos-
seini. Nano/microﬂuidics for diagnosis of in-
fectious diseases in developing countries. Ad-
vanced Drug Delivery Reviews, 62(4):449–457,
2010.
[85] Curtis D Chin, Tassaneewan Laksanasopin,
Yuk Kee Cheung, David Steinmiller, Vincent
Linder, Hesam Parsa, Jennifer Wang, Han-
nah Moore, Robert Rouse, Gisele Umviligi-
hozo, et al. Microﬂuidics-based diagnostics of
infectious diseases in the developing world. Na-
ture Medicine, 17(8):1015–1019, 2011.
[86] M.L. Rogers, D. Feuerstein, C.L. Leong,
M. Takagaki, X. Niu, R. Graf, and M.G.
Boutelle. Continuous online microdialysis
using microﬂuidic sensors: dynamic neu-
rometabolic changes during spreading de-
polarization. ACS Chemical Neuroscience,
4(5):799–807, 2013.
[87] M. Wang, G.T. Roman, K. Schultz, C. Jen-
nings, and R.T. Kennedy. Improved tem-
poral resolution for in vivo microdialysis by
using segmented ﬂow. Analytical Chemistry,
80(14):5607–5615, 2008.
[88] M. Rogers, C. Leong, X. Niu, A. de Mello, K.H.
Parker, and M.G. Boutelle. Optimisation of
a microﬂuidic analysis chamber for the place-
ment of microelectrodes. Physical Chemistry
Chemical Physics, 13(12):5298–5303, 2011.
[89] S. Sun, T.R. Slaney, and R.T. Kennedy. La-
bel free screening of enzyme inhibitors at fem-
tomole scale using segmented ﬂow electro-
spray ionization mass spectrometry. Analytical
Chemistry, 84(13):5794–5800, 2012.
[90] G.A. Rivas, M.D. Rubianes, M.C. Rodriguez,
N.F. Ferreyra, G.L. Luque, M.L. Pedano,
S.A. Miscoria, and C. Parrado. Carbon nan-
otubes for electrochemical biosensing. Talanta,
74(3):291–307, 2007.
[91] R.P. Singh. Prospects of nanobiomaterials for
biosensing. International Journal of Electro-
chemistry, 2011, 2011.
[92] S. Liu and X. Guo. Carbon nanomaterials ﬁeld-
eﬀect-transistor-based biosensors. NPG Asia
Materials, 4(8):e23, 2012.
[93] A.K. Geim and K.S. Novoselov. The rise of
graphene. Nature Materials, 6(3):183–191, 03
2007.
208 BIBLIOGRAPHY
[94] M. Pumera, A. Ambrosi, A. Bonanni, E.L.K.
Chng, and H.L. Poh. Graphene for electro-
chemical sensing and biosensing. TrAC Trends
in Analytical Chemistry, 29(9):954 – 965, 2010.
[95] T. Kuila, S. Bose, P. Khanra, A.K. Mishra,
N.H. Kim, and J.H. Lee. Recent advances
in graphene-based biosensors. Biosensors and
Bioelectronics, 26(12):4637–4648, 2011.
[96] M. Pumera. Graphene in biosensing. Materials
Today, 14(7):308–315, 2011.
[97] D. Chen, H. Feng, and J. Li. Graphene ox-
ide: Preparation, functionalization, and elec-
trochemical applications. Chemical Reviews,
112(11):6027–6053, 2012.
[98] S. Iijima. Helical microtubules of graphitic car-
bon. Nature, 354(6348):56–58, 1991.
[99] Q. Zhao, Z. Gan, and Q. Zhuang. Electrochem-
ical sensors based on carbon nanotubes. Elec-
troanalysis, 14(23):1609–1613, 2002.
[100] S. Jo, H. Jeong, S.R. Bae, and S. Jeon. Mod-
iﬁed platinum electrode with phytic acid and
single-walled carbon nanotube: Application to
the selective determination of dopamine in the
presence of ascorbic and uric acids.Microchem-
ical Journal, 88(1):1–6, 2008.
[101] S. Sansuk, E. Bitziou, M.B. Joseph, J.A.
Covington, M.G. Boutelle, P.R. Unwin, and
J.V. Macpherson. Ultrasensitive detection of
dopamine using a carbon nanotube network
microﬂuidic ﬂow electrode. Analytical Chem-
istry, 85(1):163–169, 2012.
[102] E.M. Materon, A. Wong, S.I. Klein, J. Liu,
and M.D.P.T. Sotomayor. Multi-walled carbon
nanotubes modiﬁed screen-printed electrodes
for cisplatin detection. Electrochimica Acta,
158:271–276, 2015.
[103] K.S. Novoselov, A.K. Geim, S.V. Morozov,
D. Jiang, Y. Zhang, S.V. Dubonos, , I.V.
Grigorieva, and A.A. Firsov. Electric ﬁeld ef-
fect in atomically thin carbon ﬁlms. Science,
306(5696):666–669, 2004.
[104] Z. Zhu, L. Garcia-Gancedo, A.J. Flewitt,
H. Xie, F. Moussy, and W.I. Milne. A criti-
cal review of glucose biosensors based on car-
bon nanomaterials: Carbon nanotubes and
graphene. Sensors, 12(5):5996–6022, 2012.
[105] W. Yang, K.R. Ratinac, S.P. Ringer, P. Thor-
darson, J.J. Gooding, and F. Braet. Carbon
nanomaterials in biosensors: Should you use
nanotubes or graphene? Angewandte Chemie
International Edition, 49(12):2114–2138, 2010.
[106] H.L. Poh, F. Šaněk, A. Ambrosi, G. Zhao,
Z. Sofer, and M. Pumera. Graphenes pre-
pared by Staudenmaier, Hofmann and Hum-
mers methods with consequent thermal exfo-
liation exhibit very diﬀerent electrochemical
properties. Nanoscale, 4(11):3515–3522, 2012.
[107] M. Fu, Q. Jiao, Y. Zhao, and H. Li. Va-
por diﬀusion synthesis of CoFe2O4 hollow
sphere/graphene composites as absorbing ma-
terials. Journal of Materials Chemistry A,
2(3):735–744, 2014.
[108] D.R. Dreyer, S. Park, C.W. Bielawski, and
R.S. Ruoﬀ. The chemistry of graphene ox-
ide. Chemical Society Reviews, 39(1):228–240,
2010.
BIBLIOGRAPHY 209
[109] L. Sun and B. Fugetsu. Massive production of
graphene oxide from expanded graphite. Ma-
terials Letters, 109:207 – 210, 2013.
[110] J. Song, X. Wang, and C. Chang. Preparation
and characterization of graphene oxide. Jour-
nal of Nanomaterials, 2014:1–6, 2014.
[111] G. Eda and M. Chhowalla. Chemically derived
graphene oxide: towards large-area thin-ﬁlm
electronics and optoelectronics. Advanced Ma-
terials, 22(22):2392–2415, 2010.
[112] S.Y. Toh, K.S. Loh, S.K. Kamarudin, and
W.R.W. Daud. Graphene production via elec-
trochemical reduction of graphene oxide: Syn-
thesis and characterisation. Chemical Engi-
neering Journal, 251:422–434, 2014.
[113] B. Unnikrishnan, S. Palanisamy, and S. Chen.
A simple electrochemical approach to fabricate
a glucose biosensor based on graphene–glucose
oxidase biocomposite. Biosensors and Bioelec-
tronics, 39(1):70–75, 2013.
[114] A. Ambrosi, C.K. Chua, B. Khezri, Z. Sofer,
R.D. Webster, and M. Pumera. Chemically re-
duced graphene contains inherent metallic im-
purities present in parent natural and synthetic
graphite. Proceedings of the National Academy
of Sciences, 109(32):12899–12904, 2012.
[115] S. Stankovich, D.A. Dikin, R.D. Piner, K.A.
Kohlhaas, A. Kleinhammes, Y. Jia, Y. Wu,
S.T. Nguyen, and R.S. Ruoﬀ. Synthesis of
graphene-based nanosheets via chemical re-
duction of exfoliated graphite oxide. Carbon,
45(7):1558 – 1565, 2007.
[116] B. Zhao, P. Liu, Y. Jiang, D. Pan, H. Tao,
J. Song, T. Fang, and W. Xu. Supercapacitor
performances of thermally reduced graphene
oxide. Journal of Power Sources, 198:423 –
427, 2012.
[117] J. Wei, J. Qiu, L. Li, L. Ren, X. Zhang,
J. Chaudhuri, and S. Wang. A reduced
graphene oxide based electrochemical biosen-
sor for tyrosine detection. Nanotechnology,
23(33):335707, 2012.
[118] J. Zhang, F. Zhang, H. Yang, X. Huang,
H. Liu, J. Zhang, and S. Guo. Graphene oxide
as a matrix for enzyme immobilization. Lang-
muir, 26(9):6083–6085, 2010.
[119] J.H. Pazur and K. Kleppe. The oxidation of
glucose and related compounds by glucose ox-
idase from aspergillus niger*. Biochemistry,
3(4):578–583, 1964.
[120] Y. Wan, Y. Wang, J. Wu, and D. Zhang.
Graphene oxide sheet-mediated silver enhance-
ment for application to electrochemical biosen-
sors. Analytical Chemistry, 83(3):648–653,
2010.
[121] Y. Liu, D. Yu, C. Zeng, Z. Miao, and L. Dai.
Biocompatible graphene oxide-based glucose
biosensors. Langmuir, 26(9):6158–6160, 2010.
[122] A.A. Sehat, A.A. Khodadadi, F. Shemirani,
and Y. Mortazavi. Fast immobilization of
glucose oxidase on graphene oxide for highly
sensitive glucose biosensor fabrication. Inter-
national Journal of Electrochemical Science,
10(20145):272–286, 2015.
[123] W.S. Hummers and R.E. Oﬀeman. Prepara-
tion of graphitic oxide. Journal of the Ameri-
can Chemical Society, 80(6):1339–1339, 1958.
210 BIBLIOGRAPHY
[124] R.J. Seresht, M. Jahanshahi, A.M. Rashidi,
and A.A. Ghoreyshi. Synthesis and character-
ization of thermally-reduced graphene. Iranica
Journal of Energy and Environment, 4:53–59,
2013.
[125] H. Wahab, G. Xu, C. Jansing, M. Gilbert,
M.F. Tesch, J. Jin, H. Mertins, and H. Tim-
mers. Signatures of diﬀerent carbon bonds in
graphene oxide from soft x-ray reﬂectometry.
X-Ray Spectrometry, 44(6):468–473, 2015.
[126] F. Babak, H. Abolfazl, R. Alimorad, and
G. Parviz. Preparation and mechanical prop-
erties of graphene oxide: Cement nanocompos-
ites. The Scientific World Journal, 2014, 2014.
[127] W.L. Zhang and H.J. Choi. Fast and facile fab-
rication of a graphene oxide/titania nanocom-
posite and its electro-responsive characteris-
tics. Chemical Communications, 47(45):12286–
12288, 2011.
[128] C. Fu, G. Zhao, H. Zhang, and S. Li.
Evaluation and characterization of reduced
graphene oxide nanosheets as anode materials
for lithium-ion batteries. International Journal
of Electrochemical Science, 8:6269–6280, 2013.
[129] Z. Wu, W. Ren, L. Gao, B. Liu, C. Jiang, and
H. Cheng. Synthesis of high-quality graphene
with a pre-determined number of layers. Car-
bon, 47(2):493–499, 2009.
[130] P.N. Bartlett and K.F.E. Pratt. A study of
the kinetics of the reaction between ferrocene
monocarboxylic acid and glucose oxidase using
the rotating-disc electrode. Journal of Electro-
analytical Chemistry, 397(1–2):53 – 60, 1995.
[131] D. Pletcher. Why microelectrodes? In Mi-
croelectrodes: Theory and applications, pages
3–16. Springer, 1991.
[132] M.L. Rogers. A biosensor-based digital mi-
crofluidic system for neuroanalysis in the in-
tensive care unit. PhD thesis, Imperial College
London, 2011.
[133] Y. Xia and G.M. Whitesides. Soft lithog-
raphy. Annual Review of Materials Science,
28(1):153–184, 1998.
[134] J. Friend and L. Yeo. Fabrication of mi-
croﬂuidic devices using polydimethylsiloxane.
Biomicrofluidics, 4(2):026502, 2010.
[135] C.M. Wong, K.H. Wong, and X.D. Chen. Glu-
cose oxidase: Natural occurrence, function,
properties and industrial applications. Applied
Microbiology and Biotechnology, 78(6):927–
938, 2008.
[136] E.I. Iwuoha, A.R. Williams-Dottin, L.A. Hall,
A. Morrin, G.N. Mathebe, M.R. Smyth, and
A. Killard. Electrochemistry and application
of a novel monosubstituted squarate electron-
transfer mediator in a glucose oxidase-doped
poly (phenol) sensor. Pure and Applied Chem-
istry, 76(4):789–799, 2004.
[137] G. Wohlfahrt, S. Witt, J. Hendle, D. Schom-
burg, H.M. Kalisz, and H.J. Hecht. 1.8 and 1.9
å resolution structures of the penicillium am-
agasakiense and aspergillus niger glucose oxi-
dases as a basis for modelling substrate com-
plexes. Acta Crystallographica Section D: Bio-
logical Crystallography, 55(5):969–977, 1999.
[138] Y. Umena, K. Yorita, T. Matsuoka, A. Kita,
K. Fukui, and Y. Morimoto. The crystal struc-
BIBLIOGRAPHY 211
ture of l-lactate oxidase from aerococcus viri-
dans at 2.1 å resolution reveals the mecha-
nism of strict substrate recognition. Biochemi-
cal and Biophysical Research Communications,
350(2):249–256, 2006.
[139] Q. Chen, G.L. Kenausis, and A. Heller. Sta-
bility of oxidases immobilized in silica gels.
Journal of the American Chemical Society,
120(19):4582–4585, 1998.
[140] I.A. Borisov, A.V. Lobanov, A.N. Reshetilov,
and B.I. Kurganov. Quantitative analysis
of the calibration dependences for biosen-
sors. Applied Biochemistry and Microbiology,
36(3):215–220, 2000.
[141] S.B. Hall, E.A. Khudaish, and A.L. Hart. Elec-
trochemical oxidation of hydrogen peroxide at
platinum electrodes. Part 1. An adsorption-
controlled mechanism. Electrochimica Acta,
43(5):579–588, 1998.
[142] N. Vasylieva, B. Barnych, A. Meiller, C. Mau-
cler, L. Pollegioni, J. Lin, D. Barbier, and
S. Marinesco. Covalent enzyme immobi-
lization by poly (ethylene glycol) diglycidyl
ether (pegde) for microelectrode biosensor
preparation. Biosensors and Bioelectronics,
26(10):3993–4000, 2011.
[143] S.A.N. Gowers. Microﬂuidic biosensor system
for real-time in vivo clinical bioanalysis, March
2015.
[144] Y. Cheng, X. Luo, J. Betz, S. Buckhout-White,
O. Bekdash, G.F. Payne, W.E. Bentley, and
G.W. Rubloﬀ. In situ quantitative visualiza-
tion and characterization of chitosan electrode-
position with paired sidewall electrodes. Soft
Matter, 6(14):3177–3183, 2010.
[145] Q. Zhou, Q. Xie, Y. Fu, Z. Su, X. Jia, and
S. Yao. Electrodeposition of carbon nanotubes-
chitosan-glucose oxidase biosensing composite
ﬁlms triggered by reduction of p-benzoquinone
or H2O2. The Journal of Physical Chemistry
B, 111(38):11276–11284, 2007.
[146] X. Luo, D.L. Berlin, J. Betz, G.F. Payne, W.E.
Bentley, and G.W. Rubloﬀ. In situ genera-
tion of pH gradients in microﬂuidic devices for
biofabrication of freestanding, semi-permeable
chitosan membranes. Lab on a Chip, 10(1):59–
65, 2010.
[147] S. Fusco, G. Chatzipirpiridis, K.M. Sivara-
man, O. Ergeneman, B.J. Nelson, and S. Pané.
Chitosan electrodeposition for microrobotic
drug delivery. Advanced Healthcare Materials,
2(7):1037–1044, 2013.
[148] H. Bao, Q. Chen, L. Zhang, and G. Chen.
Immobilization of trypsin in the layer-by-layer
coating of graphene oxide and chitosan on in-
channel glass ﬁber for microﬂuidic proteolysis.
Analyst, 136(24):5190–5196, 2011.
[149] D. Feuerstein, A. Manning, P. Hashemi,
R. Bhatia, M. Fabricius, C. Tolias, C. Pahl,
M. Ervine, A.J. Strong, and M.G. Boutelle.
Dynamic metabolic response to multiple
spreading depolarizations in patients with
acute brain injury: An online microdialysis
study. Journal of Cerebral Blood Flow &
Metabolism, 30(7):1343–1355, 2010.
[150] J.A. Stenken. Methods and issues in micro-
dialysis calibration. Analytica Chimica Acta,
379(3):337–358, 1999.
[151] L.J. Mellander, R. Trouillon, M.I. Svensson,
and A.G. Ewing. Amperometric post spike
212 BIBLIOGRAPHY
feet reveal most exocytosis is via extended kiss-
and-run fusion. Scientific Reports, 2, 2012.
[152] C. Amatore, A.I. Oleinick, and I. Svir. Re-
construction of aperture functions during full
fusion in vesicular exocytosis of neurotransmit-
ters. ChemPhysChem, 11(1):159–174, 2010.
[153] R.M. Wightman, L.J. May, and A.C. Michael.
Detection of dopamine dynamics in the
brain. Analytical Chemistry, 60(13):769A–
793A, 1988.
[154] S. Janezic, S. Threlfell, P.D. Dodson, M.J.
Dowie, T.N. Taylor, D. Potgieter, L. Parkki-
nen, S.L. Senior, S. Anwar, B. Ryan, Deltheil
T., P. Kosillo, M. Cioroch, K. Wagner, O. An-
sorge, Bannerman D.M., J.P. Bolam, P.J. Mag-
ill, S.J. Cragg, and R. Wade-Martins. Deﬁcits
in dopaminergic transmission precede neuron
loss and dysfunction in a new Parkinson model.
Proceedings of the National Academy of Sci-
ences, 110(42):E4016–E4025, 2013.
[155] P. Remy, M. Doder, A. Lees, N. Turjanski, and
D. Brooks. Depression in parkinson’s disease:
loss of dopamine and noradrenaline innervation
in the limbic system. Brain, 128(6):1314–1322,
2005.
[156] B.W. Dunlop and C.B. Nemeroﬀ. The role
of dopamine in the pathophysiology of de-
pression. Archieves of General Psychiatry,
64(3):327–337, 2007.
[157] E.S. Bucher and R.M. Wightman. Electro-
chemical analysis of neurotransmitters. Annual
Review of Analytical Chemistry, (0), 2015.
[158] J.L. Ponchon, R. Cespuglio, F. Gonon, M. Jou-
vet, and J.F. Pujol. Normal pulse polarogra-
phy with carbon ﬁber electrodes for in vitro
and in vivo determination of catecholamines.
Analytical Chemistry, 51(9):1483–1486, 1979.
[159] D. Budai, K. Gulya, B. Mészáros, I. Hernándi,
and Z.K. Bali. Electrochemical responses of
carbon ﬁber microelectrodes to dopamine in
vitro and in vivo. Acta Biologica Szegediensis,
54(2):155–160, 2010.
[160] B.D. Bath, D.J. Michael, B.J. Trafton, J.D.
Joseph, P.L. Runnels, and R.M. Wight-
man. Subsecond adsorption and desorption of
dopamine at carbon-ﬁber microelectrodes. An-
alytical Chemistry, 72(24):5994–6002, 2000.
[161] H. Jeong and S. Jeon. Determination of
dopamine in the presence of ascorbic acid by
naﬁon and single-walled carbon nanotube ﬁlm
modiﬁed on carbon ﬁber microelectrode. Sen-
sors, 8(11):6924–6935, 2008.
[162] B.E.K. Swamy and B.J. Venton. Carbon
nanotube-modiﬁed microelectrodes for simul-
taneous detection of dopamine and serotonin
in vivo. Analyst, 132(9):876–884, 2007.
[163] A.N. Patel, S. Tan, T.S. Miller, J.V. Macpher-
son, and P.R. Unwin. Comparison and reap-
praisal of carbon electrodes for the voltammet-
ric detection of dopamine. Analytical Chem-
istry, 85(24):11755–11764, 2013.
[164] J. Ping, J. Wu, Y. Wang, and Y. Ying.
Simultaneous determination of ascor-
bic acid, dopamine and uric acid using
high-performance screen-printed graphene
electrode. Biosensors and Bioelectronics,
34(1):70–76, 2012.
BIBLIOGRAPHY 213
[165] F. Gao, X. Cai, X. Wang, C. Gao, S. Liu,
F. Gao, and Q. Wang. Highly sensitive and
selective detection of dopamine in the presence
of ascorbic acid at graphene oxide modiﬁed
electrode. Sensors and Actuators B: Chemi-
cal, 186:380–387, 2013.
[166] A.C. Schmidt, X. Wang, Y. Zhu, and L.A.
Sombers. Carbon nanotube yarn electrodes
for enhanced detection of neurotransmitter
dynamics in live brain tissue. ACS Nano,
7(9):7864–7873, 2013.
[167] American Cancer Society. GLobal Cancer facts
& figures 3rd Edition. American Cancer Soci-
ety, 2015.
[168] G.F. Sousa, S.R. Wlodarczyk, and G. Mon-
teiro. Carboplatin: Molecular mechanisms
of action associated with chemoresistance.
Brazilian Journal of Pharmaceutical Sciences,
50(4):693–701, 2014.
[169] C.C. Sun, D.C. Bodurka, C.B. Weaver,
R. Rasu, J.K. Wolf, M.W. Bevers, J.A. Smith,
J.T. Wharton, and E.B. Rubenstein. Rankings
and symptom assessments of side eﬀects from
chemotherapy: insights from experienced pa-
tients with ovarian cancer. Supportive Care in
Cancer, 13(4):219–227, 2005.
[170] D.R. Nerenz, H. Leventhal, and R.R. Love.
Factors contributing to emotional distress dur-
ing cancer chemotherapy. Cancer, 50(5):1020–
1027, 1982.
[171] A.M.O. Brett C.M.A., Brett and S.H.P. Ser-
rano. On the adsorption and electrochemical
oxidation of dna at glassy carbon electrodes.
Journal of Electroanalytical Chemistry, 366(1-
2):225–231, 1994.
[172] P. Niedziałkowski, R. Bogdanowicz, P. Zięba,
J. Wysocka, J. Ryl, M. Sobaszek, and T. Os-
sowski. Melamine-modiﬁed boron-doped di-
amond towards enhanced detection of ade-
nine, guanine and caﬀeine. Electroanalysis,
28(1):211–221, 2016.
[173] J. Lokich and N. Anderson. Carboplatin ver-
sus cisplatin in solid tumors: An analysis of
the literature. Annals of Oncology, 9(1):13–21,
1998.
[174] N. Katsumata, M. Yasuda, F. Takahashi,
S. Isonishi, T. Jobo, D. Aoki, H. Tsuda,
T. Sugiyama, S. Kodama, E. Kimura,
K Ochiai, K. Noda, and Japanese Gynecologic
Oncology Group. Dose-dense paclitaxel once
a week in combination with carboplatin every
3 weeks for advanced ovarian cancer: A phase
3, open-label, randomised controlled trial. The
Lancet, 374(9698):1331–1338, 2009.
[175] H. Fukuhara, M. Yagi, K. Ando, and
Y. Tomita. Long-term administration of single-
agent carboplatin (auc 4) for advanced tes-
ticular seminoma safely achieved complete re-
sponse in an 80-year-old man with chronic
heart failure: A case report. Canadian Urolog-
ical Association Journal, 8(11-12):E931, 2014.
[176] M.H. Cohen, H. Chen, S. Shord, C. Fuchs,
K. He, H. Zhao, S. Sickafuse, P. Keegan, and
R. Pazdur. Approval summary: Cetuximab in
combination with cisplatin or carboplatin and
5-ﬂuorouracil for the ﬁrst-line treatment of pa-
tients with recurrent locoregional or metastatic
squamous cell head and neck cancer. The On-
cologist, 18(4):460–466, 2013.
214 BIBLIOGRAPHY
[177] A. Sandler, R. Gray, M.C. Perry, J. Brahmer,
J.H. Schiller, A. Dowlati, R. Lilenbaum, and
D.H. Johnson. Paclitaxel–carboplatin alone
or with bevacizumab for non–small-cell lung
cancer. New England Journal of Medicine,
355(24):2542–2550, 2006.
[178] C.M. Rudin, R. Salgia, X. Wang, L.D. Hodg-
son, G.A. Masters, M. Green, and E.E. Vokes.
Randomized phase II study of carboplatin and
etoposide with or without the bcl-2 antisense
oligonucleotide oblimersen for extensive-stage
small-cell lung cancer: CALGB 30103. Jour-
nal of Clinical Oncology, 26(6):870–876, 2008.
[179] T.J. Lynch, I. Bondarenko, A. Luft, P. Serwa-
towski, F. Barlesi, R. Chacko, M. Sebastian,
J. Neal, H. Lu, J. Cuillerot, and M. Reck. Ip-
ilimumab in combination with paclitaxel and
carboplatin as ﬁrst-line treatment in stage
IIIB/IV non–small-cell lung cancer: Results
from a randomized, double-blind, multicenter
phase II study. Journal of Clinical Oncology,
30(17):2046–2054, 2012.
[180] B. Rosenberg, L. Van Camp, and T. Krigas.
Inhibition of cell division in escherichia coli
by electrolysis products from a platinum elec-
trode. Nature, 205(4972):698–699, 1965.
[181] S. Trzaska. Cisplatin. Chemical & Engineering
News, 83(25):52–52, 2005.
[182] A.M.O. Brett, S.H.P. Serrano, T.A. Macedo,
D. Raimundo, M. Helena-Marques, and M.A.
La-Scalea. Electrochemical determination of
carboplatin in serum using a DNA-modiﬁed
glassy carbon electrode. Electroanalysis,
8(11):992–995, 1996.
[183] S.S. Hah, K.M. Stivers, R.W. de Vere White,
and P.T. Henderson. Kinetics of carboplatin-
dna binding in genomic dna and bladder cancer
cells as determined by accelerator mass spec-
trometry. Chemical Research in Toxicology,
19(5):622–626, 2006.
[184] D.K. Jangir, G. Tyagi, R. Mehrotra, and
S. Kundu. Carboplatin interaction with calf-
thymus DNA: A ftir spectroscopic approach.
Journal of Molecular Structure, 969(1):126–
129, 2010.
[185] H. Troujman and J. Chottard. Com-
parison between HPLC and capillary elec-
trophoresis for the separation and identiﬁca-
tion of the platination products of oligonu-
cleotides withcis-[Pt(NH3)2 (H2O)2]2+ and
[Pt(NH3)3 (H2O)]2+. Analytical Biochemistry,
252(1):177–185, 1997.
[186] M.Y. Khuhawar and G.M. Arain. Liquid
chromatographic determination of cis-platin as
platinum (II) in pharmaceutical preparation,
serum and urine samples of cancer patients.
Talanta, 66(1):34–39, 2005.
[187] J.G. Morrison, P. White, S. McDougall, J.W.
Firth, S.G. Woolfrey, M.A. Graham, and
D. Greenslade. Validation of a highly sensitive
ICP-MS method for the determination of plat-
inum in bioﬂuids: application to clinical phar-
macokinetic studies with oxaliplatin. Jour-
nal of pharmaceutical and biomedical analysis,
24(1):1–10, 2000.
[188] M. Sharma, R. Jain, E. Ionescu, and H.K.
Slocum. Capillary electrophoretic separation
and laser-induced ﬂuorescence detection of the
BIBLIOGRAPHY 215
major DNA adducts of cisplatin and carbo-
platin. Analytical Biochemistry, 228(2):307–
311, 1995.
[189] M.H. Banitaba, S.S.H. Davarani, and A. Meh-
dinia. Study of interactions between DNA
and aﬂatoxin B1 using electrochemical and ﬂu-
orescence methods. Analytical Biochemistry,
411(2):218–222, 2011.
[190] B. Raﬁque, A.M. Khalid, K. Akhtar, and
A. Jabbar. Interaction of anticancer drug
methotrexate with DNA analyzed by electro-
chemical and spectroscopic methods. Biosen-
sors and Bioelectronics, 44:21–26, 2013.
[191] S. Krizkova, V. Adam, J. Petrlova, O. Zitka,
K. Stejskal, J. Zehnalek, B. Sures, L. Trnkova,
M. Beklova, and R. Kizek. A suggestion of
electrochemical biosensor for study of plat-
inum (II)-DNA interactions. Electroanalysis,
19(2):331–338, 2007.
[192] G. Marrazza, I. Chianella, and M. Mascini.
Disposable DNA electrochemical sensor for hy-
bridization detection. Biosensors and Bioelec-
tronics, 14(1):43–51, 1999.
[193] V. Brabec. DNA sensor for the determina-
tion of antitumor platinum compounds. Elec-
trochimica Acta, 45(18):2929–2932, 2000.
[194] J. Wang, A. Kawde, and M. Musameh.
Carbon-nanotube-modiﬁed glassy carbon elec-
trodes for ampliﬁed label-free electrochemi-
cal detection of DNA hybridization. Analyst,
128(7):912–916, 2003.
[195] J. Wang, G. Liu, and M.R. Jan. Ultra-
sensitive electrical biosensing of proteins and
DNA: Carbon-nanotube derived ampliﬁcation
of the recognition and transduction events.
Journal of the American Chemical Society,
126(10):3010–3011, 2004.
[196] C. Sengiz, G. Congur, E. Eksin, and A. Erdem.
Multiwalled carbon nanotubes-chitosan mod-
iﬁed single-use biosensors for electrochemical
monitoring of drug-DNA interactions. Electro-
analysis, 2015.
[197] E. Yapasan, A. Caliskan, H. Karadeniz, and
A. Erdem. Electrochemical investigation of
biomolecular interactions between platinum
derivatives and DNA by carbon nanotubes
modiﬁed sensors. Materials Science and En-
gineering: B, 169(1):169–173, 2010.
[198] X. Tang, S. Bansaruntip, N. Nakayama, E. Ye-
nilmez, Y. Chang, and Q. Wang. Carbon
nanotube DNA sensor and sensing mechanism.
Nano Letters, 6(8):1632–1636, 2006.
[199] A.M.O. Brett, J.A.P. Piedade, L.A. Silva, and
V.C. Diculescu. Voltammetric determination
of all DNA nucleotides. Analytical Biochem-
istry, 332(2):321–329, 2004.
[200] A.M.O. Brett. Electrochemistry for probing
DNA damage. Encyclopedia of Sensors, 3:301–
314, 2006.
[201] A.J.P. Piedade. Electrochemistry of dna. Ap-
plications of Kinetic Modelling, page 91, 1999.
[202] A.E. Simpson, J.A. Gilbert, D.E. Rudnick,
D.H. Geroski, T.M. Aaberg, and H.F. Edel-
hauser. Transscleral diﬀusion of carboplatin:
an in vitro and in vivo study. Archives of Oph-
thalmology, 120(8):1069–1074, 2002.
Appendix
Table 1: Copyright permissions
Figure Publisher Publication Licence number
number
1.1 Elsevier Trends in Neurosciences 3767760620677
1.4 Nature Publishing
Group
Nature Materials 3767760862857
2.1 Royal Society of
Chemistry
Journal of Materials Chem-
istry A
3767760101208
4.1 Springer Applied Microbiology and
Biotechnology
3767770371842
4.3 Elsevier Biochemical and Biophysical
Research Communications
3767780176976
4.5 Elsevier Electrochimica Acta 3767780340294

